

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Indicators of optimal diabetes care and burden of diabetes complications in Africa: A systematic review and meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-060786
Article Type:	Original research
Date Submitted by the Author:	06-Jan-2022
Complete List of Authors:	<p>Kibirige, Davis; Lubaga Hospital, Medicine Chamba, Nyasatu; Kilimanjaro Christian Medical Centre, Internal Medicine; Kilimanjaro Christian Medical University College, Medicine Andia-Biraro, Irene; Makerere University College of Health Sciences, Internal Medicine; MRC/UVRI and LSHTM Uganda Research Unit, Immunomodulation and Vaccines</p> <p>Kilonzo, Kajiru; Kilimanjaro Christian Medical Centre; Kilimanjaro Christian Medical University College</p> <p>Laizer, Sweetness; Kilimanjaro Christian Medical University College</p> <p>Sekitoleko, Isaac; Uganda Virus Research Institute, Non-communicable Diseases</p> <p>Kyazze, Andrew ; Makerere University College of Health Sciences</p> <p>Ninsiima, Sandra; Makerere University College of Health Sciences, Immunology</p> <p>Ssekamatte , Phillip ; Makerere University College of Health Sciences, Immunology</p> <p>Bongomin, Felix; Makerere University College of Health Sciences, Internal Medicine</p> <p>Mrema, Lucy; NIMR-Mbeya Medical Research Programme, Medicine</p> <p>Olomi, Willyhelmina; NIMR-Mbeya Medical Research Programme, Medical Statistics</p> <p>Mbunda, Theodora ; NIMR-Mbeya Medical Research Programme</p> <p>Ntinginya, Nyanda; NIMR-Mbeya Medical Research Programme</p> <p>Sabi, Issa; NIMR-Mbeya Medical Research Programme</p> <p>Sharples, Katrina; University of Otago, Centre for International Health</p> <p>Hill, Philip; University of Otago, Centre for International Health</p> <p>te Brake, Lindsey; Radboud University Nijmegen, Pharmacology</p> <p>VandeMaat, Josephine; Radboud University Nijmegen, Medicine</p> <p>vanCrevel, Reinout; Radboud University Nijmegen, Internal Medicine;</p> <p>University of Oxford Centre for Tropical Medicine and Global Health</p> <p>Critchley, Julia; St George's University of London</p>
Keywords:	Epidemiology < TROPICAL MEDICINE, EPIDEMIOLOGY, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

Indicators of optimal diabetes care and burden of diabetes complications in Africa: A systematic review and meta-analysis

Davis Kibirige^{1,2*}, Nyasatu Chamba^{3,4}, Irene Andia-Biraro^{2,5}, Kajiru Kilonzo^{3,4}, Sweetness Naftal Laizer^{3,4}, Isaac Sekitoleko⁶, Andrew Peter Kyazze², Sandra Ninsiima², Phillip Ssekamatte², Felix Bongomin⁵, Lucy Elauteri Mrema⁷, Willyhelmina Olomi⁷, Theodora D Mbunda⁷, Nyanda Elias Ntinginya⁷, Issa Sabi⁷, Katrina Sharples⁸, Philip C Hill⁸, Lindsey te Brake⁹, Josephine VandeMaat¹⁰, Reinout Van Crevel^{10,11}, Julia Critchley¹² on behalf of PROTID consortium.

Author affiliations

1. Department of Medicine, Uganda Martyrs' Hospital Lubaga, Kampala Uganda
2. Tuberculosis And Comorbidities Consortium, Kampala Uganda
3. Department of Medicine, Kilimanjaro Christian Medical Centre, Moshi, Tanzania.
4. Department of Medicine, Kilimanjaro Christian Medical University College, Moshi, Tanzania
5. Department of Medicine, Makerere University College of Health Sciences, Kampala Uganda.
6. Chronic Diseases and Cancer Program, Medical Research Council/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe Uganda.
7. National Institute for Medical Research - Mbeya Medical Research Centre, Mbeya, Tanzania.
8. Centre for International Health, Otago University, Dunedin, New Zealand.

- 1
2
3 9. Department of Pharmacy, Radboud Institute for Health Sciences, Radboud
4 University Medical Centre, Nijmegen, Netherlands.
5
6
7
8 10. Department of Internal Medicine and Radboud Centre for Infectious Diseases,
9 Radboud University Medical Centre, Nijmegen, Netherlands.
10
11
12 11. Centre for Tropical Medicine and Global Health, Nuffield Department of
13 Medicine, University of Oxford, Oxford, United Kingdom.
14
15
16
17 12. Population Health Research Institute, St. George's University of London,
18 London, United Kingdom.
19
20
21
22
23

24 **Corresponding author**

25
26 Davis Kibirige

27
28 Department of Medicine, Uganda Martyrs' Hospital Lubaga, Kampala Uganda

29
30 Email: kibirigedavis@gmail.com.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objective

Contemporary data on attainment of optimal diabetes treatment goals and the burden of diabetes complications in adult populations with type 2 diabetes in Africa is lacking. We aimed to document the current status of attainment of three key indicators of optimal diabetes care and the prevalence of five diabetes complications in adult African populations with type 2 diabetes.

Methods

We systematically searched EMBASE, PubMed and the Cochrane library for published studies from January 2000 to December 2020. Included studies reported any information on proportion of attainment of optimal glycated haemoglobin (HbA1c), blood pressure (BP) and low-density lipoprotein cholesterol (LDLC) goals, and/or prevalence of five diabetes complications (diabetic peripheral neuropathy, retinopathy, nephropathy, foot ulcers, and peripheral arterial disease). Random-effect model meta-analysis was performed to determine the pooled proportion of attainment of the three treatment goals and the prevalence of five diabetes complications.

Results

In total, 109 studies with a total of 63, 890 participants (53.3% being females) were included in the meta-analysis. Most of the studies were conducted in Eastern African countries (n=44, 40.4%). The pooled proportion of attainment of an optimal HbA1c, BP and LDLC goal were 27% (95% CI 24-30, $I^2=94.7\%$), 38% (95% CI 30-46, $I^2=98.7\%$), and 42% (95% CI 32-52, $I^2=97.4\%$), respectively. The pooled prevalence of diabetic peripheral neuropathy, retinopathy, diabetic nephropathy, peripheral arterial disease, and foot ulcers was 38% (95% CI 31-45, $I^2=98.2\%$), 32% (95% CI 28-

1
2
3 36, $I^2=98\%$), 31% (95% CI 22-41, $I^2=99.3\%$), 19% (95% CI 12-25, $I^2=98.1\%$), and 11%
4
5 (95% CI 9-14, $I^2=97.4\%$), respectively.
6
7

8 **Conclusion**

9
10 Attainment of optimal treatment goals of diabetes, especially HbA1c, in adult patients
11 with type 2 diabetes in Africa remains a challenge. Diabetes complications, especially
12 diabetic peripheral neuropathy and retinopathy are highly prevalent in adult African
13
14
15
16
17
18 populations with type 2 diabetes in Africa.

19 **KEY WORDS**

20
21 Optimal diabetes care, diabetes complications, adult patients with type 2 diabetes,
22
23
24 Africa.
25

26 **SUMMARY BOX**

27 **What is already known?**

- 28
29
30
31
32
33
34
35
36
37
- Suboptimal diabetes care is highly prevalent in most clinical settings. This ultimately translates to early onset and rapid progression of diabetes complications, increasing morbidity and mortality.

38 **What are the new findings?**

- 39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
- This is the first systematic review and meta-analysis to simultaneously document current status of attainment of three key diabetes treatment goals (optimal glycated haemoglobin, blood pressure, and low-density lipoprotein cholesterol) and prevalence of five diabetes complications in adult patients with type 2 diabetes in Africa.
 - It showed that, of the three treatment goals, an optimal glycated haemoglobin target is the least achieved. It also reported that diabetic peripheral neuropathy and retinopathy are the most prevalent diabetes complications.

58 **What do the new findings imply?**

- There is an urgent need to develop simple and pragmatic interventions to improve diabetes care and reduce burden of diabetes complications in adult patients with type 2 diabetes in Africa.

Strengths and limitations of the study

- To our knowledge, it is the first systematic review and meta-analysis to simultaneously investigate the status of attainment of the three key diabetes treatment goals and burden of five common diabetes complications in an adult indigenous African population with type 2 diabetes.
- There was high heterogeneity among the studies included in the meta-analysis.
- A relative number of studies included in the meta-analysis had low to moderate quality on assessment.

INTRODUCTION

Globally, the burden of diabetes mellitus (DM) continues to exponentially rise to epidemic proportions, disproportionately affecting low-and middle-income countries. The recent 2021 International Diabetes Federation (IDF) estimates show that about 24 million adults (1 in 22 adults) live with DM in Africa. The IDF also predicts that the greatest future increase in the prevalence of DM will occur in Africa because of the predicted ageing of Africa's currently very young populations, as well as increasing urbanisation and associated lifestyle changes.¹ This will ultimately lead to an immense strain on weak healthcare systems that are poorly structured and inadequately financed to manage non-communicable diseases (NCD) like DM.²

In addition, the rates of undiagnosed DM continue to increase in Africa. Among the IDF regions, Africa has the highest proportion of undiagnosed diabetes; about 54% of all cases.¹ The majority of patients are diagnosed late with co-existing debilitating complications and suboptimal diabetes care remains common in most clinical settings

1
2
3 in Africa.³ This could be explained by low awareness about DM, healthcare systems
4 that are structured mainly to manage communicable diseases as opposed to NCD,
5 low screening rates of DM to ensure early diagnosis, low availability of affordable
6 essential diagnostic tests and medicines of DM and knowledge-practice gaps among
7 healthcare practitioners.^{2 4-6}

8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Published diabetes treatment guidelines by most international organisations like the
IDF and American Diabetes Association (ADA) recommend targets of glycated
haemoglobin level (HbA1c) of <7% (53 mmol/mol), blood pressure (BP) <140/90
mmHg and low density lipoprotein cholesterol (LDLC) <2.6 mmol/l (100 mg/dl) as key
indicators of optimal diabetes care.⁷⁻⁹ Attainment of these treatment goals in diabetes
care ultimately translates to reduced risk of onset and progression of diabetes
complications and mortality.

Despite the increasing burden of DM and its related complications, in addition to the
prevalent suboptimal diabetes care in clinical settings in Africa, there is an information
gap regarding the current status of attainment of the recommended diabetes treatment
goals and burden of common diabetes complications. This systematic review and
meta-analysis aimed to document the proportion of attainment of optimal HbA1c, BP
and LDLC goals and the prevalence of five diabetes complications (diabetic peripheral
neuropathy, nephropathy, retinopathy, foot ulcers and peripheral arterial disease) in
adult native populations with type 2 diabetes in Africa.

METHODS

This systematic review and meta-analysis was conducted according to the criteria
outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement.¹⁰ The PRISMA checklist is available as a supplementary table

1
2
3 1. The study protocol was registered in the PROSPERO International Prospective
4 Register of systematic reviews (CRD42020215576).
5
6

7 **Search strategy**

8
9
10 We searched EMBASE, PubMed and the Cochrane library for published studies from
11
12 January 2000 to December 2020. The following search terms were used after
13
14 discussion with a medical librarian: “Quality of diabetes care” OR “Indicators of
15
16 diabetes care” OR “status of diabetes care” OR “diabetes care” OR “glycaemic control”
17
18 OR “blood pressure control” OR “lipid profile control” OR “screening of diabetes
19
20 complications” OR “diabetes complications” OR “screening for diabetic retinopathy”
21
22 OR “screening for diabetic peripheral nephropathy” OR screening for diabetic
23
24 neuropathy” OR screening for diabetic foot ulcers OR “screening for peripheral arterial
25
26 disease” OR “prevalence of diabetic retinopathy” OR “prevalence of diabetic peripheral
27
28 nephropathy” OR “prevalence of diabetic peripheral neuropathy” OR “prevalence of
29
30 diabetic foot ulcers” OR “prevalence of peripheral arterial disease”, AND “type 2
31
32 diabetes mellitus” OR “type 2 diabetes” AND Algeria OR Angola OR Benin OR
33
34 Botswana OR “Burkina Faso” OR Burundi OR Cameroon OR “Cape Verde” OR
35
36 “Central African Republic” OR Chad OR Comoros OR “Democratic Republic of
37
38 Congo” OR Djibouti OR Egypt OR “Equatorial Guinea” OR Eritrea OR Ethiopia OR
39
40 Gabon OR Gambia OR Ghana OR Guinea OR “Guinea Bissau” OR “Ivory Coast” OR
41
42 “Cote d’Ivoire” OR Kenya OR Lesotho OR Liberia OR Libya OR Libya OR
43
44 Madagascar OR Malawi OR Mali OR Mauritania OR Mauritius OR Morocco OR
45
46 Mozambique OR Namibia OR Niger OR Nigeria OR Rwanda OR “Sao Tome” OR
47
48 Senegal OR Seychelles OR “Sierra Leone” OR Somalia OR “South Africa” OR “South
49
50 Sudan” OR Sudan OR Swaziland OR Tanzania OR Togo OR Tunisia OR Uganda OR
51
52 Zaire OR Zambia OR Zimbabwe OR “Central Africa” OR “West Africa” OR “Western
53
54
55
56
57
58
59
60

1
2
3 Africa” OR “East Africa” OR “Eastern Africa” OR “North Africa” OR “Northern Africa”
4
5 OR “Southern Africa” OR “sub Saharan Africa” OR “sub-Saharan Africa” OR Africa.
6

7
8 In addition, references of included articles were hand-searched for any other original
9
10 articles. The search and selection were restricted to studies written only in English
11
12 language.
13

14 **Study selection criteria**

15
16
17 The preliminary screening of titles and abstracts to identify potentially eligible articles
18
19 was done by two independent reviewers (NC and DK). This was followed by removing
20
21 all duplicates. After the initial screening, full texts of the potentially eligible studies were
22
23 retrieved and closely reviewed for eligibility.
24
25

26
27 The inclusion criteria of studies were: cross-sectional, cohort or randomised controlled
28
29 trials published between January 2000 and December 2020 in English language,
30
31 studies reporting any data on proportion of adult patients with type 2 diabetes who
32
33 attained the recommended optimal HbA1c, BP or LDLC targets and residing in African
34
35 countries, and studies reporting data on any of prevalence of diabetic nephropathy,
36
37 peripheral neuropathy, retinopathy, foot ulcers or peripheral arterial disease in adult
38
39 patients with type 2 diabetes in African countries.
40
41

42
43 Any disagreements that arose were resolved by consensus. We excluded
44
45 retrospective studies, case series and reports, studies published in languages other
46
47 than English, and studies whose full texts could not be retrieved.
48

49 **Data extraction**

50
51
52 After identifying the eligible original studies, they were collated and sent to additional
53
54 reviewers to extract the relevant study information using a Microsoft Excel 2016 form.
55
56 The information of interest that was extracted from the eligible studies included: last
57
58 name of first author and year of publication, country (ies) and region (s) of Africa where
59
60

1
2
3 the study was conducted, type of study design, number of study participants, mean
4 age of study participants, proportion of female participants, proportion of participants
5 with a current or history of smoking, proportion of participants on oral hypoglycaemic
6 agents, insulin, lipid lowering agents (statins) and anti-hypertensive agents, mean
7 body mass index (BMI) and HbA1c of study participants, proportions of participants
8 with optimal HbA1c, BP and LDLC targets, and prevalence of diabetic nephropathy,
9 peripheral neuropathy, retinopathy, foot ulcers and peripheral arterial disease.

19 **Operational definitions**

21 All included studies defined optimal targets of HbA1c, BP and LDLC as <7% (53
22 mmol/mol), <140/90 mmHg, and <2.6 mmol/l or 100 mg/dl, respectively as
23 recommended by the IDF and ADA diabetes treatment guidelines.^{9 11}

28 The definitions and measurements of diabetes complications greatly varied between
29 studies. The following definitions were used for each diabetes complication by the
30 various studies: micro/macroalbuminuria and/or an estimated glomerular filtration rate
31 <60 ml/min/1.73 m² for presence of diabetic nephropathy, signs and symptoms
32 suggestive of peripheral neuropathy, use of neuropathy screening scores like
33 neuropathy disability score, Michigan Neuropathy Screening Instrument, neuropathy
34 symptom score, and 10g monofilament testing for presence of diabetic peripheral
35 neuropathy, presence of lesions like soft or hard exudates, cotton wool spots, micro-
36 aneurysms, neovascularisation, and retinal hemorrhages on fundoscopy for diabetic
37 retinopathy, presence of foot ulcers on clinical inspection for diabetic foot ulcers, and
38 presence of measured ankle brachial index <0.9 using doppler studies for peripheral
39 arterial disease.

56 **Assessment of quality of studies**

1
2
3 Quality of all eligible studies included in the systematic review and meta-analysis were
4 assessed using the Newcastle-Ottawa Scale (NOS).¹² This was done by two
5 independent authors (NC and SNL). The total score of the adapted scale is eight stars.
6
7
8
9
10 Studies with more than six stars were considered high quality, while those with 5 and
11
12
13 6 stars, and <5 stars were considered moderate and low quality.

14 **Study outcomes**

15
16
17 The study outcomes were the pooled proportions of attainment of the recommended
18 optimal HbA1c, BP and LDLC goals and the pooled prevalence of diabetic
19 nephropathy, peripheral neuropathy, retinopathy, foot ulcers and peripheral arterial
20
21
22
23
24 disease in adult patients with type 2 diabetes in Africa.

25 **Data analysis**

26
27
28 All analyses were performed using STATA 16.0 statistical software (Stata Corp, USA).
29
30
31 The descriptive data of all eligible studies included in the systematic review and meta-
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
analysis was summarised using frequencies and 95% confidence intervals (CI) and
mean \pm standard deviation (SD). The pooled proportions achieving optimal HbA1c, BP
and LDLC goals and prevalence of diabetic nephropathy, peripheral neuropathy,
retinopathy, foot ulcers and peripheral arterial disease were determined using a
random-effect model meta-analysis and presented in forest plots.

Heterogeneity of studies was assessed using I^2 value. The I^2 values of <25, 25-50,
and >50% were considered low, medium, and high levels of heterogeneity. To further
explore heterogeneity effects across studies, we conducted a meta-regression
analysis to assess whether the variations were associated with study level
characteristics i.e., age, and sex of participants, and region in which the study was
conducted.

1
2
3 We assessed the presence of publication bias using the Egger test of bias with $p < 0.05$
4 indicating significant publication bias.¹³ A narrative review was also used to present
5 the study results. Information about all included studies was also summarised in
6
7
8
9
10 tables.

11 **Patient and Public Involvement**

12
13
14 The main research question and outcomes of interest of the systematic review and
15 meta-analysis were informed by the need to understand burden of diabetes
16 complications in patients with type 2 diabetes in Africa and extent of attainment of
17 optimal diabetes care in order to inform strategies aimed to improve optimal
18 management of diabetes in the region. Because it was a systematic review and meta-
19 analysis, we did not involve patients in its design, recruitment, and conduct.
20
21
22
23
24
25
26
27

28 **Ethical approval**

29
30 Because this was a systematic review and meta-analysis of published studies, no prior
31 ethical approval was required.
32
33
34

35 **RESULTS**

36
37 Figure 1 summarises the article selection in a PRISMA flow diagram.

38
39 The literature search returned a total of 835 articles. From these , 222 duplicates were
40 removed. Titles and abstracts of the remaining 613 articles were reviewed and 235
41 articles were identified for full text retrieval. Of the 235 articles, 126 were excluded and
42 the remaining 109 articles were included in this systematic review and meta-analysis
43
44
45
46
47
48 A total of 48 and 89 studies included contained information of optimal diabetes
49 treatment goals and diabetes complications, respectively while 28 studies reported
50 information on both.
51
52
53
54

55
56 The 126 excluded articles included five studies published in French language, 21
57 retrospective studies, six studies with general populations (not entirely patients with
58
59
60

1
2
3 type 2 DM), 18 studies whose full texts were unable to be retrieved, and 76 studies
4 that did not report outcomes of interest.
5
6

7 ***Characteristics of included studies***

8
9
10 The majority of studies were performed in Eastern African countries (44, 40.4%).^{3 14-56}
11
12 The proportion of studies conducted in Western, Northern, Southern and Central Africa
13 was 22% (n=24 studies)^{3 57-78}, 16.5% (n=18 studies)⁷⁹⁻⁹⁷, 15.6% (n=17 studies)⁹⁸⁻¹¹⁴,
14 and 8.3% (n=9 studies)^{3 57 115-121}, respectively. Three studies were conducted in more
15 than one region of Africa (Western, Central and Eastern).^{3 56 57} Most of the studies
16 were cross-sectional in design (100, 91.7%).
17
18
19
20
21
22

23
24 A high heterogeneity was noted across all the studies with the I² value ranging from
25 97.4% to 99.3% for studies reporting burden of diabetes complications and 94.7% to
26 98.7% for studies reporting extent of attainment of optimal diabetes treatment goals.
27
28 However, on meta-regression after adjusting for age and sex of study participants, and
29 region where each study was conducted, the heterogeneity based on I² of studies on
30 prevalence of diabetes complications decreased, ranging from 1.4% for studies on
31 diabetic foot ulcers to 95.6% for studies on diabetic nephropathy. For studies on
32 proportion of attainment of optimal treatment goals, the heterogeneity also decreased,
33 to 56.3%, 92.1%, and 95.4%, for studies on optimal HbA1c, LDLC, and BP goal.
34
35
36
37
38
39
40
41
42
43

44 ***Characteristics of study participants***

45
46
47 Table 1 summarises the characteristics of all participants in the studies included in the
48 systematic review and meta-analysis.
49

50
51 The studies had a total of 63, 890 participants (ranging from 40 to 11,866) with 53.3%
52 being female. The cumulative mean \pm SD age, BMI, and HbA1c of the participants
53 was 54.9 \pm 4.7 years (ranging from 40.5 to 63.9 years), 27.9 \pm 0.5 kg/m² (ranging from
54 20.6 to 42.9 kg/m²), and 9.0 \pm 1.5% (ranging from 6.5% to 13.9%), respectively.
55
56
57
58
59
60

1
2
3 Among the studies that reported data on type of glucose-lowering therapies used by
4 participants, treatment with oral hypoglycaemic agents, insulin, statins, and anti-
5 hypertensives was noted in about 65% (95% CI 34-96.6), 31.3% (95% CI 26.3-36.2),
6
7
8 25.7% (95% CI 0.5-86.7), and 73.3% (95% CI 64.1-82.5) of participants, respectively.
9

12 **Assessment of study quality and publication bias**

14 The assessment of quality of studies and funnel plots assessing publication bias are
15 summarised in supplementary table 2 and supplementary figure 1 and 2, respectively.
16
17 Based on the NOS, 84 (77.1%) of the included studies were of high quality, with 17
18 (15.6%) studies and 8 (7.3%) studies being of moderate and low quality, respectively.
19
20 Regarding assessment of publication bias, there was observed publication bias
21 especially in studies about the prevalence of diabetic nephropathy, peripheral
22 neuropathy, and attainment of optimal BP control. The proportion of studies
23 investigating the prevalence of diabetic nephropathy, peripheral neuropathy,
24 peripheral arterial disease, retinopathy, and foot ulcers located within the funnel plot
25 was 30% (n=12), 46.1% (n=13), 55.6% (n=10), 57% (29), and 90% (n=26),
26
27 respectively. About 46%, 65%, and 73% of studies that reported proportion of
28 attainment of optimal BP, HbA1c, and LDLC treatment goal were located within the
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

44 **Extent of attainment of optimal HbA1c, BP and LDLC goals**

46 Data on the reported proportions achieving the three diabetes treatment goals is
47 summarised in tables 2, 3, and 4 and as forest plots in figures 2, 3 and 4.
48
49

51 Data on attainment of optimal HbA1c, BP and LDLC goals was reported in 34 studies³
52 18 19 21 33-35 42-45 57-59 61 62 65 82 85 90 91 95-97 102 103 109 114 115 118 122 123, 26 studies³ 16 18 19 22 34
53
54
55 38 39 43 45 59 62 65 68 75 85 89 94 95 103 105 109 111 118 119 122, and 11 studies¹⁹ 35 37 45 59 85 95 109 114
56
57
58 122 124, respectively. The pooled proportion of attainment of an optimal HbA1c, BP and
59
60

LDLC goal in the respective studies was 27% (95% CI 24-30, $I^2=94.7\%$), 38% (95% CI 30-46, $I^2=98.7\%$), and 42% (95% CI 32-52, $I^2=97.4\%$), respectively.

The lowest proportion of attainment of an optimal HbA1c was reported in a study performed in Egypt (4.4%)⁹⁵ and the highest in a study performed in Nigeria (52.5%)⁶². Regarding attainment of an optimal BP goal, the proportion ranged from 1.5% in a study performed in Uganda⁴⁵ to 85.9% in a study performed in Ethiopia²². Among the studies reporting information on the optimal LDLC goal, attainment of optimal targets ranged from 20.4% in a study performed in Botswana¹⁰⁹ to 84.8% in a study performed in Sudan⁹².

Prevalence of diabetic retinopathy, peripheral neuropathy, nephropathy, foot ulcers and peripheral arterial disease

Information on the pooled and specific prevalence of diabetes complications as reported by the different studies is summarised in tables 5, 6, 7, 8, and 9 and as forest plots in figures 5, 6, 7, 8, and 9.

The prevalence of diabetic retinopathy, nephropathy, peripheral neuropathy, foot ulcers and peripheral arterial disease was reported in 51 studies^{3 17 22 24 26 28 36 39 46 49 51 52 54-56 64 65 68 70 72 74 75 79 80 84 86 87 89 93-95 101-105 107 110-114 116 118-121 125-127}, 40 studies^{3 17 19 25 26 28-30 36 44 46 51 55 58 60 62 64 65 67 68 74 79 80 84 86 87 89 94 95 98 103 106-108 111 112 115-117 125}, 36 studies^{3 17 23 25 26 28 31 32 35 36 41 46 49-51 55 56 65 66 71 74 77 79 83-86 94 95 103 107 116 125 126 128}, 29 studies^{3 14-17 19 20 23 25 27 36 40 41 46 47 49 51 52 55 56 65 78 83 85 93 95 111 112 125}, and 18 studies^{3 18 23 28 41 45 48 50 59 65 68 73 76 83 84 89 95 103}, respectively.

Prevalence of diabetic peripheral neuropathy and retinopathy

Diabetic peripheral neuropathy and retinopathy were the most prevalent diabetes complications in the included studies with pooled prevalence of 38% (95% CI 31-45, $I^2=98.2\%$) and 32% (95% CI 28-36, $I^2=98\%$), respectively. A wide variation was noted

1
2
3 in the burden of diabetic peripheral neuropathy across the studies, with prevalence
4 ranging from 4% in a study conducted in Eritrea ⁴⁹ to 83.3% in a study conducted in
5 Nigeria ⁶⁶. A study by Makwero and colleagues conducted in Lesotho reported the
6 lowest prevalence of diabetic retinopathy of 4.7% ¹⁰⁷ while the study by Megalla and
7 colleagues conducted in Egypt reported the highest (90%)⁹⁵.

14 ***Prevalence of diabetic nephropathy, peripheral arterial disease, and foot ulcers***

15
16 The pooled prevalence of diabetic nephropathy, peripheral arterial disease, and foot
17 ulcers in the included studies was 31% (95% CI 22-41, I²=99.3%), 19% (95% CI 12-
18 25, I²=98.1%), and 11% (95% CI 9-14, I²=97.4%), respectively.

19
20 The prevalence of diabetic nephropathy and peripheral arterial disease ranged from
21 2.2% in Ethiopia¹⁷ to 90% in Nigeria⁶² and 2.7% in a study performed in Morocco⁸⁹ to
22 52.5% in a study performed in Nigeria⁷⁶, respectively. Regarding the burden of diabetic
23 foot ulcers, there was also an observed heterogeneity, with prevalence ranging from
24 0.4% in Ethiopia⁵¹ to 86.7% in Egypt⁹⁵.

35 **DISCUSSION**

36
37 To our knowledge, this is the first systematic review and meta-analysis to
38 simultaneously document the proportion of attainment of the three key indicators of
39 optimal diabetes care (HbA1c, BP, and LDLC goals) and the burden of five diabetes
40 complications in an indigenous adult population with type 2 diabetes in Africa. In this
41 study of a total of 63,890 study participants, we report that, generally, a small
42 proportion of adult patients with type 2 diabetes in Africa attain optimal diabetes
43 treatment targets, especially HbA1c and BP goals (less than 40%). In addition,
44 diabetes complications are relatively common with diabetic neuropathy being the most
45 prevalent (38%) followed by diabetic retinopathy (32%), nephropathy (31%),
46 peripheral arterial disease (19%), and foot ulcers (11%).

Proportions of attainment of optimal diabetes treatment goals

Similar to our study findings, achievement of optimal HbA1c, BP and LDLC treatment goals has also been widely reported to be a significant clinical challenge in several studies performed in Caucasian and Asian populations with type 2 diabetes in high- and middle-income countries.¹²⁹⁻¹³⁴ In one large registry-based study of >100, 000 adults with a self-reported diagnosis of diabetes carried out between 1999 to 2010 in USA, 33.4 to 48.7% of adult patients with diabetes did not achieve the recommended HbA1c, BP and LDLC treatment targets. Less than 15% met all the three treatment targets in addition to smoking cessation.¹²⁹

Similarly, a low proportion of achievement of an optimal HbA1c target was also reported by a large international, multicenter observational study of 2,704 multi-racial adult population with diabetes from 10 countries (two from Africa, five from Middle East and three from South Asia). About 46% of the participants were Caucasian. An optimal HbA1c goal of <7% (53 mmol/mol) was reported in only 25.8% of the participants.¹³¹

In the Japan Epidemiology Collaboration on Occupational Health (J-ECOH) study which enrolled 3,070 adult employees of large manufacturing companies, optimal HbA1c, BP, and LDLC goals as recommended by the American Diabetes Association were noted in 44.9%, 76.6%, and 27.1% of participants, respectively. Only 11.2% of participants attained all the three treatment goals.¹³²

Burden of diabetes complications in Africa

Regarding studies on the burden of diabetes complications in Africa, there were few investigating the prevalence of diabetic foot ulcers and peripheral arterial disease with diabetic retinopathy, peripheral nephropathy and neuropathy being the most studied. Diabetic peripheral neuropathy and retinopathy remain the most prevalent diabetes complication and diabetic foot ulcers the least prevalent.

1
2
3 With regards to prevalence of diabetic foot ulcers, an earlier published systematic
4 review and meta-analysis on characteristics, prevalence, and outcomes of diabetic
5 foot ulcers in Africa by Rigato et al reported a pooled prevalence of diabetic foot ulcers
6 of 13%, a finding close to what we observed (11%).¹³⁵ In another systematic review
7 and meta-analysis on prevalence of diabetic peripheral neuropathy in African
8 populations with DM, Shiferaw et al reported a slightly higher overall prevalence of
9 46% compared to what we found in our study (38%), while including fewer studies
10 (n=23).¹³⁶

11
12 Similar to our study, considerable heterogeneity was also reported in the documented
13 prevalence of the varied diabetes complications in Africa in most previously published
14 systematic reviews. This may be due to variations in clinical definitions of diabetes
15 complications in the studies. Burgess et al¹³⁷ and Achigbu et al¹³⁸, reported a wide
16 disparity in prevalence of diabetic retinopathy in the included studies of 7-62.4%, and
17 13-82.6%, respectively. Noubiap JJ et al in a systematic review on burden of diabetic
18 nephropathy in 2015 reported an overall prevalence of chronic kidney disease in
19 patients with diabetes ranging between 11-83.7%.¹³⁹ Johnston LE et al in a systematic
20 review that aimed to assess the epidemiological and clinical reports regarding PAD in
21 SSA documented the prevalence of PAD in patients with diabetes as reported by three
22 studies to range from 39% to 52%.¹⁴⁰

23
24 Compared to Caucasian and Asian adult populations with type 2 diabetes, our study
25 has demonstrated that adult African patients are disproportionately affected by
26 complications of DM. The Joint Asia Diabetes Evaluation (JADE) program that
27 undertook comprehensive risk assessments of 3,687 adult patients with type 2 DM
28 recruited from seven Asian countries reported prevalence of peripheral arterial
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 disease, diabetic neuropathy, macro-and microalbuminuria, and diabetic retinopathy
4
5 of 3.1%, 15%, 18.8%, and 20.4%, respectively.¹⁴¹
6
7

8 The National Health and Nutrition Examination Survey conducted from the 1988–1994
9
10 and 1999–2018 in USA in 1,486 nonpregnant adults (aged ≥ 20 years) with newly
11
12 diagnosed diabetes (diagnosed within the past 2 years) also documented a low burden
13
14 of most diabetes complications. Diabetic foot ulcers, peripheral arterial disease,
15
16 diabetic retinopathy, neuropathy, and nephropathy (albuminuria) were prevalent in
17
18 6.3%, 9.2%, 12.1%, 14.5%, 18.7%, respectively.¹⁴²
19
20

21 The documented low proportions of attainment of optimal diabetes treatment goals
22
23 (optimal HbA1c, BP and LDLC targets) in Africa is associated with an increased risk
24
25 of onset and progression of diabetes complications, hence increasing morbidity and
26
27 mortality in addition to causing a significant economic strain on meagre health
28
29 resources. This generally observed low proportion of attainment of key diabetes
30
31 treatment goals and high prevalence of diabetes complications, notably diabetic
32
33 neuropathy, retinopathy, and nephropathy in Africa exists broadly due to challenges
34
35 related to screening, diagnosis, and management of DM.
36
37
38

39 Awareness of diabetes in the general African population and healthcare practitioners
40
41 remains very poor, resulting in delayed diagnosis of diabetes. The challenge of ready
42
43 access to affordable essential diabetes medicines like insulin and statins and
44
45 diagnostic tests or equipment like glucometers for home self-monitoring of glucose,
46
47 HbA1c and lipid profile tests remains highly prevalent in most African countries.¹⁴³⁻¹⁴⁷
48
49

50 Effective management of diabetes and its related cardiovascular risk factors like
51
52 hypertension and dyslipidaemia in most healthcare settings in Africa also remains a
53
54 significant clinical challenge.³ Most healthcare facilities especially the lower-tier ones
55
56 lack local or institution-specific comprehensive diabetes treatment guidelines to guide
57
58
59
60

1
2
3 healthcare practitioners on how to optimally manage diabetes, in addition to the
4 evident knowledge-practice gaps in healthcare practitioners.²
5

6
7 Healthcare systems in most African countries remain poorly structured to optimally
8 manage most non-communicable diseases like diabetes along with an inadequately
9 funded health sector. Most African countries have not yet fulfilled the 2001 Abuja
10 Declaration of allocating 15% of their national annual budget to the health sector.^{2 148}
11

12
13 This systematic review and meta-analysis had its strengths and limitations. To our
14 knowledge, it is the first to simultaneously investigate the status of attainment of the
15 three key diabetes treatment goals and burden of five common diabetes complications
16 in an adult indigenous African population with type 2 diabetes.
17

18
19 It also had its limitations. There was also an observed heterogeneity in the included
20 studies. This could be explained by the differences in study sites (tertiary vs low-tier
21 hospitals or private vs public hospitals), patient characteristics (age, duration of
22 diabetes, co-existing medical conditions), regions of study, and diagnostic modalities
23 used to identify diabetes complications. The systematic review also excluded studies
24 published in French which is an official language of some African countries. However,
25 these were very few. There was evidence of publication bias some the included
26 studies especially studies investigating the prevalence of diabetic nephropathy and
27 peripheral neuropathy and proportion of attainment of an optimal BP goal. About 23%
28 of the included studies had moderate and low quality on assessment using the
29 adapted NOS for cross-sectional studies.
30

31 **CONCLUSION**

32
33 Achievement of optimal diabetes treatment goals, especially HbA1c and BP, in adult
34 African patients with type 2 diabetes remains low in Africa. Diabetes complications
35 especially diabetic peripheral neuropathy and retinopathy also remain highly
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

1
2
3 prevalent. Implementation of universal diabetes screening and education initiatives
4
5 coupled with improving knowledge about diabetes management among healthcare
6
7 practitioners, ready access to affordable essential diabetes diagnostic tests and
8
9 medicines in Africa are integral in improving overall optimal diabetes care and reducing
10
11 the burden of diabetes complications.
12
13

14
15 Considering the projected future increase in the prevalence of diabetes globally, with
16
17 Africa to be the most affected region, there is an urgent need to address glaring gaps
18
19 in diabetes care and to develop simple and pragmatic interventions to improve
20
21 treatment outcomes and reduce burden of diabetes complications
22
23

24 **Acknowledgements**

25
26 We would like to thank Miss Laura Russel, a medical librarian based at the Education
27
28 and Research Centre, Wythenshawe Hospital, Manchester UK who was very helpful
29
30 in performing the initial search of the databases and retrieval of all the studies that
31
32 were screened. Patient advisers were not involved in this systematic review and meta-
33
34 analysis.
35
36

37 **Funding**

38
39 The systematic review and meta-analysis is part of the Preventive Treatment Of Latent
40
41 Tuberculosis Infection In People With Diabetes Mellitus (PROTID) study funded by the
42
43 European Developing Countries Clinical Trials Partnership 2 (EDCTP) programme
44
45 supported by the European Union (grant number RIA2018CO-2514-PROTID).
46
47
48

49 **Conflict of interest statement**

50
51 All the authors report no conflict of interest.
52
53

54 **Availability of data**

55
56 The data sets that were analysed are available on reasonable request to the
57
58 corresponding author.
59
60

Contributorship statement

DK and NC-Conceived the research idea, performed the preliminary screening of titles and abstracts to identify potentially eligible articles, and wrote the initial draft of the manuscript, DK, NC, IAB, SNL, IS (Sekitoleko), APK, SN- Retrieved full texts and identified the eligible articles, KK, SNL, APK, SN, PS, FB, LEM, WO, TDM, NEN, IS (Sabi)-extracted data from the identified eligible articles, DK and IS (Sekitoleko) performed the data analysis and interpretation, NC, KK, and SNL- performed the assessment of quality of studies, KS, PCH, LB, JVM, RVC, JC- offered additional data interpretation and supervised this work. All the authors reviewed the different versions of the manuscript and read and approved the final draft of the manuscript.

REFERENCES

1. IDF. International Diabetes Federation Diabetes Atlas 10th edition. <https://diabetes.atlas.org> (accessed 12 November 2021) 2021
2. Atun R, Davies JI, Gale EAM, et al. Diabetes in sub-Saharan Africa: from clinical care to health policy. *Lancet Diabetes Endocrinol* 2017;5(8):622-67. doi: 10.1016/s2213-8587(17)30181-x [published Online First: 2017/07/10]
3. Sobngwi E, Ndour-Mbaye M, Boateng KA, et al. Type 2 diabetes control and complications in specialised diabetes care centres of six sub-Saharan African countries: the Diabcare Africa study. *Diabetes research and clinical practice* 2012;95(1):30-6. doi: 10.1016/j.diabres.2011.10.018 [published Online First: 2011/11/11]
4. Gill GV, Mbanya JC, Ramaiya KL, et al. A sub-Saharan African perspective of diabetes. *Diabetologia* 2009;52(1):8-16. doi: 10.1007/s00125-008-1167-9 [published Online First: 2008/10/11]

- 1
2
3 5. Hall V, Thomsen RW, Henriksen O, et al. Diabetes in Sub Saharan Africa 1999-
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
2011: epidemiology and public health implications. A systematic review. *BMC
Public Health* 2011;11:564. doi: 10.1186/1471-2458-11-564 [published Online
First: 2011/07/16]
6. Nuche-Berenguer B, Kupfer LE. Readiness of Sub-Saharan Africa Healthcare
Systems for the New Pandemic, Diabetes: A Systematic Review. *Journal of
Diabetes Research* 2018;2018:9262395. doi: 10.1155/2018/9262395
7. American Diabetes Association. Cardiovascular Disease and Risk Management:
Standards of Medical Care in Diabetes—2021. *Diabetes care* 2021;44:S125-
S50; DOI: 10.2337/dc21-S010.
8. American Diabetes Association. Pharmacologic Approaches to Glycemic
Treatment: Standards of Medical Care in Diabetes—2021. *Diabetes care*
2021;44(Supplement 1):S111. doi: 10.2337/dc21-S009
9. IDF. International Diabetes Federation. IDF Clinical Practice Recommendations for
Managing Type 2 Diabetes in Primary Care. [https://www.idf.org/e-
library/guidelines/128-idf-clinical-practice-recommendations-for-managing-
type-2-diabetes-in-primary-care.html](https://www.idf.org/e-library/guidelines/128-idf-clinical-practice-recommendations-for-managing-type-2-diabetes-in-primary-care.html) (accessed on 17 September 2021). 2018
10. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic
reviews and meta-analyses: the PRISMA statement. *PLoS Med*
2009;6(7):e1000097. doi: 10.1371/journal.pmed.1000097 [published Online
First: 2009/07/22]
11. ADA. American Diabetes Association. Classification and Diagnosis of Diabetes:
Standards of Medical Care in Diabetes-2021. *Diabetes Care* 2021;44(Suppl
1):S15-s33. doi: 10.2337/dc21-S002 [published Online First: 2020/12/11]

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
12. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohrica/programs/clinical_epidemiology/oxfordasp (accessed 2 September 2021) 2021
 13. Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315(7109):629-34. doi: 10.1136/bmj.315.7109.629
 14. Gulam-Abbas Z, Lutale JK, Morbach S, et al. Clinical outcome of diabetes patients hospitalized with foot ulcers, Dar es Salaam, Tanzania. *Diabetic medicine : a journal of the British Diabetic Association* 2002;19(7):575-9. doi: 10.1046/j.1464-5491.2002.00740.x [published Online First: 2002/07/09]
 15. Abbas ZG, Lutale JK, Bakker K, et al. The 'Step by Step' Diabetic Foot Project in Tanzania: a model for improving patient outcomes in less-developed countries. *Int Wound J* 2011;8(2):169-75. doi: 10.1111/j.1742-481X.2010.00764.x [published Online First: 2011/01/27]
 16. Abdissa D, Aduugna T, Gerema U, et al. Prevalence of Diabetic Foot Ulcer and Associated Factors among Adult Diabetic Patients on Follow-Up Clinic at Jimma Medical Center, Southwest Ethiopia, 2019: An Institutional-Based Cross-Sectional Study. *J Diabetes Res* 2020;2020:4106383. doi: 10.1155/2020/4106383 [published Online First: 2020/04/08]
 17. Abejew AA, Belay AZ, Kerie MW. Diabetic Complications among Adult Diabetic Patients of a Tertiary Hospital in Northeast Ethiopia. *Advances in Public Health* 2015;2015:290920. doi: 10.1155/2015/290920
 18. Akalu Y, Belsti Y. Hypertension and Its Associated Factors Among Type 2 Diabetes Mellitus Patients at Debre Tabor General Hospital, Northwest

- 1
2
3 Ethiopia. *Diabetes Metab Syndr Obes* 2020;13:1621-31. doi:
4
5 10.2147/DMSO.S254537
6
7
8 19. Amour AA, Chamba N, Kayandabila J, et al. Prevalence, Patterns, and Factors
9
10 Associated with Peripheral Neuropathies among Diabetic Patients at Tertiary
11
12 Hospital in the Kilimanjaro Region: Descriptive Cross-Sectional Study from
13
14 North-Eastern Tanzania. *Int J Endocrinol* 2019;2019:5404781. doi:
15
16 10.1155/2019/5404781 [published Online First: 2019/07/06]
17
18
19 20. Chalya PL, Mabula JB, Dass RM, et al. Surgical management of Diabetic foot
20
21 ulcers: A Tanzanian university teaching hospital experience. *BMC Res Notes*
22
23 2011;4:365. doi: 10.1186/1756-0500-4-365 [published Online First:
24
25 2011/09/29]
26
27
28 21. Chamba NG, Shao ER, Tolbert S, et al. Lipid Profile of Type 2 Diabetic Patients at
29
30 a Tertiary Hospital in Tanzania: Cross Sectional Study. *J Endocrinol Diab*
31
32 2017;4(1):1-6.
33
34
35 22. Chisha Y, Terefe W, Assefa H, et al. Prevalence and factors associated with
36
37 diabetic retinopathy among diabetic patients at Arbaminch General Hospital,
38
39 Ethiopia: Cross sectional study. *PLoS One* 2017;12(3):e0171987. doi:
40
41 10.1371/journal.pone.0171987
42
43
44 23. Chiwanga FS, Njelekela MA. Diabetic foot: prevalence, knowledge, and foot self-
45
46 care practices among diabetic patients in Dar es Salaam, Tanzania - a cross-
47
48 sectional study. *J Foot Ankle Res* 2015;8:20-20. doi: 10.1186/s13047-015-
49
50 0080-y
51
52
53 24. Cleland CR, Burton MJ, Hall C, et al. Diabetic retinopathy in Tanzania: prevalence
54
55 and risk factors at entry into a regional screening programme. *Tropical medicine*
56
57
58
59
60

1
2
3 & *international health : TM & IH* 2016;21(3):417-26. doi: 10.1111/tmi.12652

4
5 [published Online First: 2015/12/09]

- 6
7
8 25. Deribe B, Woldemichael K, Nemera G. Prevalence and Factors Influencing
9
10 Diabetic Foot Ulcer among Diabetic Patients Attending Arbaminch Hospital,
11
12 South Ethiopia. *J Diabetes Metab Disord*;2:322.
13
- 14
15 26. Fasil A, Biadgo B, Abebe M. Glycemic control and diabetes complications among
16
17 diabetes mellitus patients attending at University of Gondar Hospital, Northwest
18
19 Ethiopia. *Diabetes Metab Syndr Obes* 2018;12:75-83. doi:
20
21 10.2147/DMSO.S185614
22
- 23
24 27. Gebrekirstos K, Gebrekiros S, Fantahun A. Prevalence and Factors Associated
25
26 With Diabetic Foot Ulcer among Adult Patients in Ayder Referral Hospital
27
28 Diabetic Clinic Mekelle, North Ethiopia, 2013. *J Diabetes Metab* 2015;6:579.
29
- 30
31 28. Gill G, Gebrekidan A, English P, et al. Diabetic complications and glycaemic
32
33 control in remote North Africa. *QJM : monthly journal of the Association of*
34
35 *Physicians* 2008;101(10):793-8. doi: 10.1093/qjmed/hcn096 [published Online
36
37 First: 2008/08/09]
38
- 39
40 29. Kumela Goro K, Desalegn Wolide A, Kerga Dibaba F, et al. Patient Awareness,
41
42 Prevalence, and Risk Factors of Chronic Kidney Disease among Diabetes
43
44 Mellitus and Hypertensive Patients at Jimma University Medical Center,
45
46 Ethiopia. *BioMed Research International* 2019;2019:2383508. doi:
47
48 10.1155/2019/2383508
49
- 50
51 30. Janmohamed MN, Kalluvya SE, Mueller A, et al. Prevalence of chronic kidney
52
53 disease in diabetic adult out-patients in Tanzania. *BMC Nephrol* 2013;14:183-
54
55 83. doi: 10.1186/1471-2369-14-183
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
31. Jarso G, Ahmed A, Feleke Y. The prevalence, clinical features and management of peripheral neuropathy among diabetic patients in Tikur Anbessa and St. Paul's Specialized University Hospitals, Addis Ababa, Ethiopia. *Ethiop Med J* 2011;49(4):299-311. [published Online First: 2011/10/01]
32. Jember G, Melsew YA, Fisseha B, et al. Peripheral Sensory Neuropathy and associated factors among adult diabetes mellitus patients in Bahr Dar, Ethiopia. *Journal of diabetes and metabolic disorders* 2017;16:16-16. doi: 10.1186/s40200-017-0295-5
33. Kibirige D, Akabwai GP, Kampiire L, et al. Frequency and predictors of suboptimal glycemic control in an African diabetic population. *Int J Gen Med* 2017;10:33-38. doi: 10.2147/IJGM.S124548
34. Kimando MW, Otieno FCF, Ogola EN, et al. Adequacy of control of cardiovascular risk factors in ambulatory patients with type 2 diabetes attending diabetes out-patients clinic at a county hospital, Kenya. *BMC Endocrine Disorders* 2017;17(1):73. doi: 10.1186/s12902-017-0223-1
35. Kisozi T, Mutebi E, Kisekka M, et al. Prevalence, severity and factors associated with peripheral neuropathy among newly diagnosed diabetic patients attending Mulago hospital: a cross-sectional study. *Afr Health Sci* 2017;17(2):463-73. doi: 10.4314/ahs.v17i2.21 [published Online First: 2017/10/25]
36. Lebeta KR, Argaw Z, Birhane BW. Prevalence of Diabetic Complications and Its Associated Factors Among Diabetes Mellitus Patients Attending Diabetes Mellitus Clinics; Institution Based Cross Sectional Study. *American Journal of Health Research*;5(2):38-43.

- 1
2
3 37. Lumu W, Kampiire L, Akabwai GP, et al. Dyslipidaemia in a Black African diabetic
4 population: burden, pattern and predictors. *BMC Research Notes*
5 2017;10(1):587. doi: 10.1186/s13104-017-2916-y
6
7
8
9
10 38. Lumu W, Kampiire L, Akabwai GP, et al. Statin therapy reduces the likelihood of
11 suboptimal blood pressure control among Ugandan adult diabetic patients.
12 *Ther Clin Risk Manag* 2017;13:215-21. doi: 10.2147/TCRM.S120423
13
14
15
16 39. Magan T, Pouncey A, Gadhvi K, et al. Prevalence and severity of diabetic
17 retinopathy in patients attending the endocrinology diabetes clinic at Mulago
18 Hospital in Uganda. *Diabetes research and clinical practice* 2019;152:65-70.
19
20
21
22
23
24
25
26
27 40. Mamo T, Yifter H, Lemessa T. Risk factors assessment of diabetic foot ulcer using
28 the sixty second screening tool: A hospital based cross-sectional study at Tikur
29 Anbessa Specialised Hospital. *Ethiop Med J* 2015;Suppl 2:45-9. [published
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
41. Mariam TG, Alemayehu A, Tesfaye E, et al. Prevalence of Diabetic Foot Ulcer and
Associated Factors among Adult Diabetic Patients Who Attend the Diabetic
Follow-Up Clinic at the University of Gondar Referral Hospital, North West
Ethiopia, 2016: Institutional-Based Cross-Sectional Study. *J Diabetes Res*
2017;2017:2879249. doi: 10.1155/2017/2879249 [published Online First:
2017/08/10]
42. Mbwete GW, Kilonzo KG, Shao ER, et al. Suboptimal Blood Pressure Control,
Associated Factors, and Choice of Antihypertensive Drugs among Type 2
Diabetic Patients at KCMC, Tanzania. *J Diabetes Res* 2020;2020:4376251. doi:
10.1155/2020/4376251 [published Online First: 2020/08/11]

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
43. Muddu M, Mutebi E, Mondo C. Prevalence, types and factors associated with echocardiographic abnormalities among newly diagnosed diabetic patients at Mulago Hospital. *Afr Health Sci* 2016;16(1):183-93. doi: 10.4314/ahs.v16i1.25 [published Online First: 2016/07/01]
44. Muddu M, Mutebi E, Ssinabulya I, et al. Utility of albumin to creatinine ratio in screening for microalbuminuria among newly diagnosed diabetic patients in Uganda: a cross sectional study. *Afr Health Sci* 2019;19(1):1607-16. doi: 10.4314/ahs.v19i1.36 [published Online First: 2019/06/01]
45. Mwebaze RM, Kibirige D. Peripheral arterial disease among adult diabetic patients attending a large outpatient diabetic clinic at a national referral hospital in Uganda: a descriptive cross sectional study. *PLoS One* 2014;9(8):e105211. doi: 10.1371/journal.pone.0105211 [published Online First: 2014/08/19]
46. Neuhann HF, Warter-Neuhann C, Lyaruu I, et al. Diabetes care in Kilimanjaro region: clinical presentation and problems of patients of the diabetes clinic at the regional referral hospital-an inventory before structured intervention. *Diabetic medicine : a journal of the British Diabetic Association* 2002;19(6):509-13. doi: 10.1046/j.1464-5491.2002.00673.x [published Online First: 2002/06/13]
47. Nyamu PN, Otieno CF, Amayo EO, et al. Risk factors and prevalence of diabetic foot ulcers at Kenyatta National Hospital, Nairobi. *East Afr Med J* 2003;80(1):36-43. doi: 10.4314/eamj.v80i1.8664 [published Online First: 2003/05/21]
48. Okello S, Millard A, Owori R, et al. Prevalence of lower extremity peripheral artery disease among adult diabetes patients in southwestern Uganda. *BMC*

- 1
2
3 *Cardiovasc Disord* 2014;14:75. doi: 10.1186/1471-2261-14-75 [published
4
5 Online First: 2014/06/11]
6
7
- 8 49. Seyum B, Mebrahtu G, Usman A, et al. Profile of patients with diabetes in Eritrea:
9
10 results of first phase registry analyses. *Acta Diabetol* 2010;47(1):23-7. doi:
11
12 10.1007/s00592-009-0093-8 [published Online First: 2009/02/03]
13
14
- 15 50. Smide B. Outcome of foot examinations in Tanzanian and Swedish diabetic
16
17 patients, a comparative study. *J Clin Nurs* 2009;18(3):391-8. doi:
18
19 10.1111/j.1365-2702.2008.02492.x [published Online First: 2009/02/05]
20
21
- 22 51. Tesfaye D, Tessema F, Taha M. Coexistence of Chronic Complications among
23
24 Diabetic Patients at Nigist Eleni Mohammed Memorial Hospital, Hossana,
25
26 South Ethiopia. *Open Access Library Journal* 2015;2:1-10.
27
28
- 29 52. Tilahun AN, Waktola C, Tewodros GM, et al. Major Micro vascular Complications
30
31 and Associated Risk Factors among Diabetic Outpatients in Southwest
32
33 Ethiopia. *Endocrinol Metab Syndr* 2017;6:272.
34
35
- 36 53. Vogt EC, Øksnes M, Suleiman F, et al. Assessment of diabetic polyneuropathy in
37
38 Zanzibar: Comparison between traditional methods and an automated point-of-
39
40 care nerve conduction device. *Journal of clinical & translational endocrinology*
41
42 2017;10:9-14. doi: 10.1016/j.jcte.2017.09.001
43
44
- 45 54. Woodward R, Mgaya E, Mwanansao C, et al. Retinopathy in adults with
46
47 hypertension and diabetes mellitus in Western Tanzania: a cross-sectional
48
49 study. *Tropical medicine & international health : TM & IH* 2020;25(10):1214-25.
50
51 doi: 10.1111/tmi.13463 [published Online First: 2021/01/06]
52
53
- 54 55. Worku D, Hamza L, Woldemichael K. Patterns of diabetic complications at jimma
55
56 university specialized hospital, southwest ethiopia. *Ethiop J Health Sci*
57
58 2010;20(1):33-39. doi: 10.4314/ejhs.v20i1.69424
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
56. Ekoru K, Doumatey A, Bentley AR, et al. Type 2 diabetes complications and comorbidity in Sub-Saharan Africans. *EClinicalMedicine* 2019;16:30-41. doi: 10.1016/j.eclinm.2019.09.001
57. Camara A, Baldé NM, Sobngwi-Tambekou J, et al. Poor glycemic control in type 2 diabetes in the South of the Sahara: the issue of limited access to an HbA1c test. *Diabetes research and clinical practice* 2015;108(1):187-92. doi: 10.1016/j.diabres.2014.08.025 [published Online First: 2015/02/24]
58. Adetunji OR, Adeleye JO, Agada NO, et al. Microalbuminuria and clinical correlates in black African patients with type 2 diabetes. *West African journal of medicine* 2006;25(4):279-83. [published Online First: 2007/04/04]
59. Agboghoroma OF, Akemokwe FM, Puepet FH. Peripheral arterial disease and its correlates in patients with type 2 diabetes mellitus in a teaching hospital in northern Nigeria: a cross-sectional study. *BMC Cardiovascular Disorders* 2020;20(1):102. doi: 10.1186/s12872-020-01395-3
60. Alebiosu CO. Clinical diabetic nephropathy in a tropical African population. *West African journal of medicine* 2003;22(2):152-5. doi: 10.4314/wajm.v22i2.27938 [published Online First: 2003/10/08]
61. Attoye TE, Adebobola PA, Inem V. An Assessment of Glycaemic Control and Modes of Health Financing among Type 2 Diabetic Patients Attending a Teaching Hospital in South-western Nigeria. *West African journal of medicine* 2020;37(3):237-47. [published Online First: 2020/06/02]
62. Balogun WO, Abbiyesuku FM. Excess renal insufficiency among type 2 diabetic patients with dip-stick positive proteinuria in a tertiary hospital. *Afr J Med Med Sci* 2011;40(4):399-403. [published Online First: 2012/07/13]

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
63. Bello A, Biliaminu S, Wahab K, et al. Distal symmetrical polyneuropathy and cardiovascular autonomic neuropathy among diabetic patients in Ilorin: Prevalence and predictors. *Niger Postgrad Med J* 2019;26(2):123-28. doi: 10.4103/npmj.npmj_30_19 [published Online First: 2019/06/13]
64. Bello BT, Amira CO. Pattern and predictors of urine protein excretion among patients with type 2 diabetes attending a single tertiary hospital in Lagos, Nigeria. *Saudi J Kidney Dis Transpl* 2017;28(6):1381-88. doi: 10.4103/1319-2442.220869 [published Online First: 2017/12/22]
65. Uloko AE, Ofoegbu EN, Chinenye S, et al. Profile of Nigerians with diabetes mellitus - Diabcare Nigeria study group (2008): Results of a multicenter study. *Indian J Endocrinol Metab* 2012;16(4):558-64. doi: 10.4103/2230-8210.98011
66. Ede O, Eyichukwu G, Madu K, et al. Evaluation of Peripheral Neuropathy in Diabetic Adults with and without Foot Ulcers in an African Population. *Journal of Biosciences and Medicines* 2018;6:71-78.
67. Eghan BA, Jr., Frempong MT, Adjei-Poku M. Prevalence and predictors of microalbuminuria in patients with diabetes mellitus: a cross-sectional observational study in Kumasi, Ghana. *Ethn Dis* 2007;17(4):726-30. [published Online First: 2007/12/13]
68. Hayfron-Benjamin C, van den Born BJ, Maitland-van der Zee AH, et al. Microvascular and macrovascular complications in type 2 diabetes Ghanaian residents in Ghana and Europe: The RODAM study. *J Diabetes Complications* 2019;33(8):572-78. doi: 10.1016/j.jdiacomp.2019.04.016 [published Online First: 2019/06/07]
69. Iwuala SO, Olamoyegun MA, Sabir AA, et al. The relationship between self-monitoring of blood glucose and glycaemic control among patients attending an

- 1
2
3 urban diabetes clinic in Nigeria. *Ann Afr Med* 2015;14(4):182-7. doi:
4 10.4103/1596-3519.155992 [published Online First: 2015/10/17]
5
6
7
8 70. Kizor-Akaraiwe NN, Ezegwui IR, Oguego N, et al. Prevalence, Awareness and
9 Determinants of Diabetic Retinopathy in a Screening Centre in Nigeria. *J*
10 *Community Health* 2016;41(4):767-71. doi: 10.1007/s10900-016-0151-4
11 [published Online First: 2016/01/27]
12
13
14
15
16
17 71. Kuate-Tegueu C, Temfack E, Ngankou S, et al. Prevalence and determinants of
18 diabetic polyneuropathy in a sub-Saharan African referral hospital. *J Neurol Sci*
19 2015;355(1-2):108-12. doi: 10.1016/j.jns.2015.05.035 [published Online First:
20 2015/06/07]
21
22
23
24
25
26 72. Larrey SY, Aikins AK. Visual impairment amongst adult diabetics attending a
27 tertiary outpatient clinic. *Ghana medical journal* 2018;52(2):84-87. doi:
28 10.4314/gmj.v52i2.4 [published Online First: 2019/01/22]
29
30
31
32
33 73. Ogbera AO, Adeleye O, Solagberu B, et al. Screening for peripheral neuropathy
34 and peripheral arterial disease in persons with diabetes mellitus in a Nigerian
35 University Teaching Hospital. *BMC Research Notes* 2015;8(1):533. doi:
36 10.1186/s13104-015-1423-2
37
38
39
40
41
42 74. Olamoyegun M, Ibraheem W, Iwuala S, et al. Burden and pattern of micro vascular
43 complications in type 2 diabetes in a tertiary health institution in Nigeria. *Afr*
44 *Health Sci* 2015;15(4):1136-41. doi: 10.4314/ahs.v15i4.12 [published Online
45 First: 2016/03/10]
46
47
48
49
50
51 75. Onakpoya OH, Kolawole BA, Adeoye AO, et al. Visual impairment and blindness
52 in type 2 diabetics: Ife-Ijesa diabetic retinopathy study. *Int Ophthalmol*
53 2016;36(4):477-85. doi: 10.1007/s10792-015-0145-8 [published Online First:
54 2015/11/06]
55
56
57
58
59
60

- 1
2
3 76. Oyelade BO, OlaOlorun AD, Odeigah LO, et al. The prevalence of peripheral
4 arterial disease in diabetic subjects in south-west Nigeria. *Afr J Prim Health*
5 *Care Fam Med* 2012;4(1):354. doi: 10.4102/phcfm.v4i1.354
6
7
8
9
10 77. Ugoya SO, Echejoh GO, Ugoya TA, et al. Clinically diagnosed diabetic neuropathy:
11 frequency, types and severity. *J Natl Med Assoc* 2006;98(11):1763-6.
12 [published Online First: 2006/11/30]
13
14
15
16 78. Unachukwu C, Babatunde S, Ihekwaba AE. Diabetes, hand and/or foot ulcers: a
17 cross-sectional hospital-based study in Port Harcourt, Nigeria. *Diabetes*
18 *research and clinical practice* 2007;75(2):148-52. doi:
19 10.1016/j.diabres.2006.05.016 [published Online First: 2006/07/11]
20
21
22
23 79. Mohmad AH, Hassan A. Correlation between retinopathy, nephropathy and
24 peripheral neuropathy among adult Sudanese diabetic patients. *Sudan J Me*
25 *Sci* 2011;6(1)
26
27
28
29 80. Ahmed MH, Elwali ES, Awadalla H, et al. The relationship between diabetic
30 retinopathy and nephropathy in Sudanese adult with diabetes: population
31 based study. *Diabetes & metabolic syndrome* 2017;11 Suppl 1:S333-s36. doi:
32 10.1016/j.dsx.2017.03.011 [published Online First: 2017/03/23]
33
34
35
36 81. Albalawi HB, Alali NM, Alenezi SH, et al. The relationship between periodontitis
37 and diabetic retinopathy: A cross-sectional longitudinal study. *Australasian*
38 *Medical Journal* 2020;13:50-54.
39
40
41
42 82. Ashur ST, Shah SA, Bosseri S, et al. Glycaemic control status among type 2
43 diabetic patients and the role of their diabetes coping behaviours: a clinic-based
44 study in Tripoli, Libya. *The Libyan journal of medicine* 2016;11:31086. doi:
45 10.3402/ljm.v11.31086 [published Online First: 2016/03/24]
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 83. Assaad-Khalil SH, Zaki A, Abdel Rehim A, et al. Prevalence of diabetic foot
4 disorders and related risk factors among Egyptian subjects with diabetes.
5
6 *Primary care diabetes* 2015;9(4):297-303. doi: 10.1016/j.pcd.2014.10.010
7
8 [published Online First: 2014/12/30]
9
10
11
12 84. Khalil SA, Megallaa MH, Rohoma KH, et al. Prevalence of Chronic Diabetic
13 Complications in Newly Diagnosed versus Known Type 2 Diabetic Subjects in
14 a Sample of Alexandria Population, Egypt. *Curr Diabetes Rev* 2019;15(1):74-
15
16 83. doi: 10.2174/1573399814666180125100917 [published Online First:
17
18 2018/01/26]
19
20
21
22
23 85. Awadalla H, Noor SK, Elmadhoun WM, et al. Diabetes complications in Sudanese
24 individuals with type 2 diabetes: Overlooked problems in sub-Saharan Africa?
25
26 *Diabetes & metabolic syndrome* 2017;11 Suppl 2:S1047-s51. doi:
27
28 10.1016/j.dsx.2017.07.039 [published Online First: 2017/08/10]
29
30
31
32
33 86. Bentata Y, Chemlal A, Karimi I, et al. Diabetic kidney disease and vascular
34 comorbidities in patients with type 2 diabetes mellitus in a developing country.
35
36 *Saudi J Kidney Dis Transpl* 2015;26(5):1035-43. doi: 10.4103/1319-
37
38 2442.164602 [published Online First: 2015/09/12]
39
40
41
42 87. Bouaziz A, Zidi I, Zidi N, et al. Nephropathy following type 2 diabetes mellitus in
43 Tunisian population. *West Indian Med J* 2012;61(9):881-9. doi:
44
45 10.7727/wimj.2012.053 [published Online First: 2013/09/12]
46
47
48
49 88. Chadli A, El Aziz S, El Ansari N, et al. Management of diabetes in Morocco: results
50 of the International Diabetes Management Practices Study (IDMPS) - wave 5.
51
52 *The Adv Endocrinol Metab* 2016;7(3):101-9. doi: 10.1177/2042018816643227
53
54 [published Online First: 2016/06/14]
55
56
57
58
59
60

- 1
2
3 89. Chahbi Z, Lahmar B, Hadri SE, et al. The prevalence of painful diabetic neuropathy
4 in 300 Moroccan diabetics. *Pan Afr Med J* 2018;31:158-58. doi:
5 10.11604/pamj.2018.31.158.14687
6
7
8
9
10 90. Chetoui A, Kaoutar K, Elmoussaoui S, et al. Prevalence and determinants of poor
11 glycaemic control: a cross-sectional study among Moroccan type 2 diabetes
12 patients. *International health* 2020 doi: 10.1093/inthealth/ihz107 [published
13 Online First: 2020/01/21]
14
15
16
17
18 91. Diaf M, Khaled BM. Metabolic profile, nutritional status and determinants of
19 glycaemic control in Algerian type 2 diabetic patients. *Kuwait Medical Journal*
20 2017;49:135-41.
21
22
23
24
25 92. Elnasri HA, Ahmed AM. Patterns of lipid changes among type 2 diabetes patients
26 in Sudan. *Eastern Mediterranean Health Journal* 2008;14(2):314-24.
27
28
29
30 93. Elwali ES, Almobarak AO, Hassan MA, et al. Frequency of diabetic retinopathy
31 and associated risk factors in Khartoum, Sudan: population based study. *Int J*
32 *Ophthalmol* 2017;10(6):948-54. doi: 10.18240/ijo.2017.06.18
33
34
35
36
37 94. Kahloun R, Jelliti B, Zaouali S, et al. Prevalence and causes of visual impairment
38 in diabetic patients in Tunisia, North Africa. *Eye (Lond)* 2014;28(8):986-91. doi:
39 10.1038/eye.2014.131 [published Online First: 2014/06/14]
40
41
42
43
44 95. Megallaa MH, Ismail AA, Zeitoun MH, et al. Association of diabetic foot ulcers with
45 chronic vascular diabetic complications in patients with type 2 diabetes.
46 *Diabetes & metabolic syndrome* 2019;13(2):1287-92. doi:
47 10.1016/j.dsx.2019.01.048 [published Online First: 2019/07/25]
48
49
50
51
52
53 96. Noor SK, Elmadhoun WM, Bushara SO, et al. Glycaemic control in Sudanese
54 individuals with type 2 diabetes: Population based study. *Diabetes &*
55
56
57
58
59
60

- 1
2
3 *metabolic syndrome* 2017;11 Suppl 1:S147-S51. doi:
4
5 10.1016/j.dsx.2016.12.024
6
7
8 97. Omar SM, Musa IR, Osman OE, et al. Assessment of glycemic control in type 2
9
10 diabetes in the Eastern Sudan. *BMC Research Notes* 2018;11(1):373. doi:
11
12 10.1186/s13104-018-3480-9
13
14
15 98. Adeniyi OV, Owolabi EO. Cross-sectional study of diabetes kidney disease in the
16
17 Eastern Cape, South Africa. *Medicine (Baltimore)* 2020;99(50):e23303. doi:
18
19 10.1097/md.00000000000023303 [published Online First: 2020/12/18]
20
21
22 99. Amod A, Riback W, Schoeman H. Diabetes guidelines and clinical practice: Is
23
24 there a gap? The South African cohort of the International Diabetes
25
26 Management Practices Study. *Journal of Endocrinology, Metabolism and*
27
28 *Diabetes of South Africa* 2012;17:85-90.
29
30
31 100. Blake AM, Munby HN, Katlego PM, et al. Characteristics of patients with diabetic
32
33 retinopathy in Gaborone, Botswana. *Tanzania Journal of Health Research*
34
35 2015;17:1.
36
37
38 101. Burgess PI, Allain TJ, García-Fiñana M, et al. High prevalence in Malawi of sight-
39
40 threatening retinopathy and visual impairment caused by diabetes:
41
42 identification of population-specific targets for intervention. *Diabetic medicine :*
43
44 *a journal of the British Diabetic Association* 2014;31(12):1643-50. doi:
45
46 10.1111/dme.12492 [published Online First: 2014/05/16]
47
48
49 102. Cairncross JP, Steinberg WJ, Labuschagne MJ. Prevalence of eye pathology in
50
51 a group of diabetic patients at National District Hospital Outpatient Department
52
53 in Bloemfontein, South Africa. *Afr J Prim Health Care Fam Med* 2017;9(1):e1-
54
55 e7. doi: 10.4102/phcfm.v9i1.1440 [published Online First: 2017/10/19]
56
57
58
59
60

- 1
2
3 103. Cohen DB, Allain TJ, Glover S, et al. A survey of the management, control, and
4 complications of diabetes mellitus in patients attending a diabetes clinic in
5 Blantyre, Malawi, an area of high HIV prevalence. *Am J Trop Med Hyg*
6 2010;83(3):575-81. doi: 10.4269/ajtmh.2010.10-0104
7
8
9
10
11
12 104. Glover SJ, Burgess PI, Cohen DB, et al. Prevalence of diabetic retinopathy,
13 cataract and visual impairment in patients with diabetes in sub-Saharan Africa.
14 *The British journal of ophthalmology* 2012;96(2):156-61. doi:
15 10.1136/bjo.2010.196071 [published Online First: 2011/04/26]
16
17
18
19
20
21 105. Lewis AD, Hogg RE, Chandran M, et al. Prevalence of diabetic retinopathy and
22 visual impairment in patients with diabetes mellitus in Zambia through the
23 implementation of a mobile diabetic retinopathy screening project in the
24 Copperbelt province: a cross-sectional study. *Eye (Lond)* 2018;32(7):1201-08.
25 doi: 10.1038/s41433-018-0055-x [published Online First: 2018/03/06]
26
27
28
29
30
31
32
33 106. Machingura PI, Chikwasha V, Okwanga PN, et al. Prevalence of and Factors
34 Associated with Nephropathy in Diabetic Patients Attending an Outpatient
35 Clinic in Harare, Zimbabwe. *Am J Trop Med Hyg* 2017;96(2):477-82. doi:
36 10.4269/ajtmh.15-0827 [published Online First: 2016/12/21]
37
38
39
40
41
42 107. Makwero MT, Mollentze WF, Joubert G, et al. Anthropometric profile and
43 complications in patients with diabetes mellitus seen at Maluti Adventist
44 Hospital, Lesotho. *South African Family Practice* 2018;60:97-102.
45
46
47
48
49 108. Molefe-Baikai OJ, Molefi M, Cainelli F, et al. The prevalence of microalbuminuria
50 and associated factors among patients with type 2 diabetes mellitus in
51 Botswana. *Nigerian journal of clinical practice* 2018;21(11):1430-37. doi:
52 10.4103/njcp.njcp_224_18 [published Online First: 2018/11/13]
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
109. Mwita JC, Francis JM, Omech B, et al. Glycaemic, blood pressure and low-density lipoprotein-cholesterol control among patients with diabetes mellitus in a specialised clinic in Botswana: a cross-sectional study. *BMJ Open* 2019;9(7):e026807. doi: 10.1136/bmjopen-2018-026807 [published Online First: 2019/07/26]
110. Pirie FJ, Maharaj S, Esterhuizen TM, et al. Retinopathy in subjects with type 2 diabetes at a tertiary diabetes clinic in Durban, South Africa: Clinical, biochemical and genetic factors. *J Clin Transl Endocrinol* 2014;1(1):e9-e12. doi: 10.1016/j.jcte.2013.12.002 [published Online First: 2013/12/19]
111. Rotchford AP, Rotchford KM. Diabetes in rural South Africa--an assessment of care and complications. *S Afr Med J* 2002;92(7):536-41. [published Online First: 2002/08/29]
112. Thinyane KH, Theketsa CE. Characteristics of patients admitted with diabetes in Maseru, Lesotho. *African Journal of Diabetes Medicine* 2013;21:17-19.
113. Thomas RL, Distiller L, Luzio SD, et al. Ethnic differences in the prevalence of diabetic retinopathy in persons with diabetes when first presenting at a diabetes clinic in South Africa. *Diabetes Care* 2013;36(2):336-41. doi: 10.2337/dc12-0683 [published Online First: 2012/10/04]
114. Webb EM, Rheeder P, Van Zyl DG. Diabetes care and complications in primary care in the Tshwane district of South Africa. *Primary care diabetes* 2015;9(2):147-54. doi: 10.1016/j.pcd.2014.05.002 [published Online First: 2014/06/17]
115. Blum J, Chaney M, Mudji J, et al. Glycaemic control among patients with type 2 diabetes followed in a rural African primary care setting - A reality check in the

- 1
2
3 Democratic Republic of Congo. *Primary care diabetes* 2020;14(2):139-46. doi:
4 10.1016/j.pcd.2019.08.002 [published Online First: 2019/08/29]
5
6
7
8 116. Dzudie A, Choukem SP, Adam AK, et al. Prevalence and determinants of
9 electrocardiographic abnormalities in sub-Saharan African individuals with type
10 2 diabetes. *Cardiovasc J Afr* 2012;23(10):533-7. doi: 10.5830/cvja-2012-054
11 [published Online First: 2012/09/21]
12
13
14
15
16
17 117. Efundem NT, Assob JCN, Fetei VF, et al. Prevalence and associations of
18 microalbuminuria in proteinuria-negative patients with type 2 diabetes in two
19 regional hospitals in Cameroon: a cross-sectional study. *BMC Research Notes*
20 2017;10(1):477. doi: 10.1186/s13104-017-2804-5
21
22
23
24
25
26 118. Hall KK, Tambekou J, Penn L, et al. Association between depression, glycaemic
27 control and the prevalence of diabetic retinopathy in a diabetic population in
28 Cameroon. *S Afr J Psychiatr* 2017;23:983-83. doi:
29 10.4102/sajpsychiatry.v23i0.983
30
31
32
33
34
35 119. Jingi AM, Nansseu JR, Noubiap JJ, et al. Diabetes and visual impairment in sub-
36 Saharan Africa: evidence from Cameroon. *J Diabetes Metab Disord*
37 2015;14:21. doi: 10.1186/s40200-015-0151-4 [published Online First:
38 2015/04/14]
39
40
41
42
43
44 120. Jingi AM, Noubiap JJN, Ellong A, et al. Epidemiology and treatment outcomes of
45 diabetic retinopathy in a diabetic population from Cameroon. *BMC*
46 *Ophthalmology* 2014;14(1):19. doi: 10.1186/1471-2415-14-19
47
48
49
50
51 121. Njikam EJ, Kariuki MM, Kollmann MK, et al. The magnitude and pattern of
52 diabetic retinopathy in Yaoundé, Cameroon - a cross-sectional hospital-based
53 study. *Acta Ophthalmol* 2016;94(2):e156-7. doi: 10.1111/aos.12747 [published
54 Online First: 2015/05/29]
55
56
57
58
59
60

- 1
2
3 122. Chadli A, El Aziz S, El Ansari N, et al. Management of diabetes in Morocco:
4 results of the International Diabetes Management Practices Study (IDMPS) -
5 wave 5. *Ther Adv Endocrinol Metab* 2016;7(3):101-09. doi:
6 10.1177/2042018816643227 [published Online First: 2016/04/13]
7
8
9
10
11
12 123. Iwuala S, Olamoyegun M, Sabir A, et al. The relationship between self-monitoring
13 of blood glucose and glycaemic control among patients attending an urban
14 diabetes clinic in Nigeria. *Ann Afr Med* 2015;14(4):182-87. doi: 10.4103/1596-
15 3519.155992
16
17
18
19
20
21 124. Elnasri HA, Ahmed AM. Patterns of lipid changes among type 2 diabetes patients
22 in Sudan. *Eastern Mediterranean health journal = La revue de sante de la*
23 *Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit*
24 2008;14(2):314-24.
25
26
27
28
29
30 125. Albalawi HB, Alali NM, Alenezi SH, et al. The relationship between periodontitis
31 and diabetic retinopathy: A cross-sectional longitudinal study. *AMJ*
32 2020;13(2):50-54.
33
34
35
36
37 126. Bello A, Biliaminu S, Wahab K, et al. Distal symmetrical polyneuropathy and
38 cardiovascular autonomic neuropathy among diabetic patients in Ilorin:
39 Prevalence and predictors. *Niger Postgrad Med J* 2019;26(2):123-28. doi:
40 10.4103/npmj.npmj_30_19
41
42
43
44
45
46 127. Blake AM, Munby HN, Katlego PM, et al. Characteristics of patients with diabetic
47 retinopathy in Gaborone, Botswana. *Tanzania Journal of Health Research*
48 2015;17(1) doi: 10.4314/thrb.v17i1.
49
50
51
52
53 128. Vogt EC, Øksnes M, Suleiman F, et al. Assessment of diabetic polyneuropathy
54 in Zanzibar: Comparison between traditional methods and an automated point-
55
56
57
58
59
60

- 1
2
3 of-care nerve conduction device. *J Clin Transl Endocrinol* 2017;10:9-14. doi:
4
5 10.1016/j.jcte.2017.09.001 [published Online First: 2017/12/06]
6
7
8 129. Ali MK, Bullard KM, Saaddine JB, et al. Achievement of goals in U.S. diabetes
9
10 care, 1999-2010. *N Engl J Med* 2013;368(17):1613-24. doi:
11
12 10.1056/NEJMsa1213829 [published Online First: 2013/04/26]
13
14
15 130. Carls G, Huynh J, Tuttle E, et al. Achievement of Glycated Hemoglobin Goals in
16
17 the US Remains Unchanged Through 2014. *Diabetes Therapy* 2017;8(4):863-
18
19 73. doi: 10.1007/s13300-017-0280-5
20
21
22 131. Al Mansari A, Obeid Y, Islam N, et al. GOAL study: clinical and non-clinical
23
24 predictive factors for achieving glycemic control in people with type 2 diabetes
25
26 in real clinical practice. *BMJ Open Diabetes Research & Care*
27
28 2018;6(1):e000519. doi: 10.1136/bmjdr-2018-000519
29
30
31 132. Hu H, Hori A, Nishiura C, et al. Hba1c, Blood Pressure, and Lipid Control in
32
33 People with Diabetes: Japan Epidemiology Collaboration on Occupational
34
35 Health Study. *PLoS One* 2016;11(7):e0159071. doi:
36
37 10.1371/journal.pone.0159071 [published Online First: 2016/07/22]
38
39
40 133. Schmieder RE, Tschöpe D, Koch C, et al. Individualised treatment targets in
41
42 patients with type-2 diabetes and hypertension. *Cardiovascular Diabetology*
43
44 2018;17(1):18. doi: 10.1186/s12933-018-0661-8
45
46
47 134. Kumar KVS, Modi K. A1c, blood pressure and cholesterol goal achievement in
48
49 patients of Type 2 diabetes. *Medical Journal of Dr DY Patil University*
50
51 2016;9(2):195-99. doi: 10.4103/0975-2870.177659
52
53
54 135. Rigato M, Pizzol D, Tiago A, et al. Characteristics, prevalence, and outcomes of
55
56 diabetic foot ulcers in Africa. A systemic review and meta-analysis. *Diabetes*
57
58
59
60

- 1
2
3 *research and clinical practice* 2018;142:63-73. doi:
4
5 10.1016/j.diabres.2018.05.016 [published Online First: 2018/05/29]
6
7
8 136. Shiferaw WS, Akalu TY, Work Y, et al. Prevalence of diabetic peripheral
9
10 neuropathy in Africa: a systematic review and meta-analysis. *BMC Endocrine*
11 *Disorders* 2020;20(1):49. doi: 10.1186/s12902-020-0534-5
12
13
14
15 137. Burgess PI, MacCormick IJC, Harding SP, et al. Epidemiology of diabetic
16
17 retinopathy and maculopathy in Africa: a systematic review. *Diabetic medicine*
18 : *a journal of the British Diabetic Association* 2013;30(4):399-412. doi:
19 10.1111/j.1464-5491.2012.03756.x
20
21
22
23
24 138. Achigbu E, Agweye C, Achigbu K, et al. Diabetic Retinopathy in Sub-Saharan
25
26 Africa: A Review of Magnitude and Risk Factors. *Nigerian Journal of*
27 *Ophthalmology* 2021;29(1):3-12. doi: 10.4103/njo.njo_49_20
28
29
30
31 139. Noubiap JJN, Naidoo J, Kengne AP. Diabetic nephropathy in Africa: A systematic
32
33 review. *World J Diabetes* 2015;6(5):759-73. doi: 10.4239/wjd.v6.i5.759
34
35
36 140. Johnston LE, Stewart BT, Yangni-Angate H, et al. Peripheral Arterial Disease in
37
38 Sub-Saharan Africa: A Review. *JAMA Surg* 2016;151(6):564-72. doi:
39 10.1001/jamasurg.2016.0446 [published Online First: 2016/04/07]
40
41
42 141. So WY, Raboca J, Sobrepena L, et al. Comprehensive risk assessments of
43
44 diabetic patients from seven Asian countries: The Joint Asia Diabetes
45 Evaluation (JADE) program. *J Diabetes* 2011;3(2):109-18. doi: 10.1111/j.1753-
46 0407.2011.00115.x [published Online First: 2011/05/24]
47
48
49
50
51 142. Fang M, Selvin E. Thirty-Year Trends in Complications in U.S. Adults With Newly
52
53 Diagnosed Type 2 Diabetes. *Diabetes Care* 2021;44(3):699-706. doi:
54 10.2337/dc20-2304 [published Online First: 2021/01/10]
55
56
57
58
59
60

- 1
2
3 143. Beran D, Yudkin JS, de Courten M. Access to care for patients with insulin-
4 requiring diabetes in developing countries: case studies of Mozambique and
5 Zambia. *Diabetes Care* 2005;28(9):2136-40. doi: 10.2337/diacare.28.9.2136
6
7 [published Online First: 2005/08/27]
8
9
10
11
12 144. Beran D, Yudkin JS. Looking beyond the issue of access to insulin: what is
13 needed for proper diabetes care in resource poor settings. *Diabetes research*
14 *and clinical practice* 2010;88(3):217-21. doi: 10.1016/j.diabres.2010.03.029
15
16 [published Online First: 2010/05/08]
17
18
19
20
21 145. Kibirige D, Atuhe D, Kampiire L, et al. Access to medicines and diagnostic tests
22 integral in the management of diabetes mellitus and cardiovascular diseases in
23 Uganda: insights from the ACCODAD study. *International Journal for Equity in*
24 *Health* 2017;16(1):154. doi: 10.1186/s12939-017-0651-6
25
26
27
28
29
30
31 146. Jingi AM, Noubiap JJ, Ewane Onana A, et al. Access to diagnostic tests and
32 essential medicines for cardiovascular diseases and diabetes care: cost,
33 availability and affordability in the West Region of Cameroon. *PLoS One*
34 2014;9(11):e111812. doi: 10.1371/journal.pone.0111812 [published Online
35
36
37
38
39
40
41 First: 2014/11/05]
42
43 147. Mendis S, Al Bashir I, Dissanayake L, et al. Gaps in capacity in primary care in
44 low-resource settings for implementation of essential noncommunicable
45 disease interventions. *Int J Hypertens* 2012;2012:584041. doi:
46
47
48
49
50
51
52 148. WHO. WHO. The Abuja Declaration: Ten Years On.
53 <https://www.who.int/healthsystems/publications/Abuja10pdf> (accessed on 8
54
55
56
57
58
59
60 October 2021) 2011

Table 1. General characteristics of all participants (n=63,890) included in the systematic review and meta-analysis

Characteristic	Cumulative value	Number of studies
Mean \pm SD age, years	54.9 \pm 4.7	88
Gender-Females (% , 95% CI)	55.3 (95% CI 52.7-57.8)	101
Smokers, (% ,95% CI)	9.9 (95% CI 0.5-55.6)	44
Participants on OHA, (% ,95% CI)	65 (95% CI 34-96.6)	51
Participants on insulin, (% ,95% CI)	31.3 (95% CI 26.3-36.2)	52
Participants on lipid lowering agents, (% ,95% CI)	25.7 (95% CI 0.5-86.7)	14
Participants on anti-hypertensive agents, (% ,95% CI)	73.3 (95% CI 64.1-82.5)	18
Mean \pm SD, BMI, kg/m ²	27.9 \pm 0.5	40
Mean \pm SD, HbA1c, %	9 \pm 1.5	40
Mean \pm SD, HbA1c, mmol/mol	75 \pm 1.5	40

BMI- Body mass index, HbA1c- Glycated haemoglobin, OHA- Oral hypoglycaemic agents, SD- Standard deviation

Table 2. Indicators of optimal glycated haemoglobin goal

Optimal glycated haemoglobin (HbA1c) goal (n= 34 studies)
Pooled rate of attainment of optimal HbA1c goal = 27% (95% CI 24-30, I²=94.7% and I² after meta-regression-56.3%)

Author & year	Country (ies)	Region of Africa	No of study participants	Mean age of participants	% of females	% with optimal HbA1c
Megallaa et al, 2019	Egypt	Northern	180		24.4	4.4
Muddu et al. 2019	Uganda	Eastern	175	46	48.6	8.1
Muddu et al., 2016	Uganda	Eastern	202	46	49.5	8.4
Amour et al, 2019	Tanzania	Eastern	238	57.2	65.7	9.2
Blum et al 2020	DRC	Central	319		33.5	14.1
Noor et al., 2016	Sudan	Northern	387		49.6	15
Awadalla et al, 2017	Sudan	Northern	424		49.3	15.6
Agboghroma et al, 2020	Nigeria	Western	200			19.0
Mwebaze et al 2014	Uganda	Eastern	146	53.9	48.6	19.2
Ashur et al 2016	Libya	Northern	523	54.4	47	21.8
Kisozi et al 2017	Uganda	Eastern	288	48.5	38	23.3
Camara et al 2015	Cameroon and Guinea Conakry	Central and Western	1267	58	61	26
Kibirige et al 2017	Uganda	Eastern	425		67	26.5
Chadli et al. 2016	Morocco	Northern	498	58	62.4	26.8
Hall et al, 2017	Cameroon	Central	261	56	56.3	27.2
Omara et al 2018	Sudan	Northern	339	54.8	69.9	28.1
Sobngwi et al 2011	Tanzania, Kenya, Cameroon, Ghana, Senegal, and Nigeria	Eastern, Western, Central	2352	53	61.1	29.2
Molefe-Baikai et al, 2018	Botswana	Southern	289	50.7	66.1	29.4
Bentata et al, 2015	Morocco	Northern	637	58.5	62.3	30.1
Amod et al 2012	South Africa	Southern	701	57.4	43.9	30.4
Cairncross et al, 2017	South Africa	Southern	203		72.5	31.3
Mwita et al 2019	Botswana	Southern	500	58.9	66	32.3
Uloko et al., 2012	Nigeria	Western	531	57.1	60.5	32.4
Chetoui et al 2019	Morocco	Northern	1456	56.2	73.4	33.7
Attoye et al 2020	Nigeria	Western	260			34.62
Cohen DB et al 2010	Malawi	Southern	620	52.2	60.1	36
Chamba et al 2017	Tanzania	Eastern	119	58.1	49.6	39.3
Kimando et al 2017	Kenya	Eastern	385	62.1	65.5	39.5
Akalu et al 2020	Ethiopia	Eastern	378		38.6	40.7
Iwuala et al 2015	Nigeria	Western	100	59.9	62	45
Mbwete et al., 2020	Tanzania	Eastern	161	63.9	67.1	49.7
Diab et al 2017	Algeria	Northern	210	55.6	65	51.4
Adentunji et al 2006	Nigeria	Western	50			52
Balogun et al 2011	Nigeria	Western	40	59.4	62.5	52.5

Table 3. Indicators of optimal blood pressure goal

6 **Optimal blood pressure goal (n=26 studies)**
7 Pooled rate of attainment of optimal blood pressure goal = 38% (95% CI 30-46, I²=98.7% and I² after meta-
8 regression-95.4%)

9 Author & year	10 Country (ies)	11 Region of Africa	12 No of study participants	13 Mean age of participants	14 % of females	15 % with optimal BP
16 Mwebaze et al 2014	Uganda	Eastern	146	53.9	48.6	1.5
17 Rotchford et al., 2002	South Africa	Southern	253	56.5	73.1	14
18 Uloko et al., 2012	Nigeria	Western	531	57.1	60.5	17
19 Chadli et al. 2016	Morocco	Northern	498	58	62.4	20.2
20 Sobngwi et al 2011	Tanzania, Kenya, Cameroon, Ghana, Senegal, and Nigeria	Eastern, Western, Central	2352	53	61.1	21
21 Amour et al, 2019	Tanzania	Eastern	238	57.2	65.7	21.7
22 Onakpoya et al, 2015	Nigeria	Western	133		48.1	24.1
23 Agboghroma et al, 2020	Nigeria	Western	200			30.0
24 Abdissa et al, 2020	Ethiopia	Eastern	229		40.4	31
25 Chahbi et al, 2018	Morocco	Northern	300		93	32.6
26 Magan et al, 2019	Uganda	Eastern	44	50.4	63.4	34.1
27 Megallaa et al, 2019	Egypt	Northern	180		24.4	37.8
28 Hayfron-Benjamin et al, 2019	Ghana	Western	206	52.9	68.9	37.9
29 Muddu et al., 2016	Uganda	Eastern	202	46	49.5	38.1
30 Jingi et al, 2015	Cameroon	Central	407	54.2	41.8	40.4
31 Hall et al, 2017	Cameroon	Central	261	56	56.3	43
32 Lewis et al, 2018	Zambia	Southern	921	56	45	46.6
33 Cohen DB et al 2010	Malawi	Southern	620	52.2	60.1	48
34 Kimando et al 2017	Kenya	Eastern	385	62.1	65.5	50.4
35 Mwitwa JC et al 2019	Botswana	Southern	500	58.9	66	54.2
36 Lumu et al 2017	Uganda	Eastern	425	52.2	67	54.7
37 Balogun et al 2011	Nigeria	Western	40	59.4	62.5	55
38 Akalu et al 2020	Ethiopia	Eastern	378		38.6	57.7
39 Awadalla et al, 2017	Sudan	Northern	424		49.3	60.1
40 Kahloun et al, 2014	Tunisia	Northern	2320	54.5	60.2	62.5
41 Chisha et al 2017	Ethiopia	Eastern	270		48.9	85.9

Table 4. Indicators of optimal LDLC goal

6 **Optimal LDLC goal (n= 11 studies)**
7 Pooled rate of attainment of optimal LDLC goal = 42% (95% CI 32-52, I²=97.4% and I² after meta-regression-
8 92.1%)

9 Author & year	10 Country (ies)	11 Region of Africa	12 No of study participants	13 Mean age of participants	14 % of females	15 % with optimal LDLC
16 Mwita et al 2019	Botswana	Southern	500	58.9	66	20.4
17 Amour et al, 2019	Tanzania	Eastern	238	57.2	65.7	26
18 Chamba et al 2017	Tanzania	Eastern	119	58.1	49.6	27.7
19 Kisozi et al 2017	Uganda	Eastern	288	48.5	38	37.0
20 Megallaa et al, 2019	Egypt	Northern	180		24.4	37.8
21 Chadli et al. 2016	Morocco	Northern	498	58	62.4	38.6
22 Lumu et al 2017	Uganda	Eastern	425	52.2	67	38.9
23 Awadalla et al, 2017	Sudan	Northern	424		49.3	47.4
24 Mwebaze et al 2014	Uganda	Eastern	146	53.9	48.6	48.6
25 Agboghroma et al, 2020	Nigeria	Western	200			50.5
26 Elnasri et al. 2008	Sudan	Northern	250	52	62	84.8

Table 5. Burden of diabetic nephropathy

Burden of diabetic nephropathy (n= 40 studies)
Pooled prevalence= 31% (95% CI 22-41, I²=99.3% and I² after meta-regression-95.6%)

Author & year	No of study participants	Country (ies)	Region of Africa	Mean age of participants	% of females	Prevalence of nephropathy, %
Abejew et al, 2015	216	Ethiopia	Eastern	45	42.6	2.2
Sobngwi et al 2011	2352	Tanzania, Kenya, Cameroon, Ghana, Senegal, and Nigeria	Eastern, Western, Central	53	61.1	2.4
Uloko et al, 2012	531	Nigeria	Western	57.1	60.5	3.2
Kahloun et al, 2014	2320	Tunisia	Northern		60.2	3.4
Fasil, et al 2019	367	Ethiopia	Eastern	48.6	59.3	4.4
Thinyane et al 2013	80	Lesotho	Southern	49	49	6.0
Tesfaye et al 2015	247	Ethiopia	Eastern		40.5	6.5
Makwero et al 2018	150	Lesotho	Southern	58.2	80.7	6.7
Neuhann et al 2001	474	Tanzania	Eastern	53.8	46	7.5
Deribe et al, 2014	216	Ethiopia	Eastern	50.7	40.3	8.8
Bouaziz et al 2012	73	Tunisia	Northern	59.3		11.0
Lebeta et al, 2017	344	Ethiopia	Eastern	40.5	42.7	11.4
Efundem et al, 2017	162	Cameroon	Central	55.3	67.3	14.2
Worku et al 2010	305	Ethiopia	Eastern	44.4	37.1	15.7
Dzudie et al 2012	420	Cameroon	Central	56.7	51	15.9
Adeniyi et al, 2020	327	South Africa	Southern		70.3	24.5
Goro et al, 2019	208	Ethiopia	Eastern	54.8	47.1	26
Chahbi et al, 2018	300	Morocco	Northern		93	26.3
Albalawi et al 2020	159	Sudan	Northern	58.1	65.4	26.4
Alebiosu et al 2013	342	Nigeria	Western	53.4		28.4
Hayfron-Benjamin et al, 2019	206	Ghana	Western	52.9	68.9	32
Khalil et al 2019	506	Egypt	Northern			33.2
Cohen et al 2010	620	Malawi	Southern	52.2	60.1	34.7
Blum et al 2020	319	DRC	Central		33.5	38.6
Ahmed et al, 2017	316	Sudan	Northern	58	41.5	40.2
Eghan-Jr et al 2007	109	Ghana	Western	54.1	75	43.0
Molefe-Baikai et al, 2018	289	Botswana	Southern	50.7	66.1	44.6
Machingura et al, 2017	260	Zimbabwe	Southern	57.6	72.7	45.4
Rotchford et al., 2002	253	South Africa	Southern	56.5	73.1	46.4
Muddu et al. 2019	175	Uganda	Eastern	46	48.6	47.4
Mohmad et al 2011	71	Sudan	Central		42	50.7
Gill et al 2008	105	Ethiopia	Eastern	41	30	51
Bello et al, 2017	358	Nigeria	Western	57.8	61.7	53.4
Olamoyegun et al, 2015	90	Nigeria	Western	62.5	50	54.3
Amour et al 2019	315	Tanzania	Eastern	57.2	65.7	72.2
Bentata et al, 2015	637	Morocco	Northern	58.5	62.3	77.2

1
2

Adentunji et al 2006	50	Nigeria	Western			83
Janmohamed et al 2013	369	Tanzania	Eastern	54	53.4	83.7
Megallaa et al, 2019	180	Egypt	Northern		24.4	86.1
Balogun et al 2011	40	Nigeria	Western	59.4	62.5	90

9
10
11**Table 6. Burden of diabetic peripheral neuropathy**

Burden of diabetic peripheral neuropathy (n=36 studies)						
Pooled prevalence= 38% (95% CI 31-45, I ² =98.2% and I ² after meta-regression-88%)						
Author & year	No of study participants	Country (ies)	Region of Africa	Mean age of participants	% of females	Prevalence of neuropathy, %
Seyum et al 2010	429	Eritrea	Eastern	57.4		4
Ebeta et al, 2017	344	Ethiopia	Eastern	40.5	42.7	7.7
Fasil, et al 2019	367	Ethiopia	Eastern	48.6	59.3	7.9
Miriam et al, 2017	279	Ethiopia	Eastern	48.8	44.8	10
Tesfaye et al 2015	247	Ethiopia	Eastern		40.5	10.1
Deribe et al, 2014	216	Ethiopia	Eastern	50.7	40.3	10.6
Abejew et al, 2015	216	Ethiopia	Eastern	45	42.6	14.4
Kahloun et al, 2014	2320	Tunisia	Northern		60.2	18.7
Khalil et al 2019	506	Egypt	Northern			20.0
Dzudie et al 2012	420	Cameroon	Central	56.7	51	22.4
Tilahun et al, 2017	236	Ethiopia	Eastern	47.8	46.6	25.4
Assaad-Khalil et al 2014	958	Egypt	Northern	57.3	50	29.3
Kisozi et al 2017	288	Uganda	Eastern	48.5	38	29.4
Worku et al 2010	305	Ethiopia	Eastern	44.4	37.1	29.5
Smide et al 2009	145	Tanzania	Eastern	46	48	30
Kuate-Tegueu et al 2016	321	Cameroon	Western	59.8	64.1	33.3
Bentata et al, 2015	637	Morocco	Northern	58.5	62.3	39.6
Albalawi et al 2020	159	Sudan	Northern	58.1	65.4	40.3
Gill et al 2008	105	Ethiopia	Eastern	41	30	41
Bello et al 2019	175	Nigeria	Western	59.8	57.7	41.7
Makwero et al 2018	150	Lesotho	Southern	58.2	80.7	43.3
Chiwanga et al, 2015	404	Tanzania	Eastern	53.6	55.4	44
Neuhann et al 2001	474	Tanzania	Eastern	53.8	46	44.0
Vogt et al 2017	100	Zanzibar	Eastern	54	49	45.0
Ekoru K et al. 2019	2784	Nigeria, Ghana, Kenya	Western and Eastern	56	61	46
Cohen et al 2010	620	Malawi	Southern	52.2	60.1	46.4
Sobngwi et al 2011	2352	Tanzania, Kenya, Cameroon, Ghana, Senegal, and Nigeria	Eastern, Western, Central	53	61.1	48.4
Jember et al 2017	368	Ethiopia	Eastern	49	41.6	52.2
Uloko et al, 2012	531	Nigeria	Western	57.1	60.5	59.2
Awadalla et al 2017	424	Sudan	Northern		49.3	68.2

57
58
59
60

1

2

3	Mohmad et al 2011	71	Sudan	Central		42	69.0
4	Olamoyegun et al, 2015	90	Nigeria	Western	62.5	50	69.6
5	Ugoya et al 2006	180	Nigeria	Western	53	51.6	75
6	Jarso et al 2011	384	Ethiopia	Eastern		54.1	77.0
7	Megallaa et al, 2019	180	Egypt	Northern		24.4	82
8	Ede et al 2018	90	Nigeria	Western	58.6	34.4	83.3

10

11

12

Table 7. Burden of diabetic retinopathy

13

Burden of diabetic retinopathy (n= 51 studies)							
Pooled prevalence= 32% (95% CI 28-36, I ² =98% and I ² after meta-regression-88.5%)							
Author & year	No of study participants	Country (ies)	Region of Africa	Mean age of participants	% of females	Prevalence of retinopathy, %	
14	Makwero et al 2018	150	Lesotho	Southern	58.2	80.7	4.7
15	Hayfron-Benjamin et al, 2019	206	Ghana	Western	52.9	68.9	11.0
16	Tesfaye et al 2015	247	Ethiopia	Eastern		40.5	11.7
17	Chisha et al 2017	270	Ethiopia	Eastern		48.9	13.0
18	Neuhann et al 2001	474	Tanzania	Eastern	53.8	46	14.0
19	Ekoru K et al. 2019	2784	Nigeria, Ghana, Kenya	Western and Eastern	56	61	15.0
20	Lartey et al, 2018	208	Ghana	Western	57.5	70.7	15.5
21	Dzudie et al 2012	420	Cameroon	Central	56.7	51	15.7
22	Blake et al 2015	1307	Botswana	Southern	55	67.9	17.7
23	Fasil, et al 2019	367	Ethiopia	Eastern	48.6	59.3	17.7
24	Sobngwi et al 2011	2352	Tanzania, Kenya, Cameroon, Ghana, Senegal, and Nigeria	Eastern, Western, and Central	53	61.1	18.3
25	Magan et al, 2019	44	Uganda	Eastern	50.4	63.4	19.5
26	Bello et al, 2017	358	Nigeria	Western	57.8	61.7	20.1
27	Tilahun et al, 2017	236	Ethiopia	Eastern	47.8	46.6	20.3
28	Thomas et al 2013	3978	South Africa	Southern	56.8	33.3	20.5
29	Gill et al 2008	105	Ethiopia	Eastern	41	30	21.0
30	Webb et al 2016	599	South Arica	Southern	57.8	68	24.9
31	Lebeta et al, 2017	344	Ethiopia	Eastern	40.5	42.7	25.5
32	Kahloun et al, 2014	2320	Tunisia	Northern		60.2	26.3
33	Bouaziz et al 2012	73	Tunisia	Northern	59.3		27.0
34	Hall et al, 2017	261	Cameroon	Central	56	56.3	27.2
35	Onakpoya et al, 2015	133	Nigeria	Western		48.1	27.8
36	Cleland et al, 2015	5729	Tanzania	Eastern	60.8	60.3	27.9
37	Abejew et al, 2015	216	Ethiopia	Eastern	45	42.6	28.9

60

1

2

3	Kizor-Akarairwe et al	80	Nigeria	Western	61.2	48.8	32.1
4	2018						
5	Glover et al 2011	281	Malawi	Southern	56.4	72.8	32.5
6							
7	Seyum et al 2010	429	Eritrea	Eastern	57.4		33
8	Bello et al 2019	175	Nigeria	Western	59.8	57.7	33.1
9	Worku et al 2010	305	Ethiopia	Eastern	44.4	37.1	33.8
10	Chahbi et al, 2018	300	Morocco	Northern		93	34.3
11							
12	Albalawi et al 2020	159	Sudan	Northern	58.1	65.4	34.6
13	Assaad-Khalil et al	506	Egypt	Northern			34.6
14	2019						
15	Cohen et al 2010	620	Malawi	Southern	52.2	60.1	34.7
16							
17	Thinyane et al 2013	80	Lesotho	Southern	49	49	35.0
18	Uloko et al, 2012	531	Nigeria	Western	57.1	60.5	35.5
19	Bentata et al, 2015	637	Morocco	Northern	58.5	62.3	35.6
20	Jingi et al, 2014	407	Cameroon	Central	54.2	41.8	38.8
21							
22	Pirie et al, 2014	292	South Africa	Southern	59.2	79	39.0
23							
24	Ahmed et al, 2017	316	Sudan	Northern	58	41.5	39.8
25	Jingi et al, 2015	407	Cameroon	Central		41.8	40.3
26							
27	Rotchford et al., 2002	253	South Africa	Southern	56.5	73.1	40.3
28							
29	Woodward et al, 2020	91	Tanzania	Eastern	59.2	62.6	42.9
30	Lewis et al, 2018	921	Zambia	Southern	56	45	44.0
31	Olamoyegun et al, 2015	90	Nigeria	Western	62.5	50	48.9
32	Njikam et al, 2016	371	Cameroon	Central	59.2	54.7	49.9
33							
34	Burgess et al 2014	322	Malawi	Southern	55.2	64.6	50.1
35	Mohmad et al 2011	71	Sudan	Central		42	71.2
36	Awadalla et al 2017	424	Sudan	Northern		49.3	72.6
37							
38	Elwali et al 2017	316	Sudan	Northern	58.7	40.8	82.6
39	Megallaa et al, 2019	180	Egypt	Northern		24.4	90.0

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

Table 8. Burden of diabetic foot ulcers**Burden of diabetic foot ulcers (n= 29 studies)**Pooled prevalence= 11% (95% CI 9-14, I²=97.4% and I² after meta-regression-1.4%)

Author & year	No of study participants	Country (ies)	Region of Africa	Mean age of participants	% of females	Prevalence of foot ulcers, %
Tesfaye et al 2015	247	Ethiopia	Eastern		40.5	0.4
Albalawi et al 2020	159	Sudan	Northern	58.1	65.4	2.5
Chalya et al, 2011 105	136	Tanzania	Eastern	54.3	45.6	3.2
Uloko et al, 2012	531	Nigeria	Western	57.1	60.5	3.8
Abejew et al, 2015	216	Ethiopia	Eastern	45	42.6	4.4
Nyamu et al, 2003	1788	Kenya	Eastern	56.9		4.6
Worku et al 2010	305	Ethiopia	Eastern	44.4	37.1	4.6
Ekoru K et al. 2019	2784	Nigeria, Ghana, Kenya	Western and Eastern	56	61	5
Rotchford et al., 2002	253	South Africa	Southern	56.5	73.1	6
Assaad-Khalil et al 2014	958	Egypt	Northern	57.3	50	6.1
Tilahun et al, 2017	236	Ethiopia	Eastern	47.8	46.6	8.5
Amour et al 2019	315	Tanzania	Eastern	57.2	65.7	10.0
Neuhann et al 2001	474	Tanzania	Eastern	53.8	46	10.0
Sobngwi et al 2011	2352	Tanzania, Kenya, Cameroon, Ghana, Senegal, and Nigeria	Eastern, Western, Central	53	61.1	11.7
Abbas et al, 2011	11866	Tanzania	Eastern			12
Gebre Kirstos et al, 2015	228	Ethiopia	Eastern		38	12
Abdissa et al, 2020	229	Ethiopia	Eastern		40.4	12.7
Awadalla et al 2017	424	Sudan	Northern		49.3	12.7
Mariam et al, 2017	279	Ethiopia	Eastern	48.8	44.8	13.6
Seyum et al 2010	429	Eritrea	Eastern	57.4		14
Thinyane et al 2013	80	Lesotho	Southern	49	49	14
Deribe et al, 2014	216	Ethiopia	Eastern	50.7	40.3	14.8
Abbas et al, 2002	627	Tanzania	Eastern	53	35	15
Chiwanga et al, 2015	404	Tanzania	Eastern	53.6	55.4	15
Mamo et al, 2015	200	Ethiopia	Eastern	50	72.5	15
Elwali et al 2017	316	Sudan	Northern	58.7	40.8	17.7
Unachukwu et al, 2006	315	Nigeria	Western	54.6	36.7	19.1
Lebeta et al, 2017	344	Ethiopia	Eastern	40.5	42.7	21.2
Megallaa et al, 2019	180	Egypt	Northern		24.4	86.7

Table 9. Burden of peripheral arterial disease

Burden of Peripheral arterial disease (n= 18 studies)
Pooled prevalence= 19% (95% CI 12-25, I²=98.1% and I² after meta-regression-70.9%)

Author & year	No of study participants	Country (ies)	Region of Africa	Mean age of participants	% of females	Prevalence of PAD, %
Chahbi et al, 2018	300	Morocco	Northern		93	2.7
Sobngwi et al 2011	2352	Tanzania, Kenya, Cameroon, Ghana, Senegal, and Nigeria	Eastern, Western, Central	53	61.1	4.7
Gill et al 2008	105	Ethiopia	Eastern	41	30	6
Cohen et al 2010	620	Malawi	Southern	52.2	60.1	7.6
Mariam et al, 2017	279	Ethiopia	Eastern	48.8	44.8	9.7
Uloko et al, 2012	531	Nigeria	Western	57.1	60.5	10.7
Assaad-Khalil et al 2014	958	Egypt	Northern	57.3	50	11.0
Hayfron-Benjamin et al, 2019	206	Ghana	Western	52.9	68.9	11.2
Smide et al 2008	145	Tanzania	Eastern	46	48	13
Chiwanga et al, 2015	404	Tanzania	Eastern	53.6	55.4	15
Megallaa et al, 2019	180	Egypt	Northern		24.4	20
O'kello et al 2014	229	Uganda	Eastern	60	63.7	24.0
Akalu et al, 2020	280	Ethiopia	Eastern		38.6	30.7
Khalil et al 2019	506	Egypt	Northern			32.6
Agboghroma et al, 2020	200	Nigeria	Western			38.5
Mwebaze et al 2014	146	Uganda	Eastern	53.9	48.6	39.0
Ogbera et al 2015	225	Nigeria	Western	61.4	57	40.0
Oyelade et al 2012	219	Nigeria	Western		58.9	52.5

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1. PRISMA flow diagram of selection of eligible studies




Figure 2. Forest plot summarising studies on proportion of attainment of an optimal low-density lipoprotein cholesterol goal in percentage




Figure 3. Forest plot summarising studies on proportion of attainment of an optimal blood pressure goal in percentage




Figure 4. Forest plot summarising studies on proportion of attainment of an optimal glycated haemoglobin goal in percentage





Figure 5. Forest plot summarising studies on prevalence of diabetic retinopathy



BMJ Open: first published as 10.1136/bmjopen-2022-060786 on 8 November 2022. Downloaded from <http://bmjopen.bmj.com/> on April 23, 2024 by guest. Protected by copyright.

Figure 6. Forest plot summarising studies on prevalence of diabetic foot ulcers




Figure 7. Forest plot summarising studies on prevalence of diabetic nephropathy






Figure 8. Forest plot summarising studies on prevalence of diabetic neuropathy




BMJ Open: first published as 10.1136/bmjopen-2022-060786 on 8 November 2022. Downloaded from <http://bmjopen.bmj.com/> on April 23, 2024 by guest. Protected by copyright.

Figure 9. Forest plot summarising studies on prevalence of peripheral arterial disease




Supplementary figure 1.


Funnel plot for studies investigating prevalence of diabetic nephropathy




Funnel plot for studies investigating prevalence of diabetic neuropathy



Funnel plot for studies investigating prevalence of peripheral arterial disease




Funnel plot for studies investigating prevalence of diabetic retinopathy



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Funnel plot for studies investigating prevalence of diabetic foot ulcers




review only

Supplementary figure 2.


Funnel plot for studies investigating rate of attainment of an optimal HbA1c goal



Funnel plot for studies investigating rate of attainment of an optimal BP goal



Funnel plot for studies investigating rate of attainment of an optimal LDLC goal



Supplementary table 1. PRISMA checklist for the systematic review and meta-analysis

Section and Topic	Item #	Checklist item	Page where item is reported
TITLE			
Title	1	Identify the report as a systematic review.	1
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	5-6
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	6
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	7-8
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	6
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	6-7
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	7-8
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	8
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	8-9
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	9
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	9
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	9
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	9
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	9
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	9
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity,	9

Section and Topic	Item #	Checklist item	Page where item is reported
		and software package(s) used.	
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	9-10
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	Not done
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	11
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	11
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	10
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	10
Study characteristics	17	Cite each included study and present its characteristics.	10-11
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	11
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	11-13
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	11
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	11-13
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	Not done
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	Not done
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	13
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	13
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	13-16
	23b	Discuss any limitations of the evidence included in the review.	16
	23c	Discuss any limitations of the review processes used.	16
	23d	Discuss implications of the results for practice, policy, and future research.	17
OTHER INFORMATION			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	6
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	Protocol was not prepared
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	Search period was changed from September 2020 to December 2020
Support	25	Describe sources of financial or non-financial support for the review, and	17

Section and Topic	Item #	Checklist item	Page where item is reported
		the role of the funders or sponsors in the review.	
Competing interests	26	Declare any competing interests of review authors.	17
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	17

For peer review only

Supplementary table 2. Criteria for the adapted Newcastle-Ottawa Scale regarding star allocation to assess quality of included studies

Study details (Author et al, year)	Selection				Comparability (**)	Outcome		
	Representativeness of sample (*)	Sample size (*)	Non respondents (*)	Ascertainment of exposure (*)		Assessment of outcome (*)	Statistical test (*)	Total (8*)
Mariam et al, 2017	*	*	*	*	**	*	*	8
Okello et al, 2014	*	*	*	*	**	*	*	8
Amour et al, 2019	*	*	*	*	**	*	*	8
Abdissa et al, 2019	*	*	*	*	**	*	*	8
Fasil et al, 2019	*	*	*	*	**	*	*	8
Jember et al, 2017	*	*	*	*	**	*	*	8
Chisha et al, 2017	*	*	*	*	**	*	*	8
Deribe et al, 2014	*	*	*	*	**	*	*	8
Seyum et al, 2008	*	*	*	*	**	*	*	8
Muddu et al, 2019	*	*	*	*	**	*	*	8
Mamo et al., 2015	*	*	*	*	**	*	*	8
Muddu et al., 2019	*	*	*	*	**	*	*	8
Blake et al., 2015	*	*	*	*	**	*	*	8
Bello et al., 2019	*	*	*	*	**	*	*	8
Elnasri et al., 2008	*	*	*	*	**	*	*	8
Iwuala et al., 2015	*	*	*	*	**	*	*	8
Chadli et al., 2016	*	*	*	*	**	*	*	8
Jingi et al., 2014	*	*	*	*	**	*	*	8
Hall et al., 2017	*	*	*	*	**	*	*	8
Efundem et al., 2017	*	*	*	*	**	*	*	8
Attoye et al., 2020	*	*	*	*	**	*	*	8
Chetoui et al., 2020	*	*	*	*	**	*	*	8
Diaf et al., 2017	*	*	*	*	**	*	*	8
Elwali et al., 2017	*	*	*	*	**	*	*	8
Kahloun et al., 2014	*	*	*	*	**	*	*	8
Noor et al., 2017	*	*	*	*	**	*	*	8
Bello et al., 2017	*	*	*	*	**	*	*	8
Uloko et al., 2012	*	*	*	*	**	*	*	8
Ede et al., 2018	*	*	*	*	**	*	*	8

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Hayfron-Benjamin et al., 2019	*	*	*	*	**		*	8
Kizor-Akaraiwe et al., 2016	*	*	*	*	**		*	8
Ogbera et al., 2015	*	*	*	*	**		*	8
Olamoyegun et al., 2015	*	*	*	*	**		*	8
Oyelade et al., 2012	*	*	*	*	**		*	8
Ugoya et al., 2006	*	*	*	*	**		*	8
Ahmed et al., 2017	*	*	*	*	**		*	8
Albalawi et al., 2020	*	*	*	*	**		*	8
Ashur et al., 2016	*	*	*	*	**		*	8
Blum et al., 2020	*	*	*	*	**		*	8
Burgess et al., 2014	*	*	*	*	**		*	8
Glover et al., 2012	*	*	*	*	**		*	8
Lewis et al., 2018	*	*	*	*	**		*	8
Machingura et al., 2017	*	*	*	*	**		*	8
Molefe-Baikai et al., 2018	*	*	*	*	**		*	8
Mwita et al., 2019	*	*	*	*	**		*	8
Pirie et al., 2014	*	*	*	*	**		*	8
Rotchford et al., 2002	*	*	*	*	**		*	8
Thomas et al., 2013	*	*	*	*	**		*	8
Webb et al., 2015	*	*	*	*	**		*	8
Omar et al., 2018	*	*	*	*	**		*	8
Adeniyi et al., 2020	*	*	*	*	**		*	8
Assaad-Khalil et al., 2015	*	*	*	*	**		*	8
Khalil et al., 2019	*	*	*	*	**		*	8
Awadalla et al., 2017	*	*	*	*	**		*	8
Bentata et al., 2015	*	*	*	*	**		*	8
Bouaziz et al., 2012	*	*	*	*	**		*	8
Jingi et al., 2015	*	*	*	*	**		*	8

For peer review only - http://bmjopen.bmj.com/

bmjopen-2022-06-1786 on 8 November 2022. Downloaded from http://bmjopen.bmj.com/ on April 23, 2024 by guest. Protected by copyright.

1									
2									
3	Chahbi et al., 2018	*	*	*	*	**	*	8	
4	Adetunji et al., 2006	*	*	*	*	**	*	8	
5	Jarso et al., 2011	*	*	*	*	**	*	8	
6	Janmohamed et al, 2013	*	*	*	*	*	*	7	
7									
8	Chalya et al, 2011	*	*	*	*	*	*	7	
9	Goro et al, 2019	*	*	*	*	*	*	7	
10	Muddu et al, 2016	*	*	-	*	**	*	7	
11	Kisozi et al, 2017	*	*	*	*	*	*	7	
12	Akalu et al, 2020	*	*	*	*	*	*	7	
13	Lumu et al, 2017	*	*	*	*	*	*	7	
14	Chamba et al, 2017	*	*	-	*	**	*	7	
15	Smide et al, 2008	*	-	*	*	**	*	7	
16	Sobngwi et al 2011	*	-	*	*	**	*	7	
17	Camara et al, 2014	*	-	*	*	**	*	7	
18	Ekoru et al,2019	*	-	*	*	**	*	7	
19	Mwebaze et al, 2014	*	*	*	*	*	*	7	
20	Agboghoroma et al,2020	*	*	*	*	*	*	7	
21									
22	Kimando et al, 2017	*	*	-	*	**	*	7	
23	Clealand et al, 2015	*	*	*	*	*	*	7	
24	Njikam et al., 2016	*	*	-	*	**	*	7	
25	Dzudie et al., 2012	*	*	*	-	**	-	7	
26	Alebiosu et al., 2003	*	*	-	*	**	*	7	
27	Kuate-Tegueu et al., 2015	*	*	-	*	**	*	7	
28									
29	Mohmad et al., 2011	*	*	-	*	**	*	7	
30	Cohen et al., 2010	*	*	-	*	**	*	7	
31	Makwero et al., 2018	*	*	-	*	**	*	7	
32	Onakpoya et al., 2016	*	-	-	*	**	*	7	
33	Lebeta et al, 2016	*	*	*	*	-	*	6	
34	Kibirige et al, 2017	*	-	-	*	**	*	6	
35	Mbwete et al, 2020	*	-	*	*	*	*	6	
36	Tiahun et al,2017	*	*	*	*	-	*	6	
37									
38									
39									
40									
41									
42									
43									
44									
45									
46									

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Chiwanga et al, 2015	*	-	*	*	*	*	6
Lumu et al, 2017	*	-		*	**	*	6
Balogu et al., 2011	*	-	-	*	**	*	6
Megallaa et al., 2019	*	*	*	*	-	*	6
Eghan et al., 2007	*	*	-	-	**	*	6
Unachukwu et al., 2007	*	-	-	*	**	*	6
Abejew et al, 2015	*	*	-	*	-	*	5
Nyamu et al, 2003	*	-	*	*	-	*	5
Gulam-Abbas et al, 2002	*	-	*	*	-	*	5
Abbas et al, 2011	*	*	*	*	-	-	5
Gill et al, 2008	*	*	*	*	-	-	5
Cairncross et al., 2017	-	-	-	*	**	*	5
Amod et al., 2012	*	*	*	-	-	*	5
Vogt et al, 2017	*	-	-	*	-	*	4
Worku et al, 2010	*	*	*	-	-	-	4
Gebre Kirstos et al, 2015	*	-	*	*	-	-	4
Magan et al, 2019	-	-	-	*	-	*	3
Woodward et al, 2020	-	-	-	*	-	*	3
Lartey et al., 2018	-	-	-	*	-	*	3
Tesfatsion et al, 2015	-	-	-	*	-	-	2
Neuhann et al, 2001	-	-	-	*	-	-	2

For peer review only

bmjopen-2022-061786 on 8 November 2022. Downloaded from <http://bmjopen.bmj.com/> on April 23, 2024 by guest. Protected by copyright.

BMJ Open

Indicators of optimal diabetes care and burden of diabetes complications in Africa: A systematic review and meta-analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-060786.R1
Article Type:	Original research
Date Submitted by the Author:	20-Sep-2022
Complete List of Authors:	<p>Kibirige, Davis; Lubaga Hospital, Medicine Chamba, Nyasatu; Kilimanjaro Christian Medical Centre, Internal Medicine; Kilimanjaro Christian Medical University College, Medicine Andia-Biraro, Irene; Makerere University College of Health Sciences, Internal Medicine; MRC/UVRI and LSHTM Uganda Research Unit, Immunomodulation and Vaccines</p> <p>Kilonzo, Kajiru; Kilimanjaro Christian Medical Centre; Kilimanjaro Christian Medical University College</p> <p>Laizer, Sweetness; Kilimanjaro Christian Medical University College</p> <p>Sekitoleko, Isaac; Uganda Virus Research Institute, Non-communicable Diseases</p> <p>Kyazze, Andrew ; Makerere University College of Health Sciences</p> <p>Ninsiima, Sandra; Makerere University College of Health Sciences, Immunology</p> <p>Ssekamatte , Phillip ; Makerere University College of Health Sciences, Immunology</p> <p>Bongomin, Felix; Makerere University College of Health Sciences, Internal Medicine</p> <p>Mrema, Lucy; NIMR-Mbeya Medical Research Programme, Medicine</p> <p>Olomi, Willyhelmina; NIMR-Mbeya Medical Research Programme, Medical Statistics</p> <p>Mbunda, Theodora ; NIMR-Mbeya Medical Research Programme</p> <p>Ntinginya, Nyanda; NIMR-Mbeya Medical Research Programme</p> <p>Sabi, Issa; NIMR-Mbeya Medical Research Programme</p> <p>Sharples, Katrina; University of Otago, Centre for International Health</p> <p>Hill, Philip; University of Otago, Centre for International Health</p> <p>te Brake, Lindsey; Radboud University Nijmegen, Pharmacology</p> <p>VandeMaat, Josephine; Radboud University Nijmegen, Medicine</p> <p>vanCrevel, Reinout; Radboud University Nijmegen, Internal Medicine;</p> <p>University of Oxford Centre for Tropical Medicine and Global Health</p> <p>Critchley, Julia; St George's University of London</p>
Primary Subject Heading:	Diabetes and endocrinology
Secondary Subject Heading:	Global health, Health services research, Public health
Keywords:	Epidemiology < TROPICAL MEDICINE, EPIDEMIOLOGY, Quality in health care < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, General diabetes < DIABETES & ENDOCRINOLOGY

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3 **Indicators of optimal diabetes care and burden of diabetes complications in**
4
5 **Africa: A systematic review and meta-analysis**
6
7

8 Davis Kibirige^{1,2*}, Nyasatu Chamba^{3,4}, Irene Andia-Biraro^{2,5}, Kajiru Kilonzo^{3,4},
9
10 Sweetness Naftal Laizer^{3,4}, Isaac Sekitoleko⁶, Andrew Peter Kyazze², Sandra
11
12 Ninsiima², Phillip Ssekamatte², Felix Bongomin⁵, Lucy Elauteri Mrema⁷, Willyhelmina
13
14 Olomi⁷, Theodora D Mbunda⁷, Nyanda Elias Ntinginya⁷, Issa Sabi⁷, Katrina Sharples⁸,
15
16 Philip C Hill⁸, Lindsey te Brake⁹, Josephine van de Maat¹⁰, Reinout van Crevel^{10,11},
17
18 Julia Critchley¹² on behalf of PROTID consortium.
19
20
21
22
23
24

25 **Author affiliations**

- 26
27 1. Department of Medicine, Uganda Martyrs' Hospital Lubaga, Kampala Uganda
28
29 2. Tuberculosis And Comorbidities Consortium, Kampala Uganda
30
31 3. Department of Medicine, Kilimanjaro Christian Medical Centre, Moshi,
32
33 Tanzania.
34
35 4. Department of Medicine, Kilimanjaro Christian Medical University College,
36
37 Moshi, Tanzania
38
39 5. Department of Medicine, Makerere University College of Health Sciences,
40
41 Kampala Uganda.
42
43 6. Chronic Diseases and Cancer Program, Medical Research Council/Uganda
44
45 Virus Research Institute and London School of Hygiene and Tropical Medicine
46
47 Uganda Research Unit, Entebbe Uganda.
48
49 7. National Institute for Medical Research - Mbeya Medical Research Centre,
50
51 Mbeya, Tanzania.
52
53 8. Centre for International Health, Otago University, Dunedin, New Zealand.
54
55
56
57
58
59
60

- 1
2
3 9. Department of Pharmacy, Radboud Institute for Health Sciences, Radboud
4 University Medical Centre, Nijmegen, Netherlands.
5
6
7
8 10. Department of Internal Medicine and Radboud Centre for Infectious Diseases,
9 Radboud University Medical Centre, Nijmegen, Netherlands.
10
11
12 11. Centre for Tropical Medicine and Global Health, Nuffield Department of
13 Medicine, University of Oxford, Oxford, United Kingdom.
14
15
16
17 12. Population Health Research Institute, St. George's University of London,
18 London, United Kingdom.
19
20
21
22
23

24 **Corresponding author**

25
26 Davis Kibirige

27
28 Department of Medicine, Uganda Martyrs' Hospital Lubaga, Kampala Uganda
29

30
31 Email: kibirigedavis@gmail.com.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objective

Contemporary data on the attainment of optimal diabetes treatment goals and the burden of diabetes complications in adult populations with type 2 diabetes in Africa is lacking. We aimed to document the current status of attainment of three key indicators of optimal diabetes care and the prevalence of five diabetes complications in adult African populations with type 2 diabetes.

Methods

We systematically searched EMBASE, PubMed, and the Cochrane library for published studies from January 2000 to December 2020. Included studies reported any information on the proportion of attainment of optimal glycated haemoglobin (HbA1c), blood pressure (BP), and low-density lipoprotein cholesterol (LDLC) goals, and/or prevalence of five diabetes complications (diabetic peripheral neuropathy, retinopathy, nephropathy, foot ulcers, and peripheral arterial disease). Random-effect model meta-analysis was performed to determine the pooled proportion of attainment of the three treatment goals and the prevalence of five diabetes complications.

Results

In total, 109 studies with a total of 63, 890 participants (53.3% being females) were included in the meta-analysis. Most of the studies were conducted in Eastern African countries (n=44, 40.4%). The pooled proportion of attainment of an optimal HbA1c, BP, and LDLC goal was 27% (95% CI 24-30, $I^2=94.7\%$), 38% (95% CI 30-46, $I^2=98.7\%$), and 42% (95% CI 32-52, $I^2=97.4\%$), respectively. The pooled prevalence of diabetic peripheral neuropathy, retinopathy, diabetic nephropathy, peripheral arterial disease, and foot ulcers was 38% (95% CI 31-45, $I^2=98.2\%$), 32% (95% CI 28-

1
2
3 36, $I^2=98\%$), 31% (95% CI 22-41, $I^2=99.3\%$), 19% (95% CI 12-25, $I^2=98.1\%$), and 11%
4
5 (95% CI 9-14, $I^2=97.4\%$), respectively.
6
7

8 **Conclusion**

9
10 Attainment of optimal diabetes treatment goals, especially HbA1c, in adult patients
11 with type 2 diabetes in Africa remains a challenge. Diabetes complications, especially
12 diabetic peripheral neuropathy and retinopathy are highly prevalent in adult
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
populations with type 2 diabetes in Africa.

19 **KEYWORDS**

21
22 Optimal diabetes care, diabetes complications, adult patients with type 2 diabetes,
23
24 Africa.
25

26 **Strengths and limitations of the study**

- 28 • To our knowledge, it is the first systematic review and meta-analysis to
29 simultaneously investigate the status of attainment of the three key diabetes
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
treatment goals and the burden of five common diabetes complications in an
adult indigenous African population with type 2 diabetes.
- The systematic review and meta-analysis included a large number of studies
that assessed the extent of attainment of diabetes treatment goals and the
prevalence of diabetes complications based on recommendations or definitions
by internationally recognised associations.
- There was high heterogeneity among the studies included in the meta-analysis.
- A relative number of studies included in the meta-analysis had low to moderate
quality on assessment.

INTRODUCTION

Globally, the burden of diabetes mellitus (DM) continues to exponentially rise to epidemic proportions, disproportionately affecting low-and middle-income countries.

The recent 2021 International Diabetes Federation (IDF) estimates show that about 24 million adults (1 in 22 adults) live with DM in Africa. The IDF also predicts that the greatest future increase in the prevalence of DM will occur in Africa because of the predicted aging of Africa's currently very young populations, as well as increasing urbanisation and associated lifestyle changes.¹ This will ultimately lead to an immense strain on weak healthcare systems that are poorly structured and inadequately financed to manage non-communicable diseases (NCD) like DM.²

In addition, the rates of undiagnosed DM continue to increase in Africa. Among the IDF regions, Africa has the highest proportion of undiagnosed diabetes; about 54% of all cases.¹ The majority of patients are diagnosed late with co-existing debilitating complications and suboptimal diabetes care remains common in most clinical settings in Africa.³ This could be explained by low awareness about DM, healthcare systems that are structured mainly to manage communicable diseases as opposed to NCD, low screening rates of DM to ensure early diagnosis, low availability of affordable essential diagnostic tests and medicines for DM, and knowledge-practice gaps among healthcare practitioners.^{2 4-6}

Published diabetes treatment guidelines by most international organisations like the IDF and American Diabetes Association (ADA) recommend targets of glycated haemoglobin level (HbA1c) of <7% (53 mmol/mol), blood pressure (BP) <140/90 mmHg, and low-density lipoprotein cholesterol (LDLC) <2.6 mmol/l (100 mg/dl) as key indicators of optimal diabetes care.⁷⁻⁹ Attainment of these treatment goals in diabetes

1
2
3 care ultimately translates to reduced risk of onset and progression of diabetes
4 complications and mortality.
5

6
7
8 Despite the increasing burden of DM and its related complications, late diagnosis of
9 diabetes, and prevalent suboptimal diabetes care in clinical settings in Africa, there is
10 an information gap regarding the current status of attainment of the recommended
11 diabetes treatment goals and the prevalence of common diabetes complications to
12 inform targeted strategies or interventions to reduce diabetes-related morbidity and
13 mortality. This systematic review and meta-analysis aimed to document the proportion
14 of attainment of optimal HbA1c, BP, and LDLC goals and the prevalence of five
15 diabetes complications (diabetic peripheral neuropathy, nephropathy, retinopathy, foot
16 ulcers, and peripheral arterial disease) in adult native populations with type 2 diabetes
17 in Africa.
18
19
20
21
22
23
24
25
26
27
28
29

30 **METHODS**

31
32
33 This systematic review and meta-analysis was conducted according to the criteria
34 outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
35 (PRISMA) statement.¹⁰ The PRISMA checklist is available as a supplementary table
36
37

38 1. The study protocol was registered in the PROSPERO International Prospective
39 Register of systematic reviews (CRD42020215576).
40
41
42
43

44 **Search strategy**

45
46 We searched EMBASE, PubMed, and the Cochrane library for published studies from
47 January 2000 to December 2020. The following search terms were used after
48 discussion with a medical librarian: “Quality of diabetes care” OR “Indicators of
49 diabetes care” OR “status of diabetes care” OR “diabetes care” OR “glycaemic control”
50 OR “blood pressure control” OR “lipid profile control” OR “screening of diabetes
51 complications” OR “diabetes complications” OR “screening for diabetic retinopathy”
52
53
54
55
56
57
58
59
60

1
2
3 OR "screening for diabetic peripheral nephropathy" OR screening for diabetic
4 neuropathy" OR screening for diabetic foot ulcers OR "screening for peripheral arterial
5 disease" OR "prevalence of diabetic retinopathy" OR "prevalence of diabetic peripheral
6 nephropathy" OR "prevalence of diabetic peripheral neuropathy" OR "prevalence of
7 diabetic foot ulcers" OR "prevalence of peripheral arterial disease", AND "type 2
8 diabetes mellitus" OR "type 2 diabetes" AND Algeria OR Angola OR Benin OR
9 Botswana OR "Burkina Faso" OR Burundi OR Cameroon OR "Cape Verde" OR
10 "Central African Republic" OR Chad OR Comoros OR "Democratic Republic of
11 Congo" OR Djibouti OR Egypt OR "Equatorial Guinea" OR Eritrea OR Ethiopia OR
12 Gabon OR Gambia OR Ghana OR Guinea OR "Guinea Bissau" OR "Ivory Coast" OR
13 "Cote d'Ivoire" OR Kenya OR Lesotho OR Liberia OR Libya OR Libya OR
14 Madagascar OR Malawi OR Mali OR Mauritania OR Mauritius OR Morocco OR
15 Mozambique OR Namibia OR Niger OR Nigeria OR Rwanda OR "Sao Tome" OR
16 Senegal OR Seychelles OR "Sierra Leone" OR Somalia OR "South Africa" OR "South
17 Sudan" OR Sudan OR Swaziland OR Tanzania OR Togo OR Tunisia OR Uganda OR
18 Zaire OR Zambia OR Zimbabwe OR "Central Africa" OR "West Africa" OR "Western
19 Africa" OR "East Africa" OR "Eastern Africa" OR "North Africa" OR "Northern Africa"
20 OR "Southern Africa" OR "sub Saharan Africa" OR "sub-Saharan Africa" OR Africa.

21
22 In addition, references of included articles were hand-searched for any other original
23 articles. The search and selection were restricted to studies written only in the English
24 language.

25 26 **Study selection criteria**

27
28 The preliminary screening of titles and abstracts to identify potentially eligible articles
29 was done by two independent reviewers (NC and DK). This was followed by removing
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 all duplicates. After the initial screening, full texts of the potentially eligible studies were
4
5 retrieved and closely reviewed for eligibility.
6

7
8 The inclusion criteria of studies were: cross-sectional, cohort, or randomised controlled
9
10 trials published between January 2000 and December 2020 in English language,
11
12 studies reporting any data on proportion of adult patients with type 2 diabetes who
13
14 attained the recommended optimal HbA1c, BP, or LDLC targets and residing in African
15
16 countries, and studies reporting data on any of prevalence of diabetic nephropathy,
17
18 peripheral neuropathy, retinopathy, foot ulcers, or peripheral arterial disease in adult
19
20 patients with type 2 diabetes in African countries.
21
22

23
24 Any disagreements that arose were resolved by consensus. We excluded
25
26 retrospective studies, case series and reports, studies published in languages other
27
28 than English, and studies whose full texts could not be retrieved.
29

30 31 **Data extraction**

32
33 After identifying the eligible original studies, they were collated and sent to additional
34
35 reviewers to extract the relevant study information using a Microsoft Excel 2016 form.
36
37 The information of interest that was extracted from the eligible studies included: the
38
39 last name of the first author and year of publication, country (ies) and region (s) of
40
41 Africa where the study was conducted, type of study design, number of study
42
43 participants, the mean age of study participants, the proportion of female participants,
44
45 the proportion of participants with a current or history of smoking, the proportion of
46
47 participants on oral hypoglycaemic agents, insulin, lipid-lowering agents (statins), and
48
49 anti-hypertensive agents, mean body mass index (BMI) and HbA1c of study
50
51 participants, the proportions of participants with optimal HbA1c, BP, and LDLC targets,
52
53 and the prevalence of diabetic nephropathy, peripheral neuropathy, retinopathy, foot
54
55 ulcers, and peripheral arterial disease.
56
57
58
59
60

Operational definitions

All included studies defined optimal targets of HbA1c, BP, and LDLC as <7% (53 mmol/mol), <140/90 mmHg, and <2.6 mmol/l or 100 mg/dl, respectively as recommended by the IDF and ADA diabetes treatment guidelines.^{9 11}

The definitions and measurements of diabetes complications greatly varied between studies. The following definitions were used for each diabetes complication by the various studies: micro/macroalbuminuria and/or an estimated glomerular filtration rate <60 ml/min/1.73 m² for the presence of diabetic nephropathy, signs and symptoms suggestive of peripheral neuropathy, use of neuropathy screening scores like neuropathy disability score, Michigan Neuropathy Screening Instrument, neuropathy symptom score, and 10g monofilament testing for the presence of diabetic peripheral neuropathy, presence of lesions like soft or hard exudates, cotton wool spots, microaneurysms, neovascularisation, and retinal hemorrhages on fundoscopy for diabetic retinopathy, presence of foot ulcers on clinical inspection for diabetic foot ulcers, and the presence of measured ankle brachial index <0.9 using doppler studies for peripheral arterial disease.

Assessment of quality of studies

The quality of all eligible studies included in the systematic review and meta-analysis was assessed using the Newcastle-Ottawa Scale (NOS).¹² This was done by two independent authors (NC and SNL). The total score of the adapted scale is eight stars. Studies with more than six stars were considered high quality, while those with 5 and 6 stars, and <5 stars were considered of moderate and low quality.

Study outcomes

The study outcomes were the pooled proportions of attainment of the recommended optimal HbA1c, BP, and LDLC goals and the pooled prevalence of diabetic

1
2
3 nephropathy, peripheral neuropathy, retinopathy, foot ulcers, and peripheral arterial
4 disease in adult patients with type 2 diabetes in Africa.
5
6

7 **Data analysis**

8
9
10 All analyses were performed using STATA 16.0 statistical software (Stata Corp, USA).
11
12 The descriptive data of all eligible studies included in the systematic review and meta-
13 analysis like age, gender, the proportion of participants on specific glucose-lowering
14 agents, BMI, and HbA1c were summarised using frequencies and 95% confidence
15 intervals (CI) and mean \pm standard deviation (SD).
16
17
18
19

20
21 For the continuous variables, the average estimated value was obtained from each of
22 the studies, and this was used in the final analysis while for the categorical variables,
23 the proportions were estimated for each of the studies and used in the final analysis.
24
25

26
27 The pooled proportions of achievement of optimal HbA1c, BP, and LDLC goals and
28 the prevalence of diabetic nephropathy, peripheral neuropathy, retinopathy, foot
29 ulcers, and peripheral arterial disease were determined using a random-effect model
30 meta-analysis and presented in forest plots. The DerSimonian and Laird method was
31 used for pooling random effects estimates.¹³
32
33
34
35
36
37
38
39

40
41 The heterogeneity of studies was assessed using the I^2 value and corresponding 95%
42 confidence intervals. Based on the Cochrane collaboration guide, the I^2 values of 0-
43 40%, 30-60%, 50-90%, and 75-100% were considered not important, moderate,
44 substantial, and considerable levels of heterogeneity, respectively.¹⁴ To further
45 explore heterogeneity effects across studies, we conducted a meta-regression
46 analysis to assess whether the heterogeneity could be explained by the study level
47 characteristics i.e., age, sex of participants, and region in which the study was
48 conducted. The age, BMI, and sex of the participants was defined as the estimated
49 mean age and BMI of participants and the proportion of females from each of the
50
51
52
53
54
55
56
57
58
59
60

1
2
3 study, respectively. The region of the study was defined as the area (Northern,
4 Southern, Eastern, Western, and Central Africa) where the study was conducted. One
5 effect measure per study was considered in the meta-regression. All the variables
6 were included in the model together to assess for variability.
7
8
9
10

11
12 We assessed the presence of publication bias using the Egger test of bias with $p < 0.05$
13 indicating significant publication bias.¹⁵ A narrative review was also used to present
14 the study results. Information about all included studies was also summarised in
15 tables.
16
17
18
19

20
21 We also performed a sensitivity analysis based on the NOS scores of the studies
22 (excluding moderate and low-quality studies) and compared the analysis with all the
23 eligible studies and with only high-quality studies to identify any differences in the
24 pooled estimates of the rates of attainment of optimal diabetes treatment goals and
25 the prevalence of the five diabetes complications.
26
27
28
29
30
31

32 33 **Patient and Public Involvement**

34
35 The main research question and outcomes of interest of the systematic review and
36 meta-analysis were informed by the need to understand the burden of diabetes
37 complications in patients with type 2 diabetes in Africa and the extent of attainment of
38 optimal diabetes care to inform strategies aimed to improve optimal management of
39 diabetes in the region. Because it was a systematic review and meta-analysis, we did
40 not involve patients in its design, recruitment, and conduct.
41
42
43
44
45
46
47
48

49 **RESULTS**

50
51 Figure 1 summarises the article selection in a PRISMA flow diagram.

52
53 The literature search returned a total of 835 articles. From these, 222 duplicates were
54 removed. Titles and abstracts of the remaining 613 articles were reviewed and 235
55 articles were identified for full-text retrieval. Of the 235 articles, 126 were excluded and
56
57
58
59
60

1
2
3 the remaining 109 articles were included in this systematic review and meta-analysis.

4
5 A total of 48 and 89 eligible studies contained information on optimal diabetes
6
7
8 treatment goals and diabetes complications, respectively while 28 studies reported
9
10 information on both.

11
12 The 126 excluded articles included five studies published in French language, 21
13
14 retrospective studies, six studies with general populations (not entirely patients with
15
16 type 2 DM), 18 studies whose full texts were unable to be retrieved, and 76 studies
17
18 that did not report outcomes of interest.

21 ***Characteristics of included studies***

22
23 The majority of studies were performed in Eastern African countries (44, 40.4%).^{3 16-58}

24
25 The proportion of studies conducted in Western, Northern, Southern, and Central
26
27 Africa was 22% (n=24 studies)^{3 59-80}, 16.5% (n=18 studies)⁸¹⁻⁹⁹, 15.6% (n=17 studies)
28
29 100-116, and 8.3% (n=9 studies)^{3 59 117-123}, respectively. Three studies were conducted
30
31 in more than one region of Africa (Western, Central, and Eastern).^{3 58 59} Most of the
32
33 studies were cross-sectional in design (100, 91.7%).

34
35 Considerable heterogeneity was noted across the studies with the I² value ranging
36
37 from 97.4% to 99.3% for studies reporting the burden of diabetes complications and
38
39 94.7% to 98.7% for studies reporting the extent of attainment of optimal diabetes
40
41 treatment goals. However, on meta-regression after adjusting for age and sex of study
42
43 participants, and region where each study was conducted, the heterogeneity based
44
45 on I² of studies on the prevalence of diabetes complications decreased, ranging from
46
47 1.4% for studies on diabetic foot ulcers to 95.6% for studies on diabetic nephropathy.
48
49 For studies on the proportion of attainment of optimal treatment goals, the
50
51 heterogeneity also decreased, to 56.3%, 92.1%, and 95.4%, for studies reporting
52
53 optimal HbA1c, LDLC, and BP goals.
54
55
56
57
58
59
60

Characteristics of study participants

Table 1 summarises the characteristics of all participants in the studies included in the systematic review and meta-analysis.

The studies had a total of 63, 890 participants (ranging from 40 to 11,866) with 53.3% being female. The mean \pm SD age, BMI, and HbA1c of the participants was 54.9 ± 4.7 years (ranging from 40.5 to 63.9 years), 27.9 ± 0.5 kg/m² (ranging from 20.6 to 42.9 kg/m²), and $9.0 \pm 1.5\%$ (ranging from 6.5% to 13.9%), respectively. Among the studies that reported data on the type of glucose-lowering therapies used by participants, treatment with oral hypoglycaemic agents, insulin, statins, and anti-hypertensives was reported in about 65% (95% CI 34-96.6), 31.3% (95% CI 26.3-36.2), 25.7% (95% CI 0.5-86.7), and 73.3% (95% CI 64.1-82.5) of participants, respectively.

Assessment of study quality and publication bias

The assessment of the quality of studies and funnel plots assessing publication bias are summarised in supplementary table 2 and supplementary figures 1-8, respectively. Based on the NOS, 84 (77.1%) of the included studies were of high quality, with 17 (15.6%) studies and 8 (7.3%) studies being of moderate and low quality, respectively. Regarding the assessment of publication bias, there was observed publication bias, especially in studies about the prevalence of diabetic nephropathy, peripheral neuropathy, and attainment of optimal BP control. The proportion of studies investigating the prevalence of diabetic nephropathy, peripheral neuropathy, peripheral arterial disease, retinopathy, and foot ulcers located within the funnel plot was 30% (n=12), 46.1% (n=13), 55.6% (n=10), 57% (29), and 90% (n=26), respectively. About 46%, 65%, and 73% of studies that reported the proportion of attainment of optimal BP, HbA1c, and LDLC treatment goal were located within the funnel plot respectively.

Extent of attainment of optimal HbA1c, BP and LDLC goals

Data on the reported proportions achieving the three diabetes treatment goals is summarised in tables 2, 3, and 4 and as forest plots in figures 2, 3 and 4.

Data on attainment of optimal HbA1c, BP and LDLC goals was reported in 34 studies³

20 21 23 35-37 44-47 59-61 63 64 67 84 87 92 93 97-99 104 105 111 116 117 120 124 125, 26 studies³ 18 20 21 24 36

40 41 45 47 61 64 67 70 77 87 91 96 97 105 107 111 113 120 121 124, and 11 studies²¹ 37 39 47 61 87 97 111 116

124 126, respectively. The pooled proportion of attainment of an optimal HbA1c, BP, and LDLC goal in the respective studies was 27% (95% CI 24-30, $I^2=94.7\%$), 38% (95% CI 30-46, $I^2=98.7\%$), and 42% (95% CI 32-52, $I^2=97.4\%$), respectively.

The lowest proportion of attainment of optimal HbA1c was reported in a study performed in Egypt (4.4%)⁹⁷ and the highest in a study performed in Nigeria (52.5%)⁶⁴.

Among studies reporting the extent of attainment of an optimal BP goal, the proportion ranged from 1.5% in a study performed in Uganda⁴⁷ to 85.9% in a study performed in Ethiopia²⁴. Among the studies reporting information on the optimal LDLC goal, attainment of optimal targets ranged from 20.4% in a study performed in Botswana¹¹¹ to 84.8% in a study performed in Sudan⁹⁴.

Regarding the attainment of the diabetes treatment goals in each region of Africa surveyed, the lowest and highest proportion of attainment of an optimal HbA1c goal was noted in the Central (20%, 95% CI 16-23) and Western region (37%, 95% CI 29-46), respectively. For the attainment of an optimal blood pressure control, the Western region had the least proportion (31%, 95% CI 20-43) while the Northern region had the highest (42%, 95% CI 24-61). An optimal LDLC target was least achieved in the Southern region (27%, 95% CI 24-30) and most achieved in the Northern region (53%, 95% CI 32-74).

Prevalence of diabetic retinopathy, peripheral neuropathy, nephropathy, foot ulcers and peripheral arterial disease

Information on the pooled and specific prevalence of diabetes complications as reported by the different studies is summarised in tables 5, 6, 7, 8, and 9 and as forest plots in figures 5, 6, 7, 8, and 9.

The prevalence of diabetic retinopathy, nephropathy, peripheral neuropathy, foot ulcers, and peripheral arterial disease was reported in 51 studies^{3 19 24 26 28 30 38 41 48 51 53 54 56-58 66 67 70 72 74 76 77 81 82 86 88 89 91 95-97 103-107 109 112-116 118 120-123 127-129}, 40 studies^{3 19 21 27 28 30-32 38 46 48 53 57 60 62 64 66 67 69 70 76 81 82 86 88 89 91 96 97 100 105 108-110 113 114 117-119 127}, 36 studies^{3 19 25 27 28 30 33 34 37 38 43 48 51-53 57 58 67 68 73 76 79 81 85-88 96 97 105 109 118 127 128 130}, 29 studies^{3 16-19 21 22 25 27 29 38 42 43 48 49 51 53 54 57 58 67 80 85 87 95 97 113 114 127}, and 18 studies^{3 20 25 30 43 47 50 52 61 67 70 75 78 85 86 91 97 105}, respectively.

Prevalence of diabetic peripheral neuropathy and retinopathy

Diabetic peripheral neuropathy and retinopathy were the most prevalent diabetes complications in the included studies with a pooled prevalence of 38% (95% CI 31-45, $I^2=98.2\%$) and 32% (95% CI 28-36, $I^2=98\%$), respectively. A wide variation was noted in the prevalence of diabetic peripheral neuropathy across the studies, with prevalence ranging from 4% in a study conducted in Eritrea⁵¹ to 83.3% in a study conducted in Nigeria⁶⁸. A study by Makwero and colleagues conducted in Lesotho reported the lowest prevalence of diabetic retinopathy of 4.7%¹⁰⁹ while the study by Megalla and colleagues conducted in Egypt reported the highest (90%)⁹⁷.

According to the regions of Africa surveyed, the lowest and highest prevalence of diabetic peripheral neuropathy was noted in the Central (22%, 95% CI 18-27) and Western regions (61%, 95% CI 45-75), respectively. Studies conducted in the Eastern region reported the lowest prevalence of diabetic retinopathy (23%, 95% CI 19-28)

1
2
3 while studies conducted in the Northern region reported the highest prevalence (51%,
4
5 95% CI 37-65).
6

7
8 ***Prevalence of diabetic nephropathy, peripheral arterial disease, and foot ulcers***
9

10 The pooled prevalence of diabetic nephropathy, peripheral arterial disease, and foot
11
12 ulcers in the included studies was 31% (95% CI 22-41, $I^2=99.3\%$), 19% (95% CI 12-
13
14 25, $I^2=98.1\%$), and 11% (95% CI 9-14, $I^2=97.4\%$), respectively.
15

16
17 The prevalence of diabetic nephropathy and peripheral arterial disease ranged from
18
19 2.2% in Ethiopia¹⁹ to 90% in Nigeria⁶⁴ and 2.7% in a study performed in Morocco⁹¹ to
20
21 52.5% in a study performed in Nigeria⁷⁸, respectively. Regarding the burden of diabetic
22
23 foot ulcers, there was also an observed heterogeneity, with prevalence ranging from
24
25 0.4% in Ethiopia⁵³ to 86.7% in Egypt⁹⁷.
26

27
28 Studies conducted in the Central, Eastern, and Southern regions reported a
29
30 comparable prevalence of diabetic nephropathy (22%, 25%, and 28%, respectively)
31
32 with the highest prevalence reported in studies conducted in the Western region
33
34 (47%). Regarding the prevalence of PAD, studies conducted in the Southern (8%, 95%
35
36 CI 6-10) and Western (29%, 95% CI 13-48) regions reported the lowest and highest
37
38 prevalence, respectively. A comparable prevalence of diabetic foot ulcers was noted
39
40 in studies conducted in the Southern, Western, and Eastern regions (7%, 8%, and
41
42 10%, respectively), with the highest prevalence noted in studies conducted in the
43
44 Northern region (21%).
45
46
47

48
49 On sensitivity analysis considering only high-quality studies, the pooled prevalence of
50
51 the five diabetic complications and the proportion of attainment of the three optimal
52
53 diabetes treatment goals did not differ from those obtained in the preliminary analysis
54
55 with all eligible studies included. The pooled prevalence of diabetic foot ulcers,
56
57 peripheral arterial disease, diabetic nephropathy, diabetic retinopathy, and diabetic
58
59
60

1
2
3 peripheral neuropathy after sensitivity analysis was 9% (95% CI 7-12, $I^2= 92.9\%$), 20%
4 (95% CI 13-28, $I^2= 98.4\%$), 31% (95% CI 21-42, $I^2= 99.4\%$), 33% (95% CI 28-37, $I^2=$
5
6 98.2%), and 40% (95% CI 32-48, $I^2= 99\%$), respectively. The pooled proportion of
7
8 attainment of optimal HbA1c, blood pressure, and LDLC treatment goal was 27% (95%
9
10 CI 23-30, $I^2= 94.5\%$), 37% (95% CI 29-46, $I^2= 99.0\%$), and 43% (95% CI 31-55, $I^2=$
11
12 97.9%), respectively.
13
14
15

16 17 **DISCUSSION**

18
19 To our knowledge, this is the first systematic review and meta-analysis to
20
21 simultaneously document the proportion of attainment of the three key indicators of
22
23 optimal diabetes care (HbA1c, BP, and LDLC goals) and the burden of five diabetes
24
25 complications in an indigenous adult population with type 2 diabetes in Africa. In this
26
27 study of a total of 63,890 study participants, we report that, generally, a small
28
29 proportion of adult patients with type 2 diabetes in Africa attain optimal diabetes
30
31 treatment targets, especially HbA1c and BP goals (less than 40%). In addition,
32
33 diabetes complications are relatively common with diabetic neuropathy being the most
34
35 prevalent (38%) followed by diabetic retinopathy (32%), nephropathy (31%),
36
37 peripheral arterial disease (19%), and foot ulcers (11%).
38
39
40
41

42 ***Proportions of attainment of the optimal diabetes treatment goals***

43
44 A wide heterogeneity in the attainment of the optimal diabetes treatment goals was
45
46 noted across all five regions of Africa. This could probably be explained by the marked
47
48 differences in the populations studied, healthcare systems, and knowledge-practice
49
50 gaps among healthcare practitioners.
51
52

53
54 Similar to our study findings, achievement of optimal HbA1c, BP, and LDLC treatment
55
56 goals has also been widely reported to be a significant clinical challenge in several
57
58 studies performed in Caucasian and Asian populations with type 2 diabetes in high-
59
60

1
2
3 and middle-income countries.¹³¹⁻¹³⁶ In one large registry-based study of >100, 000
4 adults with a self-reported diagnosis of diabetes carried out between 1999 to 2010 in
5 USA, 33.4 to 48.7% of adult patients with diabetes did not achieve the recommended
6 HbA1c, BP, and LDLC treatment targets. Less than 15% met all the three treatment
7 targets in addition to smoking cessation.¹³¹

8
9
10 Similarly, a low proportion of achievement of an optimal HbA1c target was also
11 reported by a large international, multicenter observational study of 2,704 multi-racial
12 adult populations with diabetes from 10 countries (two from Africa, five from the Middle
13 East, and three from South Asia). About 46% of the participants were Caucasian. An
14 optimal HbA1c goal of <7% (53 mmol/mol) was reported in only 25.8% of the
15 participants.¹³³

16
17 In the Japan Epidemiology Collaboration on Occupational Health (J-ECOH) study
18 which enrolled 3,070 adult employees of large manufacturing companies, optimal
19 HbA1c, BP, and LDLC goals as recommended by the American Diabetes Association
20 were noted in 44.9%, 76.6%, and 27.1% of participants, respectively. Only 11.2% of
21 participants attained all three treatment goals.¹³⁴

22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 **The burden of diabetes complications in Africa**

41
42 Regarding studies on the burden of diabetes complications in Africa, there were few
43 that investigated the prevalence of diabetic foot ulcers and peripheral arterial disease
44 with diabetic retinopathy, peripheral nephropathy and neuropathy being the most
45 studied. Diabetic peripheral neuropathy and retinopathy remain the most prevalent
46 diabetes complication and diabetic foot ulcers the least prevalent.

47
48 With regards to the prevalence of diabetic foot ulcers, an earlier published systematic
49 review and meta-analysis on the characteristics, prevalence, and outcomes of diabetic
50 foot ulcers in Africa by Rigato et al reported a pooled prevalence of diabetic foot ulcers
51
52
53
54
55
56
57
58
59
60

1
2
3 of 13%, a finding close to what we observed (11%).¹³⁷ In another systematic review
4 and meta-analysis on the prevalence of diabetic peripheral neuropathy in African
5 populations with DM, Shiferaw et al reported a slightly higher overall prevalence of
6
7 46% compared to what we found in our study (38%), while including fewer studies
8
9 (n=23).¹³⁸

10
11
12
13
14 Similar to our study, considerable heterogeneity was also reported in the documented
15 prevalence of the varied diabetes complications in Africa in most previously published
16
17 systematic reviews. This may be due to variations in clinical definitions of diabetes
18
19 complications in the studies. Burgess et al¹³⁹ and Achigbu et al¹⁴⁰, reported a wide
20
21 disparity in the prevalence of diabetic retinopathy in the included studies of 7-62.4%,
22
23 and 13-82.6%, respectively. Noubiap JJ et al in a systematic review on the burden of
24
25 diabetic nephropathy in 2015 reported an overall prevalence of chronic kidney disease
26
27 in patients with diabetes ranging between 11-83.7%.¹⁴¹ Johnston LE et al in a
28
29 systematic review that aimed to assess the epidemiological and clinical reports
30
31 regarding PAD in SSA documented the prevalence of PAD in patients with diabetes
32
33 as reported by three studies to range from 39% to 52%.¹⁴²

34
35
36
37
38
39
40 Compared to Caucasian and Asian adult populations with type 2 diabetes, our study
41
42 has demonstrated that adult African patients are disproportionately affected by
43
44 complications of DM. The Joint Asia Diabetes Evaluation (JADE) program that
45
46 undertook comprehensive risk assessments of 3,687 adult patients with type 2 DM
47
48 recruited from seven Asian countries reported a prevalence of peripheral arterial
49
50 disease, diabetic neuropathy, macro-and microalbuminuria, and diabetic retinopathy
51
52 of 3.1%, 15%, 18.8%, and 20.4%, respectively.¹⁴³

53
54
55
56 The National Health and Nutrition Examination Survey conducted from 1988–1994
57
58 and 1999–2018 in USA in 1,486 nonpregnant adults (aged ≥ 20 years) with newly
59
60

1
2
3 diagnosed diabetes (diagnosed within the past 2 years) also documented a low burden
4 of most diabetes complications. Diabetic foot ulcers, peripheral arterial disease,
5 diabetic retinopathy, neuropathy, and nephropathy (albuminuria) were prevalent in
6 6.3%, 9.2%, 12.1%, 14.5%, 18.7%, respectively.¹⁴⁴
7
8
9
10
11

12 The documented low proportions of attainment of optimal diabetes treatment goals
13 (optimal HbA1c, BP, and LDLC targets) in Africa is associated with an increased risk
14 of onset and progression of diabetes complications, hence increasing morbidity and
15 mortality in addition to causing a significant economic strain on the meager health
16 resources. This generally observed low proportion of attainment of key diabetes
17 treatment goals and high prevalence of diabetes complications, notably diabetic
18 neuropathy, retinopathy, and nephropathy in Africa exists broadly due to challenges
19 related to screening, diagnosis, and management of DM.
20
21
22
23
24
25
26
27
28
29

30 Awareness of diabetes in the general African population and healthcare practitioners
31 remains very poor, resulting in delayed diagnosis of diabetes. The challenge of ready
32 access to affordable essential diabetes medicines like insulin and statins and
33 diagnostic tests or equipment like glucometers for home self-monitoring of glucose,
34 HbA1c, and lipid profile tests remains highly prevalent in most African countries.¹⁴⁵⁻¹⁴⁹
35
36
37
38
39
40
41

42 Effective management of diabetes and its related cardiovascular risk factors like
43 hypertension and dyslipidaemia in most healthcare settings in Africa also remains a
44 significant clinical challenge.³ Most healthcare facilities especially the lower-tier ones
45 lack local or institution-specific comprehensive diabetes treatment guidelines to guide
46 healthcare practitioners on how to optimally manage diabetes, in addition to the
47 evident knowledge-practice gaps among healthcare practitioners.²
48
49
50
51
52
53
54
55

56 Healthcare systems in most African countries remain poorly structured to optimally
57 manage most non-communicable diseases like diabetes along with an inadequately
58
59
60

1
2
3 funded health sector. Most African countries have not yet fulfilled the 2001 Abuja
4 Declaration of allocating 15% of their national annual budget to the health sector.^{2 150}
5

6
7 This systematic review and meta-analysis had its strengths and limitations. To our
8 knowledge, it is the first to simultaneously investigate the status of attainment of the
9
10 three key diabetes treatment goals and the burden of five common diabetes
11
12 complications in an adult indigenous African population with type 2 diabetes. The
13
14 systematic review and meta-analysis included a large number of studies that assessed
15
16 the extent of attainment of diabetes treatment goals and the prevalence of diabetes
17
18 complications based on recommendations or definitions by internationally recognised
19
20 associations.
21
22
23
24

25
26 It also had its limitations. There was considerable heterogeneity in the included
27
28 studies. This could be explained by the differences in study sites (tertiary vs low-tier
29
30 hospitals or private vs public hospitals), patient characteristics (age, duration of
31
32 diabetes, co-existing medical conditions), regions where the studies were conducted,
33
34 and diagnostic modalities used to identify diabetes complications. The systematic
35
36 review also excluded studies published in French which is the official language of
37
38 some African countries. However, these were very few. There was evidence of
39
40 publication bias in some of the included studies especially studies investigating the
41
42 prevalence of diabetic nephropathy and peripheral neuropathy and the proportion of
43
44 attainment of an optimal BP goal. About 23% of the included studies were moderate
45
46 and low-quality on assessment using the NOS for cross-sectional studies.
47
48
49

50 51 **CONCLUSION**

52
53 Achievement of optimal diabetes treatment goals, especially HbA1c and BP, in adult
54
55 African patients with type 2 diabetes remains low in Africa. Diabetes complications
56
57 especially diabetic peripheral neuropathy and retinopathy also remain highly
58
59
60

1
2
3 prevalent. Implementation of universal diabetes screening and education initiatives
4
5 coupled with improving knowledge about diabetes management among healthcare
6
7 practitioners, and ready access to affordable essential diabetes diagnostic tests and
8
9 medicines in Africa are integral in improving overall optimal diabetes care and reducing
10
11 the burden of diabetes complications.
12
13

14
15 Considering the projected future increase in the prevalence of diabetes globally,
16
17 especially in the African region, there is an urgent need to address glaring gaps in
18
19 diabetes care and to develop simple and pragmatic interventions to improve treatment
20
21 outcomes and reduce the burden of diabetes complications
22
23

24 **Contributorship statement**

25
26 DK and NC-Conceived the research idea, performed the preliminary screening of titles
27
28 and abstracts to identify potentially eligible articles, and wrote the initial draft of the
29
30 manuscript, DK, NC, IAB, SNL, IS (Sekitoleko), APK, SN- Retrieved full texts and
31
32 identified the eligible articles, KK, SNL, APK, SN, PS, FB, LEM, WO, TDM, NEN, IS
33
34 (Sabi)-extracted data from the identified eligible articles, DK and IS (Sekitoleko)
35
36 performed the data analysis and interpretation, NC, KK, and SNL- performed the
37
38 assessment of the quality of studies, KS, PCH, LB, JVM, RVC, JC- offered additional
39
40 data interpretation and supervised this work. All the authors reviewed the different
41
42 versions of the manuscript and read and approved the final draft of the manuscript.
43
44
45

46 **Funding statement**

47
48
49 The systematic review and meta-analysis are part of the Preventive Treatment Of
50
51 Latent Tuberculosis Infection In People With Diabetes Mellitus (PROTID) study funded
52
53 by the European Developing Countries Clinical Trials Partnership 2 (EDCTP)
54
55 programme supported by the European Union (grant number RIA2018CO-2514-
56
57 PROTID).
58
59
60

Conflict of interest statement

There are no competing interests for any author.

Ethical approval

This study involves human participants but was not approved by an Ethics Committee(s) or Institutional Board(s) because it is a systematic review and meta-analysis of published studies.

Data sharing

Data are available upon reasonable request.

Acknowledgments

We would like to thank Miss Laura Russel, a medical librarian based at the Education and Research Centre, Wythenshawe Hospital, Manchester UK who was very helpful in performing the initial search of the databases and retrieval of all the studies that were screened. Patient advisers were not involved in this systematic review and meta-analysis.

REFERENCES

1. IDF. International Diabetes Federation Diabetes Atlas 10th edition. <https://diabetesatlas.org> (accessed 12 November 2021) 2021
2. Atun R, Davies JI, Gale EAM, et al. Diabetes in sub-Saharan Africa: from clinical care to health policy. *Lancet Diabetes Endocrinol* 2017;5(8):622-67. doi: 10.1016/s2213-8587(17)30181-x [published Online First: 2017/07/10]
3. Sobngwi E, Ndour-Mbaye M, Boateng KA, et al. Type 2 diabetes control and complications in specialised diabetes care centres of six sub-Saharan African countries: the Diabcare Africa study. *Diabetes Res Clin Pract* 2012;95(1):30-6. doi: 10.1016/j.diabres.2011.10.018 [published Online First: 2011/11/11]

- 1
2
3 4. Gill GV, Mbanja JC, Ramaiya KL, et al. A sub-Saharan African perspective of
4
5 diabetes. *Diabetologia* 2009;52(1):8-16. doi: 10.1007/s00125-008-1167-9
6
7 [published Online First: 2008/10/11]
8
9
- 10 5. Hall V, Thomsen RW, Henriksen O, et al. Diabetes in Sub Saharan Africa 1999-
11
12 2011: epidemiology and public health implications. A systematic review. *BMC*
13
14 *Public Health* 2011;11:564. doi: 10.1186/1471-2458-11-564 [published Online
15
16 First: 2011/07/16]
17
18
- 19 6. Nuche-Berenguer B, Kupfer LE. Readiness of Sub-Saharan Africa Healthcare
20
21 Systems for the New Pandemic, Diabetes: A Systematic Review. *J Diabetes*
22
23 *Res* 2018;2018:9262395. doi: 10.1155/2018/9262395
24
25
- 26 7. American Diabetes Association. Cardiovascular Disease and Risk Management:
27
28 Standards of Medical Care in Diabetes—2021. *Diabetes care* 2021;44:S125-
29
30 S50; DOI: 10.2337/dc21-S010.
31
32
- 33 8. American Diabetes Association. Pharmacologic Approaches to Glycemic
34
35 Treatment: Standards of Medical Care in Diabetes—2021. *Diabetes care*
36
37 2021;44(Supplement 1):S111. doi: 10.2337/dc21-S009
38
39
- 40 9. IDF. International Diabetes Federation. IDF Clinical Practice Recommendations for
41
42 Managing Type 2 Diabetes in Primary Care. [https://www.idf.org/e-](https://www.idf.org/e-library/guidelines/128-idf-clinical-practice-recommendations-for-managing-type-2-diabetes-in-primary-care.html)
43
44 [library/guidelines/128-idf-clinical-practice-recommendations-for-managing-](https://www.idf.org/e-library/guidelines/128-idf-clinical-practice-recommendations-for-managing-type-2-diabetes-in-primary-care.html)
45
46 [type-2-diabetes-in-primary-care.html](https://www.idf.org/e-library/guidelines/128-idf-clinical-practice-recommendations-for-managing-type-2-diabetes-in-primary-care.html) (accessed on 17 September 2021). 2018
47
48
- 49 10. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic
50
51 reviews and meta-analyses: the PRISMA statement. *PLoS Med*
52
53 2009;6(7):e1000097. doi: 10.1371/journal.pmed.1000097 [published Online
54
55 First: 2009/07/22]
56
57
58
59
60

- 1
2
3 11. ADA. American Diabetes Association. Classification and Diagnosis of Diabetes:
4
5 Standards of Medical Care in Diabetes-2021. *Diabetes Care* 2021;44(Suppl
6
7 1):S15-s33. doi: 10.2337/dc21-S002 [published Online First: 2020/12/11]
8
9
- 10
11 12. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for
12
13 assessing the quality of nonrandomised studies in meta-analyses.
14
15 http://www.ohrica/programs/clinical_epidemiology/oxfordasp (accessed 2
16
17 September 2021) 2021
- 18
19 13. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*
20
21 1986;7(3):177-88. doi: 10.1016/0197-2456(86)90046-2 [published Online First:
22
23 1986/09/01]
- 24
25 14. Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic
26
27 reviews: a new edition of the Cochrane Handbook for Systematic Reviews of
28
29 Interventions. *Cochrane Database of Systematic Reviews* 2019(10) doi:
30
31 10.1002/14651858.ED000142
- 32
33 15. Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a
34
35 simple, graphical test. *BMJ* 1997;315(7109):629-34. doi:
36
37 10.1136/bmj.315.7109.629
- 38
39 16. Gulam-Abbas Z, Lutale JK, Morbach S, et al. Clinical outcome of diabetes patients
40
41 hospitalized with foot ulcers, Dar es Salaam, Tanzania. *Diabet Med*
42
43 2002;19(7):575-9. doi: 10.1046/j.1464-5491.2002.00740.x [published Online
44
45 First: 2002/07/09]
- 46
47 17. Abbas ZG, Lutale JK, Bakker K, et al. The 'Step by Step' Diabetic Foot Project in
48
49 Tanzania: a model for improving patient outcomes in less-developed countries.
50
51 *Int Wound J* 2011;8(2):169-75. doi: 10.1111/j.1742-481X.2010.00764.x
52
53 [published Online First: 2011/01/27]
- 54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
18. Abdissa D, Adugna T, Gerema U, et al. Prevalence of Diabetic Foot Ulcer and Associated Factors among Adult Diabetic Patients on Follow-Up Clinic at Jimma Medical Center, Southwest Ethiopia, 2019: An Institutional-Based Cross-Sectional Study. *J Diabetes Res* 2020;2020:4106383. doi: 10.1155/2020/4106383 [published Online First: 2020/04/08]
 19. Abejew AA, Belay AZ, Kerie MW. Diabetic Complications among Adult Diabetic Patients of a Tertiary Hospital in Northeast Ethiopia. *Advances in Public Health* 2015;2015:290920. doi: 10.1155/2015/290920
 20. Akalu Y, Belsti Y. Hypertension and Its Associated Factors Among Type 2 Diabetes Mellitus Patients at Debre Tabor General Hospital, Northwest Ethiopia. *Diabetes Metab Syndr Obes* 2020;13:1621-31. doi: 10.2147/DMSO.S254537
 21. Amour AA, Chamba N, Kayandabila J, et al. Prevalence, Patterns, and Factors Associated with Peripheral Neuropathies among Diabetic Patients at Tertiary Hospital in the Kilimanjaro Region: Descriptive Cross-Sectional Study from North-Eastern Tanzania. *Int J Endocrinol* 2019;2019:5404781. doi: 10.1155/2019/5404781 [published Online First: 2019/07/06]
 22. Chalya PL, Mabula JB, Dass RM, et al. Surgical management of Diabetic foot ulcers: A Tanzanian university teaching hospital experience. *BMC Res Notes* 2011;4:365. doi: 10.1186/1756-0500-4-365 [published Online First: 2011/09/29]
 23. Chamba NG, Shao ER, Tolbert S, et al. Lipid Profile of Type 2 Diabetic Patients at a Tertiary Hospital in Tanzania: Cross Sectional Study. *J Endocrinol Diab* 2017;4(1):1-6.

- 1
2
3 24. Chisha Y, Terefe W, Assefa H, et al. Prevalence and factors associated with
4
5 diabetic retinopathy among diabetic patients at Arbaminch General Hospital,
6
7 Ethiopia: Cross sectional study. *PLoS One* 2017;12(3):e0171987. doi:
8
9 10.1371/journal.pone.0171987
10
11
12 25. Chiwanga FS, Njelekela MA. Diabetic foot: prevalence, knowledge, and foot self-
13
14 care practices among diabetic patients in Dar es Salaam, Tanzania - a cross-
15
16 sectional study. *J Foot Ankle Res* 2015;8:20-20. doi: 10.1186/s13047-015-
17
18 0080-y
19
20
21 26. Cleland CR, Burton MJ, Hall C, et al. Diabetic retinopathy in Tanzania: prevalence
22
23 and risk factors at entry into a regional screening programme. *Trop Med Int*
24
25 *Health* 2016;21(3):417-26. doi: 10.1111/tmi.12652 [published Online First:
26
27 2015/12/09]
28
29
30 27. Deribe B, Woldemichael K, Nemera G. Prevalence and Factors Influencing
31
32 Diabetic Foot Ulcer among Diabetic Patients Attending Arbaminch Hospital,
33
34 South Ethiopia. *J Diabetes Metab Disord* 2014;2:322.
35
36
37 28. Fasil A, Biadgo B, Abebe M. Glycemic control and diabetes complications among
38
39 diabetes mellitus patients attending at University of Gondar Hospital, Northwest
40
41 Ethiopia. *Diabetes Metab Syndr Obes* 2018;12:75-83. doi:
42
43 10.2147/DMSO.S185614
44
45
46 29. Gebrekirstos K, Gebrekiros S, Fantahun A. Prevalence and Factors Associated
47
48 With Diabetic Foot Ulcer among Adult Patients in Ayder Referral Hospital
49
50 Diabetic Clinic Mekelle, North Ethiopia, 2013. *J Diabetes Metab* 2015;6:579.
51
52
53 30. Gill G, Gebrekidan A, English P, et al. Diabetic complications and glycaemic
54
55 control in remote North Africa. *QJM* 2008;101(10):793-8. doi:
56
57 10.1093/qjmed/hcn096 [published Online First: 2008/08/09]
58
59
60

- 1
2
3 31. Kumela Goro K, Desalegn Wolide A, Kerga Dibaba F, et al. Patient Awareness,
4
5 Prevalence, and Risk Factors of Chronic Kidney Disease among Diabetes
6
7 Mellitus and Hypertensive Patients at Jimma University Medical Center,
8
9 Ethiopia. *BioMed Research International* 2019;2019:2383508. doi:
10
11 10.1155/2019/2383508
12
13
14
15 32. Janmohamed MN, Kalluvya SE, Mueller A, et al. Prevalence of chronic kidney
16
17 disease in diabetic adult out-patients in Tanzania. *BMC Nephrol* 2013;14:183-
18
19 83. doi: 10.1186/1471-2369-14-183
20
21
22 33. Jarso G, Ahmed A, Feleke Y. The prevalence, clinical features and management
23
24 of peripheral neuropathy among diabetic patients in Tikur Anbessa and St. Paul's
25
26 Specialized University Hospitals, Addis Ababa, Ethiopia. *Ethiop Med J*
27
28 2011;49(4):299-311. [published Online First: 2011/10/01]
29
30
31 34. Jember G, Melsew YA, Fisseha B, et al. Peripheral Sensory Neuropathy and
32
33 associated factors among adult diabetes mellitus patients in Bahr Dar, Ethiopia.
34
35 *J Diabetes Metab Disord* 2017;16:16-16. doi: 10.1186/s40200-017-0295-5
36
37
38 35. Kibirige D, Akabwai GP, Kampiire L, et al. Frequency and predictors of suboptimal
39
40 glycemic control in an African diabetic population. *Int J Gen Med* 2017;10:33-
41
42 38. doi: 10.2147/IJGM.S124548
43
44
45 36. Kimando MW, Otieno FCF, Ogola EN, et al. Adequacy of control of cardiovascular
46
47 risk factors in ambulatory patients with type 2 diabetes attending diabetes out-
48
49 patients clinic at a county hospital, Kenya. *BMC Endo Disord* 2017;17(1):73.
50
51 doi: 10.1186/s12902-017-0223-1
52
53
54 37. Kisozi T, Mutebi E, Kisekka M, et al. Prevalence, severity and factors associated
55
56 with peripheral neuropathy among newly diagnosed diabetic patients attending
57
58
59
60

- 1
2
3 Mulago hospital: a cross-sectional study. *Afr Health Sci* 2017;17(2):463-73. doi:
4 10.4314/ahs.v17i2.21 [published Online First: 2017/10/25]
5
6
7
8 38. Lebeta KR, Argaw Z, Birhane BW. Prevalence of Diabetic Complications and Its
9 Associated Factors Among Diabetes Mellitus Patients Attending Diabetes
10 Mellitus Clinics; Institution Based Cross Sectional Study. *American Journal of*
11 *Health Research* 2017;5(2):38-43.
12
13
14
15
16
17 39. Lumu W, Kampiire L, Akabwai GP, et al. Dyslipidaemia in a Black African diabetic
18 population: burden, pattern and predictors. *BMC Res Notes* 2017;10(1):587.
19 doi: 10.1186/s13104-017-2916-y
20
21
22
23
24 40. Lumu W, Kampiire L, Akabwai GP, et al. Statin therapy reduces the likelihood of
25 suboptimal blood pressure control among Ugandan adult diabetic patients.
26 *The Clin Risk Manag* 2017;13:215-21. doi: 10.2147/TCRM.S120423
27
28
29
30
31 41. Magan T, Pouncey A, Gadhvi K, et al. Prevalence and severity of diabetic
32 retinopathy in patients attending the endocrinology diabetes clinic at Mulago
33 Hospital in Uganda. *Diabetes Res Clin Pract* 2019;152:65-70. doi:
34 10.1016/j.diabres.2019.04.024 [published Online First: 2019/05/08]
35
36
37
38
39
40 42. Mamo T, Yifter H, Lemessa T. Risk factors assessment of diabetic foot ulcer using
41 the sixty second screening tool: A hospital based cross-sectional study at Tikur
42 Anbessa Specialised Hospital. *Ethiop Med J* 2015;Suppl 2:45-9. [published
43 Online First: 2015/11/26]
44
45
46
47
48
49 43. Mariam TG, Alemayehu A, Tesfaye E, et al. Prevalence of Diabetic Foot Ulcer and
50 Associated Factors among Adult Diabetic Patients Who Attend the Diabetic
51 Follow-Up Clinic at the University of Gondar Referral Hospital, North West
52 Ethiopia, 2016: Institutional-Based Cross-Sectional Study. *J Diabetes Res*
53
54
55
56
57
58
59
60

- 2017;2017:2879249. doi: 10.1155/2017/2879249 [published Online First: 2017/08/10]
44. Mbwete GW, Kilonzo KG, Shao ER, et al. Suboptimal Blood Pressure Control, Associated Factors, and Choice of Antihypertensive Drugs among Type 2 Diabetic Patients at KCMC, Tanzania. *J Diabetes Res* 2020;2020:4376251. doi: 10.1155/2020/4376251 [published Online First: 2020/08/11]
45. Muddu M, Mutebi E, Mondo C. Prevalence, types and factors associated with echocardiographic abnormalities among newly diagnosed diabetic patients at Mulago Hospital. *Afr Health Sci* 2016;16(1):183-93. doi: 10.4314/ahs.v16i1.25 [published Online First: 2016/07/01]
46. Muddu M, Mutebi E, Ssinabulya I, et al. Utility of albumin to creatinine ratio in screening for microalbuminuria among newly diagnosed diabetic patients in Uganda: a cross sectional study. *Afr Health Sci* 2019;19(1):1607-16. doi: 10.4314/ahs.v19i1.36 [published Online First: 2019/06/01]
47. Mwebaze RM, Kibirige D. Peripheral arterial disease among adult diabetic patients attending a large outpatient diabetic clinic at a national referral hospital in Uganda: a descriptive cross sectional study. *PLoS One* 2014;9(8):e105211. doi: 10.1371/journal.pone.0105211 [published Online First: 2014/08/19]
48. Neuhann HF, Warter-Neuhann C, Lyaruu I, et al. Diabetes care in Kilimanjaro region: clinical presentation and problems of patients of the diabetes clinic at the regional referral hospital-an inventory before structured intervention. *Diabet Med* 2002;19(6):509-13. doi: 10.1046/j.1464-5491.2002.00673.x [published Online First: 2002/06/13]
49. Nyamu PN, Otieno CF, Amayo EO, et al. Risk factors and prevalence of diabetic foot ulcers at Kenyatta National Hospital, Nairobi. *East Afr Med J*

- 2003;80(1):36-43. doi: 10.4314/eamj.v80i1.8664 [published Online First: 2003/05/21]
50. Okello S, Millard A, Owori R, et al. Prevalence of lower extremity peripheral artery disease among adult diabetes patients in southwestern Uganda. *BMC Cardiovasc Disord* 2014;14:75. doi: 10.1186/1471-2261-14-75 [published Online First: 2014/06/11]
51. Seyum B, Mebrahtu G, Usman A, et al. Profile of patients with diabetes in Eritrea: results of first phase registry analyses. *Acta Diabetol* 2010;47(1):23-7. doi: 10.1007/s00592-009-0093-8 [published Online First: 2009/02/03]
52. Smide B. Outcome of foot examinations in Tanzanian and Swedish diabetic patients, a comparative study. *J Clin Nurs* 2009;18(3):391-8. doi: 10.1111/j.1365-2702.2008.02492.x [published Online First: 2009/02/05]
53. Tesfaye D, Tessema F, Taha M. Coexistence of Chronic Complications among Diabetic Patients at Nigist Eleni Mohammed Memorial Hospital, Hossana, South Ethiopia. *Open Access Library Journal* 2015;2:1-10.
54. Tilahun AN, Waktola C, Tewodros GM, et al. Major Micro vascular Complications and Associated Risk Factors among Diabetic Outpatients in Southwest Ethiopia. *Endocrinol Metab Syndr* 2017;6:272.
55. Vogt EC, Øksnes M, Suleiman F, et al. Assessment of diabetic polyneuropathy in Zanzibar: Comparison between traditional methods and an automated point-of-care nerve conduction device. *J Clin Transl Endocrinol* 2017;10:9-14. doi: 10.1016/j.jcte.2017.09.001
56. Woodward R, Mgaya E, Mwanansao C, et al. Retinopathy in adults with hypertension and diabetes mellitus in Western Tanzania: a cross-sectional

- 1
2
3 study. *Trop Med Int Health* 2020;25(10):1214-25. doi: 10.1111/tmi.13463
4
5 [published Online First: 2021/01/06]
6
7
8 57. Worku D, Hamza L, Woldemichael K. Patterns of diabetic complications at jimma
9 university specialized hospital, southwest ethiopia. *Ethiop J Health Sci*
10 2010;20(1):33-39. doi: 10.4314/ejhs.v20i1.69424
11
12
13
14
15 58. Ekoru K, Doumatey A, Bentley AR, et al. Type 2 diabetes complications and
16 comorbidity in Sub-Saharan Africans. *EClinicalMedicine* 2019;16:30-41. doi:
17 10.1016/j.eclinm.2019.09.001
18
19
20
21 59. Camara A, Baldé NM, Sobngwi-Tambekou J, et al. Poor glycaemic control in type
22 2 diabetes in the South of the Sahara: the issue of limited access to an HbA1c
23 test. *Diabetes Res Clin Pract* 2015;108(1):187-92. doi:
24 10.1016/j.diabres.2014.08.025 [published Online First: 2015/02/24]
25
26
27
28
29
30 60. Adetunji OR, Adeleye JO, Agada NO, et al. Microalbuminuria and clinical
31 correlates in black African patients with type 2 diabetes. *West Afr J Med*
32 2006;25(4):279-83. [published Online First: 2007/04/04]
33
34
35
36
37 61. Agboghroma OF, Akemokwe FM, Puepet FH. Peripheral arterial disease and its
38 correlates in patients with type 2 diabetes mellitus in a teaching hospital in
39 northern Nigeria: a cross-sectional study. *BMC Cardiovasc Disord*
40 2020;20(1):102. doi: 10.1186/s12872-020-01395-3
41
42
43
44
45
46 62. Alebiosu CO. Clinical diabetic nephropathy in a tropical African population. *West*
47 *Afr J Med* 2003;22(2):152-5. doi: 10.4314/wajm.v22i2.27938 [published Online
48 First: 2003/10/08]
49
50
51
52
53 63. Attoye TE, Adebobola PA, Inem V. An Assessment of Glycaemic Control and
54 Modes of Health Financing among Type 2 Diabetic Patients Attending a
55
56
57
58
59
60

- 1
2
3 Teaching Hospital in South-western Nigeria. *West Afr J Med* 2020;37(3):237-
4
5 47. [published Online First: 2020/06/02]
6
7
8 64. Balogun WO, Abbiyesuku FM. Excess renal insufficiency among type 2 diabetic
9
10 patients with dip-stick positive proteinuria in a tertiary hospital. *Afr J Med Med*
11
12 *Sci* 2011;40(4):399-403. [published Online First: 2012/07/13]
13
14
15 65. Bello A, Biliaminu S, Wahab K, et al. Distal symmetrical polyneuropathy and
16
17 cardiovascular autonomic neuropathy among diabetic patients in Ilorin:
18
19 Prevalence and predictors. *Niger Postgrad Med J* 2019;26(2):123-28. doi:
20
21 10.4103/npmj.npmj_30_19 [published Online First: 2019/06/13]
22
23
24 66. Bello BT, Amira CO. Pattern and predictors of urine protein excretion among
25
26 patients with type 2 diabetes attending a single tertiary hospital in Lagos,
27
28 Nigeria. *Saudi J Kidney Dis Transpl* 2017;28(6):1381-88. doi: 10.4103/1319-
29
30 2442.220869 [published Online First: 2017/12/22]
31
32
33 67. Uloko AE, Ofoegbu EN, Chinenye S, et al. Profile of Nigerians with diabetes
34
35 mellitus - Diabcare Nigeria study group (2008): Results of a multicenter study.
36
37 *Indian J Endocrinol Metab* 2012;16(4):558-64. doi: 10.4103/2230-8210.98011
38
39
40 68. Ede O, Eyichukwu G, Madu K, et al. Evaluation of Peripheral Neuropathy in
41
42 Diabetic Adults with and without Foot Ulcers in an African Population. *Journal*
43
44 *of Biosciences and Medicines* 2018;6:71-78.
45
46
47 69. Eghan BA, Jr., Frempong MT, Adjei-Poku M. Prevalence and predictors of
48
49 microalbuminuria in patients with diabetes mellitus: a cross-sectional
50
51 observational study in Kumasi, Ghana. *Ethn Dis* 2007;17(4):726-30. [published
52
53 Online First: 2007/12/13]
54
55
56 70. Hayfron-Benjamin C, van den Born BJ, Maitland-van der Zee AH, et al.
57
58 Microvascular and macrovascular complications in type 2 diabetes Ghanaian
59
60

- 1
2
3 residents in Ghana and Europe: The RODAM study. *J Diabetes Complications*
4 2019;33(8):572-78. doi: 10.1016/j.jdiacomp.2019.04.016 [published Online
5
6 First: 2019/06/07]
7
8
9
- 10 71. Iwuala SO, Olamoyegun MA, Sabir AA, et al. The relationship between self-
11 monitoring of blood glucose and glycaemic control among patients attending an
12 urban diabetes clinic in Nigeria. *Ann Afr Med* 2015;14(4):182-7. doi:
13 10.4103/1596-3519.155992 [published Online First: 2015/10/17]
14
15
16
17
18
- 19 72. Kizor-Akaraiwe NN, Ezegwui IR, Oguego N, et al. Prevalence, Awareness and
20 Determinants of Diabetic Retinopathy in a Screening Centre in Nigeria. *J*
21 *Community Health* 2016;41(4):767-71. doi: 10.1007/s10900-016-0151-4
22 [published Online First: 2016/01/27]
23
24
25
26
27
- 28 73. Kuate-Tegueu C, Temfack E, Ngankou S, et al. Prevalence and determinants of
29 diabetic polyneuropathy in a sub-Saharan African referral hospital. *J Neurol Sci*
30 2015;355(1-2):108-12. doi: 10.1016/j.jns.2015.05.035 [published Online First:
31 2015/06/07]
32
33
34
35
36
- 37 74. Lartey SY, Aikins AK. Visual impairment amongst adult diabetics attending a
38 tertiary outpatient clinic. *Ghana Med J* 2018;52(2):84-87. doi:
39 10.4314/gmj.v52i2.4 [published Online First: 2019/01/22]
40
41
42
43
44
- 45 75. Ogbera AO, Adeleye O, Solagberu B, et al. Screening for peripheral neuropathy
46 and peripheral arterial disease in persons with diabetes mellitus in a Nigerian
47 University Teaching Hospital. *BMC Res Notes* 2015;8(1):533. doi:
48 10.1186/s13104-015-1423-2
49
50
51
52
53
- 54 76. Olamoyegun M, Ibraheem W, Iwuala S, et al. Burden and pattern of micro vascular
55 complications in type 2 diabetes in a tertiary health institution in Nigeria. *Afr*
56
57
58
59
60

- 1
2
3 *Health Sci* 2015;15(4):1136-41. doi: 10.4314/ahs.v15i4.12 [published Online
4
5 First: 2016/03/10]
6
7
- 8 77. Onakpoya OH, Kolawole BA, Adeoye AO, et al. Visual impairment and blindness
9
10 in type 2 diabetics: Ife-Ijesa diabetic retinopathy study. *Int Ophthalmol*
11
12 2016;36(4):477-85. doi: 10.1007/s10792-015-0145-8 [published Online First:
13
14 2015/11/06]
15
16
- 17 78. Oyelade BO, OlaOlorun AD, Odeigah LO, et al. The prevalence of peripheral
18
19 arterial disease in diabetic subjects in south-west Nigeria. *Afr J Prim Health*
20
21 *Care Fam Med* 2012;4(1):354. doi: 10.4102/phcfm.v4i1.354
22
23
- 24 79. Ugoya SO, Echejoh GO, Ugoya TA, et al. Clinically diagnosed diabetic neuropathy:
25
26 frequency, types and severity. *J Natl Med Assoc* 2006;98(11):1763-6.
27
28 [published Online First: 2006/11/30]
29
30
- 31 80. Unachukwu C, Babatunde S, Ihekwaba AE. Diabetes, hand and/or foot ulcers: a
32
33 cross-sectional hospital-based study in Port Harcourt, Nigeria. *Diabetes Res*
34
35 *Clin Pract* 2007;75(2):148-52. doi: 10.1016/j.diabres.2006.05.016 [published
36
37 Online First: 2006/07/11]
38
39
- 40 81. Mohmad AH, Hassan A. Correlation between retinopathy, nephropathy and
41
42 peripheral neuropathy among adult Sudanese diabetic patients. . *Sudan J Me*
43
44 *Sci* 2011;6(1)
45
46
- 47 82. Ahmed MH, Elwali ES, Awadalla H, et al. The relationship between diabetic
48
49 retinopathy and nephropathy in Sudanese adult with diabetes: population
50
51 based study. *Diabetes Metab Syndr* 2017;11 Suppl 1:S333-s36. doi:
52
53 10.1016/j.dsx.2017.03.011 [published Online First: 2017/03/23]
54
55
56
57
58
59
60

- 1
2
3 83. Albalawi HB, Alali NM, Alenezi SH, et al. The relationship between periodontitis
4 and diabetic retinopathy: A cross-sectional longitudinal study. *Australasian*
5 *Medical Journal* 2020;13:50-54.
6
7
8
9
10 84. Ashur ST, Shah SA, Bosseri S, et al. Glycaemic control status among type 2
11 diabetic patients and the role of their diabetes coping behaviours: a clinic-based
12 study in Tripoli, Libya. *Libyan J Med* 2016;11:31086. doi:
13 10.3402/ljm.v11.31086 [published Online First: 2016/03/24]
14
15
16
17
18 85. Assaad-Khalil SH, Zaki A, Abdel Rehim A, et al. Prevalence of diabetic foot
19 disorders and related risk factors among Egyptian subjects with diabetes. *Prim*
20 *Care Diabetes* 2015;9(4):297-303. doi: 10.1016/j.pcd.2014.10.010 [published
21 Online First: 2014/12/30]
22
23
24
25
26
27
28 86. Khalil SA, Megallaa MH, Rohoma KH, et al. Prevalence of Chronic Diabetic
29 Complications in Newly Diagnosed versus Known Type 2 Diabetic Subjects in
30 a Sample of Alexandria Population, Egypt. *Curr Diabetes Rev* 2019;15(1):74-
31 83. doi: 10.2174/1573399814666180125100917 [published Online First:
32 2018/01/26]
33
34
35
36
37
38
39 87. Awadalla H, Noor SK, Elmadhoun WM, et al. Diabetes complications in Sudanese
40 individuals with type 2 diabetes: Overlooked problems in sub-Saharan Africa?
41 *Diabetes Metab Syndr* 2017;11 Suppl 2:S1047-s51. doi:
42 10.1016/j.dsx.2017.07.039 [published Online First: 2017/08/10]
43
44
45
46
47
48 88. Bentata Y, Chemlal A, Karimi I, et al. Diabetic kidney disease and vascular
49 comorbidities in patients with type 2 diabetes mellitus in a developing country.
50 *Saudi J Kidney Dis Transpl* 2015;26(5):1035-43. doi: 10.4103/1319-
51 2442.164602 [published Online First: 2015/09/12]
52
53
54
55
56
57
58
59
60

- 1
2
3 89. Bouaziz A, Zidi I, Zidi N, et al. Nephropathy following type 2 diabetes mellitus in
4 Tunisian population. *West Indian Med J* 2012;61(9):881-9. doi:
5 10.7727/wimj.2012.053 [published Online First: 2013/09/12]
6
7
8
9
10 90. Chadli A, El Aziz S, El Ansari N, et al. Management of diabetes in Morocco: results
11 of the International Diabetes Management Practices Study (IDMPS) - wave 5.
12 *Ther Adv Endocrinol Metab* 2016;7(3):101-9. doi: 10.1177/2042018816643227
13 [published Online First: 2016/06/14]
14
15
16
17
18
19 91. Chahbi Z, Lahmar B, Hadri SE, et al. The prevalence of painful diabetic neuropathy
20 in 300 Moroccan diabetics. *Pan Afr Med J* 2018;31:158-58. doi:
21 10.11604/pamj.2018.31.158.14687
22
23
24
25
26 92. Chetoui A, Kaoutar K, Elmoussaoui S, et al. Prevalence and determinants of poor
27 glycaemic control: a cross-sectional study among Moroccan type 2 diabetes
28 patients. *Int Health* 2020;14(4):390-397.
29
30
31
32
33 93. Diaf M, Khaled BM. Metabolic profile, nutritional status and determinants of
34 glycaemic control in Algerian type 2 diabetic patients. *Kuwait Medical Journal*
35 2017;49:135-41.
36
37
38
39
40 94. Elnasri HA, Ahmed AM. Patterns of lipid changes among type 2 diabetes patients
41 in Sudan. *Eastern Mediterranean Health Journal* 2008;14(2):314-24.
42
43
44 95. Elwali ES, Almobarak AO, Hassan MA, et al. Frequency of diabetic retinopathy
45 and associated risk factors in Khartoum, Sudan: population based study. *Int J*
46 *Ophthalmol* 2017;10(6):948-54. doi: 10.18240/ijo.2017.06.18
47
48
49
50
51 96. Kahloun R, Jelliti B, Zaouali S, et al. Prevalence and causes of visual impairment
52 in diabetic patients in Tunisia, North Africa. *Eye (Lond)* 2014;28(8):986-91. doi:
53 10.1038/eye.2014.131 [published Online First: 2014/06/14]
54
55
56
57
58
59
60

- 1
2
3 97. Megallaa MH, Ismail AA, Zeitoun MH, et al. Association of diabetic foot ulcers with
4 chronic vascular diabetic complications in patients with type 2 diabetes.
5
6 Diabetes Metab Syndr 2019;13(2):1287-92. doi: 10.1016/j.dsx.2019.01.048
7
8 [published Online First: 2019/07/25]
9
10
11
12 98. Noor SK, Elmadhoun WM, Bushara SO, et al. Glycaemic control in Sudanese
13 individuals with type 2 diabetes: Population based study. *Diabetes Metab Syndr*
14 2017;11 Suppl 1:S147-S51. doi: 10.1016/j.dsx.2016.12.024
15
16
17
18 99. Omar SM, Musa IR, Osman OE, et al. Assessment of glycemic control in type 2
19 diabetes in the Eastern Sudan. *BMC Res Notes* 2018;11(1):373. doi:
20 10.1186/s13104-018-3480-9
21
22
23
24 100. Adeniyi OV, Owolabi EO. Cross-sectional study of diabetes kidney disease in the
25 Eastern Cape, South Africa. *Medicine (Baltimore)* 2020;99(50):e23303. doi:
26 10.1097/md.00000000000023303 [published Online First: 2020/12/18]
27
28
29
30 101. Amod A, Riback W, Schoeman H. Diabetes guidelines and clinical practice: Is
31 there a gap? The South African cohort of the International Diabetes
32 Management Practices Study. *Journal of Endocrinology, Metabolism and*
33 *Diabetes of South Africa* 2012;17:85-90.
34
35
36
37
38
39
40
41 102. Blake AM, Munby HN, Katlego PM, et al. Characteristics of patients with diabetic
42 retinopathy in Gaborone, Botswana. *Tanzan J Health Res.* 2015;17:1.
43
44
45
46
47 103. Burgess PI, Allain TJ, García-Fiñana M, et al. High prevalence in Malawi of sight-
48 threatening retinopathy and visual impairment caused by diabetes:
49 identification of population-specific targets for intervention. *Diabet Med*
50 2014;31(12):1643-50. doi: 10.1111/dme.12492 [published Online First:
51 2014/05/16]
52
53
54
55
56
57
58
59
60

- 1
2
3 104. Cairncross JP, Steinberg WJ, Labuschagne MJ. Prevalence of eye pathology in
4 a group of diabetic patients at National District Hospital Outpatient Department
5 in Bloemfontein, South Africa. *Afr J Prim Health Care Fam Med* 2017;9(1):e1-
6 e7. doi: 10.4102/phcfm.v9i1.1440 [published Online First: 2017/10/19]
7
8
9
10
11
12 105. Cohen DB, Allain TJ, Glover S, et al. A survey of the management, control, and
13 complications of diabetes mellitus in patients attending a diabetes clinic in
14 Blantyre, Malawi, an area of high HIV prevalence. *Am J Trop Med Hyg*
15 2010;83(3):575-81. doi: 10.4269/ajtmh.2010.10-0104
16
17
18
19
20
21 106. Glover SJ, Burgess PI, Cohen DB, et al. Prevalence of diabetic retinopathy,
22 cataract and visual impairment in patients with diabetes in sub-Saharan Africa.
23 *Br J Ophthalmol* 2012;96(2):156-61. doi: 10.1136/bjo.2010.196071 [published
24 Online First: 2011/04/26]
25
26
27
28
29
30 107. Lewis AD, Hogg RE, Chandran M, et al. Prevalence of diabetic retinopathy and
31 visual impairment in patients with diabetes mellitus in Zambia through the
32 implementation of a mobile diabetic retinopathy screening project in the
33 Copperbelt province: a cross-sectional study. *Eye (Lond)* 2018;32(7):1201-08.
34 doi: 10.1038/s41433-018-0055-x [published Online First: 2018/03/06]
35
36
37
38
39
40
41 108. Machingura PI, Chikwasha V, Okwanga PN, et al. Prevalence of and Factors
42 Associated with Nephropathy in Diabetic Patients Attending an Outpatient
43 Clinic in Harare, Zimbabwe. *Am J Trop Med Hyg* 2017;96(2):477-82. doi:
44 10.4269/ajtmh.15-0827 [published Online First: 2016/12/21]
45
46
47
48
49
50 109. Makwero MT, Mollentze WF, Joubert G, et al. Anthropometric profile and
51 complications in patients with diabetes mellitus seen at Maluti Adventist
52 Hospital, Lesotho. *South African Family Practice* 2018;60:97-102.
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
110. Molefe-Baikai OJ, Molefi M, Cainelli F, et al. The prevalence of microalbuminuria and associated factors among patients with type 2 diabetes mellitus in Botswana. *Niger J Clin Pract* 2018;21(11):1430-37. doi: 10.4103/njcp.njcp_224_18 [published Online First: 2018/11/13]
111. Mwita JC, Francis JM, Omech B, et al. Glycaemic, blood pressure and low-density lipoprotein-cholesterol control among patients with diabetes mellitus in a specialised clinic in Botswana: a cross-sectional study. *BMJ Open* 2019;9(7):e026807. doi: 10.1136/bmjopen-2018-026807 [published Online First: 2019/07/26]
112. Pirie FJ, Maharaj S, Esterhuizen TM, et al. Retinopathy in subjects with type 2 diabetes at a tertiary diabetes clinic in Durban, South Africa: Clinical, biochemical and genetic factors. *J Clin Transl Endocrinol* 2014;1(1):e9-e12. doi: 10.1016/j.jcte.2013.12.002 [published Online First: 2013/12/19]
113. Rotchford AP, Rotchford KM. Diabetes in rural South Africa--an assessment of care and complications. *S Afr Med J* 2002;92(7):536-41. [published Online First: 2002/08/29]
114. Thinyane KH, Theketsa CE. Characteristics of patients admitted with diabetes in Maseru, Lesotho. *African Journal of Diabetes Medicine* 2013;21:17-19.
115. Thomas RL, Distiller L, Luzio SD, et al. Ethnic differences in the prevalence of diabetic retinopathy in persons with diabetes when first presenting at a diabetes clinic in South Africa. *Diabetes Care* 2013;36(2):336-41. doi: 10.2337/dc12-0683 [published Online First: 2012/10/04]
116. Webb EM, Rheeder P, Van Zyl DG. Diabetes care and complications in primary care in the Tshwane district of South Africa. *Prim Care Diabetes* 2015;9(2):147-54. doi: 10.1016/j.pcd.2014.05.002 [published Online First: 2014/06/17]

- 1
2
3 117. Blum J, Chaney M, Mudji J, et al. Glycaemic control among patients with type 2
4 diabetes followed in a rural African primary care setting - A reality check in the
5 Democratic Republic of Congo. *Prim Care Diabetes* 2020;14(2):139-46. doi:
6 10.1016/j.pcd.2019.08.002 [published Online First: 2019/08/29]
7
8
9
10
11
12 118. Dzudie A, Choukem SP, Adam AK, et al. Prevalence and determinants of
13 electrocardiographic abnormalities in sub-Saharan African individuals with type
14 2 diabetes. *Cardiovasc J Afr* 2012;23(10):533-7. doi: 10.5830/cvja-2012-054
15 [published Online First: 2012/09/21]
16
17
18
19
20
21 119. Efundem NT, Assob JCN, Feteh VF, et al. Prevalence and associations of
22 microalbuminuria in proteinuria-negative patients with type 2 diabetes in two
23 regional hospitals in Cameroon: a cross-sectional study. *BMC Res Notes*
24 2017;10(1):477. doi: 10.1186/s13104-017-2804-5
25
26
27
28
29
30
31 120. Hall KK, Tambekou J, Penn L, et al. Association between depression, glycaemic
32 control and the prevalence of diabetic retinopathy in a diabetic population in
33 Cameroon. *S Afr J Psychiatr* 2017;23:983-83. doi:
34 10.4102/sajpsychiatry.v23i0.983
35
36
37
38
39
40 121. Jingi AM, Nansseu JR, Noubiap JJ, et al. Diabetes and visual impairment in sub-
41 Saharan Africa: evidence from Cameroon. *J Diabetes Metab Disord*
42 2015;14:21. doi: 10.1186/s40200-015-0151-4 [published Online First:
43 2015/04/14]
44
45
46
47
48
49 122. Jingi AM, Noubiap JJN, Ellong A, et al. Epidemiology and treatment outcomes of
50 diabetic retinopathy in a diabetic population from Cameroon. *BMC Ophthalmol*
51 2014;14(1):19. doi: 10.1186/1471-2415-14-19
52
53
54
55
56 123. Njikam EJ, Kariuki MM, Kollmann MK, et al. The magnitude and pattern of
57 diabetic retinopathy in Yaoundé, Cameroon - a cross-sectional hospital-based
58
59
60

- 1
2
3 study. *Acta Ophthalmol* 2016;94(2):e156-7. doi: 10.1111/aos.12747 [published
4
5 Online First: 2015/05/29]
6
7
- 8 124. Chadli A, El Aziz S, El Ansari N, et al. Management of diabetes in Morocco:
9
10 results of the International Diabetes Management Practices Study (IDMPS) -
11
12 wave 5. *Ther Adv Endocrinol Metab* 2016;7(3):101-09. doi:
13
14 10.1177/2042018816643227 [published Online First: 2016/04/13]
15
16
- 17 125. Iwuala S, Olamoyegun M, Sabir A, et al. The relationship between self-monitoring
18
19 of blood glucose and glycaemic control among patients attending an urban
20
21 diabetes clinic in Nigeria. *Ann Afr Med* 2015;14(4):182-87. doi: 10.4103/1596-
22
23 3519.155992
24
25
- 26 126. Elnasri HA, Ahmed AM. Patterns of lipid changes among type 2 diabetes patients
27
28 in Sudan. *Eastern Mediterranean health journal* 2008;14(2):314-24.
29
30
- 31 127. Albalawi HB, Alali NM, Alenezi SH, et al. The relationship between periodontitis
32
33 and diabetic retinopathy: A cross-sectional longitudinal study. *AMJ*
34
35 2020;13(2):50-54.
36
37
- 38 128. Bello A, Biliaminu S, Wahab K, et al. Distal symmetrical polyneuropathy and
39
40 cardiovascular autonomic neuropathy among diabetic patients in Ilorin:
41
42 Prevalence and predictors. *Niger Postgrad Med J* 2019;26(2):123-28. doi:
43
44 10.4103/npmj.npmj_30_19
45
46
- 47 129. Blake AM, Munby HN, Katlego PM, et al. Characteristics of patients with diabetic
48
49 retinopathy in Gaborone, Botswana. *Tanzan J Health Res* 2015;17(1) doi:
50
51 10.4314/thrb.v17i1.
52
53
- 54 130. Vogt EC, Øksnes M, Suleiman F, et al. Assessment of diabetic polyneuropathy
55
56 in Zanzibar: Comparison between traditional methods and an automated point-
57
58
59
60

- 1
2
3 of-care nerve conduction device. *J Clin Transl Endocrinol* 2017;10:9-14. doi:
4 10.1016/j.jcte.2017.09.001 [published Online First: 2017/12/06]
5
6
7
8 131. Ali MK, Bullard KM, Saaddine JB, et al. Achievement of goals in U.S. diabetes
9 care, 1999-2010. *N Engl J Med* 2013;368(17):1613-24. doi:
10 10.1056/NEJMsa1213829 [published Online First: 2013/04/26]
11
12
13
14 132. Carls G, Huynh J, Tuttle E, et al. Achievement of Glycated Hemoglobin Goals in
15 the US Remains Unchanged Through 2014. *Diabetes Ther* 2017;8(4):863-73.
16 doi: 10.1007/s13300-017-0280-5
17
18
19
20 133. Al Mansari A, Obeid Y, Islam N, et al. GOAL study: clinical and non-clinical
21 predictive factors for achieving glycemic control in people with type 2 diabetes
22 in real clinical practice. *BMJ Open Diab Res Care* 2018;6(1):e000519. doi:
23 10.1136/bmjdr-2018-000519
24
25
26
27 134. Hu H, Hori A, Nishiura C, et al. Hba1c, Blood Pressure, and Lipid Control in
28 People with Diabetes: Japan Epidemiology Collaboration on Occupational
29 Health Study. *PLoS One* 2016;11(7):e0159071. doi:
30 10.1371/journal.pone.0159071 [published Online First: 2016/07/22]
31
32
33
34 135. Schmieder RE, Tschöpe D, Koch C, et al. Individualised treatment targets in
35 patients with type-2 diabetes and hypertension. *Cardiovasc Diabetol*
36 2018;17(1):18. doi: 10.1186/s12933-018-0661-8
37
38
39
40 136. Kumar KVS, Modi K. A1c, blood pressure and cholesterol goal achievement in
41 patients of Type 2 diabetes. *Medical Journal of Dr DY Patil University*
42 2016;9(2):195-99. doi: 10.4103/0975-2870.177659
43
44
45
46 137. Rigato M, Pizzol D, Tiago A, et al. Characteristics, prevalence, and outcomes of
47 diabetic foot ulcers in Africa. A systemic review and meta-analysis. *Diabetes*
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 Res Clin Pract 2018;142:63-73. doi: 10.1016/j.diabres.2018.05.016 [published
4 Online First: 2018/05/29]
5
6
7
8 138. Shiferaw WS, Akalu TY, Work Y, et al. Prevalence of diabetic peripheral
9 neuropathy in Africa: a systematic review and meta-analysis. *BMC Endo Disord*
10 2020;20(1):49. doi: 10.1186/s12902-020-0534-5
11
12
13
14 139. Burgess PI, MacCormick IJC, Harding SP, et al. Epidemiology of diabetic
15 retinopathy and maculopathy in Africa: a systematic review. *Diabet Med*
16 2013;30(4):399-412. doi: 10.1111/j.1464-5491.2012.03756.x
17
18
19
20
21 140. Achigbu E, Agweye C, Achigbu K, et al. Diabetic Retinopathy in Sub-Saharan
22 Africa: A Review of Magnitude and Risk Factors. *Nigerian Journal of*
23 *Ophthalmology* 2021;29(1):3-12. doi: 10.4103/njo.njo_49_20
24
25
26
27
28 141. Noubiap JJN, Naidoo J, Kengne AP. Diabetic nephropathy in Africa: A systematic
29 review. *World J Diabetes* 2015;6(5):759-73. doi: 10.4239/wjd.v6.i5.759
30
31
32
33 142. Johnston LE, Stewart BT, Yangni-Angate H, et al. Peripheral Arterial Disease in
34 Sub-Saharan Africa: A Review. *JAMA Surg* 2016;151(6):564-72. doi:
35 10.1001/jamasurg.2016.0446 [published Online First: 2016/04/07]
36
37
38
39 143. So WY, Raboca J, Sobrepena L, et al. Comprehensive risk assessments of
40 diabetic patients from seven Asian countries: The Joint Asia Diabetes
41 Evaluation (JADE) program. *J Diabetes* 2011;3(2):109-18. doi: 10.1111/j.1753-
42 0407.2011.00115.x [published Online First: 2011/05/24]
43
44
45
46
47
48 144. Fang M, Selvin E. Thirty-Year Trends in Complications in U.S. Adults With Newly
49 Diagnosed Type 2 Diabetes. *Diabetes Care* 2021;44(3):699-706. doi:
50 10.2337/dc20-2304 [published Online First: 2021/01/10]
51
52
53
54
55 145. Beran D, Yudkin JS, de Courten M. Access to care for patients with insulin-
56 requiring diabetes in developing countries: case studies of Mozambique and
57
58
59
60

- 1
2
3 Zambia. *Diabetes Care* 2005;28(9):2136-40. doi: 10.2337/diacare.28.9.2136
4
5 [published Online First: 2005/08/27]
6
7
8 146. Beran D, Yudkin JS. Looking beyond the issue of access to insulin: what is
9
10 needed for proper diabetes care in resource poor settings. *Diabetes Res Clin*
11
12 *Pract* 2010;88(3):217-21. doi: 10.1016/j.diabres.2010.03.029 [published Online
13
14 First: 2010/05/08]
15
16
17 147. Kibirige D, Atuhe D, Kampiire L, et al. Access to medicines and diagnostic tests
18
19 integral in the management of diabetes mellitus and cardiovascular diseases in
20
21 Uganda: insights from the ACCODAD study. *Int J Equity Health*
22
23 2017;16(1):154. doi: 10.1186/s12939-017-0651-6
24
25
26 148. Jingi AM, Noubiap JJ, Ewane Onana A, et al. Access to diagnostic tests and
27
28 essential medicines for cardiovascular diseases and diabetes care: cost,
29
30 availability and affordability in the West Region of Cameroon. *PLoS One*
31
32 2014;9(11):e111812. doi: 10.1371/journal.pone.0111812 [published Online
33
34 First: 2014/11/05]
35
36
37 149. Mendis S, Al Bashir I, Dissanayake L, et al. Gaps in capacity in primary care in
38
39 low-resource settings for implementation of essential noncommunicable
40
41 disease interventions. *Int J Hypertens* 2012;2012:584041. doi:
42
43 10.1155/2012/584041 [published Online First: 2012/12/20]
44
45
46 150. WHO. WHO. The Abuja Declaration: Ten Years On.
47
48 <https://www.who.int/healthsystems/publications/Abuja10pdf> (accessed on 8
49
50 October 2021) 2011
51
52
53
54
55
56
57
58
59
60

Table 1. General characteristics of all participants (n=63,890) included in the systematic review and meta-analysis

Characteristic	Cumulative value	Number of studies
Age in years (Mean \pm SD)	54.9 \pm 4.7	88
Gender- Females (% , 95% CI)	55.3, 95% CI 52.7-57.8	101
Smokers (% , 95% CI)	9.9, 95% CI 0.5-55.6	44
Participants on OHA (% , 95% CI)	65.0, 95% CI 34.0-96.6	51
Participants on insulin (% , 95% CI)	31.3, 95% CI 26.3-36.2	52
Participants on lipid lowering agents (% , 95% CI)	25.7, 95% CI 0.5-86.7	14
Participants on anti-hypertensive agents (% , 95% CI)	73.3, 95% CI 64.1-82.5	18
BMI in kg/m ² (Mean \pm SD)	27.9 \pm 0.5	40
HbA1c in % (Mean \pm SD)	9.0 \pm 1.5	40
HbA1c in mmol/mol (Mean \pm SD)	75.0 \pm 1.5	40

BMI- Body mass index, HbA1c- Glycated haemoglobin, OHA- Oral hypoglycaemic agents, SD- Standard deviation

Table 2. Indicators of optimal glycated haemoglobin goal

Optimal glycated haemoglobin (HbA1c) goal (n= 34 studies): Pooled rate of attainment of optimal HbA1c goal = 27% (95% CI 24-30, I²=94.7%, 95% CI 93.6-95.8), and I² after meta-regression-56.3%)

Attainment of the optimal HbA1c goal per region: Central: 20% (95% CI 16-23), Eastern: 23% (95% CI 15-34), Northern: 24% (95% CI 17-31), Southern: 31% (95% CI 28-34), and Western: 37% (95% CI 29-46)

First author & year	Country (ies)	Region of Africa	No of study participants	Mean age of participants	% of females	% with optimal HbA1c
Adetunji et al 2006	Nigeria	Western	50	-----	-----	52.0
Agboghroma et al, 2020	Nigeria	Western	200	-----	-----	19.0
Akalu et al 2020	Ethiopia	Eastern	378	-----	38.6	40.7
Amod et al 2012	South Africa	Southern	701	57.4	43.9	30.4
Amour et al, 2019	Tanzania	Eastern	238	57.2	65.7	9.2
Ashur et al 2016	Libya	Northern	523	54.4	47.0	21.8
Attoye et al 2020	Nigeria	Western	260	-----	-----	34.6
Awadalla et al, 2017	Sudan	Northern	424	-----	49.3	15.6
Balogun et al 2011	Nigeria	Western	40	59.4	62.5	52.5
Bentata et al, 2015	Morocco	Northern	637	58.5	62.3	30.1
Blum et al 2020	DRC	Central	319	-----	33.5	14.1
Cairncross et al, 2017	South Africa	Southern	203	-----	72.5	31.3
Camara et al 2015	Cameroon and Guinea Conakry	Central and Western	1267	58.0	61.0	26.0
Chadli et al. 2016	Morocco	Northern	498	58.0	62.4	26.8
Chamba et al 2017	Tanzania	Eastern	119	58.1	49.6	39.3
Chetoui et al 2019	Morocco	Northern	1456	56.2	73.4	33.7
Cohen DB et al 2010	Malawi	Southern	620	52.2	60.1	36.0
Diaf et al 2017	Algeria	Northern	210	55.6	65.0	51.4
Hall et al, 2017	Cameroon	Central	261	56.0	56.3	27.2
Iwuala et al 2015	Nigeria	Western	100	59.9	62.0	45.0
Kibirige et al 2017	Uganda	Eastern	425	-----	67.0	26.5
Kimando et al 2017	Kenya	Eastern	385	62.1	65.5	39.5
Kisozi et al 2017	Uganda	Eastern	288	48.5	38.0	23.3
Mbwete et al., 2020	Tanzania	Eastern	161	63.9	67.1	49.7
Megallaa et al, 2019	Egypt	Northern	180	-----	24.4	4.4
Molefe-Baikai et al, 2018	Botswana	Southern	289	50.7	66.1	29.4
Muddu et al. 2019	Uganda	Eastern	175	46.0	48.6	8.1
Muddu et al., 2016	Uganda	Eastern	202	46.0	49.5	8.4
Mwebaze et al 2014	Uganda	Eastern	146	53.9	48.6	19.2
Mwita et al 2019	Botswana	Southern	500	58.9	66.0	32.3
Noor et al., 2016	Sudan	Northern	387	-----	49.6	15.0
Omar et al 2018	Sudan	Northern	339	54.8	69.9	28.1

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Sobngwi et al 2011	Tanzania, Kenya, Cameroon, Ghana, Senegal, and Nigeria	Eastern, Western, Central	2352	53.0	61.1	29.2
Uloko et al., 2012	Nigeria	Western	531	57.1	60.5	32.4

For peer review only

Table 3. Indicators of optimal blood pressure goal

Optimal blood pressure goal (n=26 studies): Pooled rate of attainment of optimal blood pressure goal = 38% (95% CI 30-46, I²=98.7% 95% CI 98.6-99.0), and I² after meta-regression-95.4%)

Attainment of the optimal blood pressure goal per region: Western: 31% (95% CI 20-43), Eastern: 40% (95% CI 24-57), Southern: 40% (95% CI 26-55), Central: 41% (95% CI 38-45), and Northern: 42% (95% CI 24-61).

Author & year	Country (ies)	Region of Africa	No of study participants	Mean age of participants	% of females	% with optimal BP
Abdissa et al, 2020	Ethiopia	Eastern	229	-----	40.4	31.0
Agboghoroma et al, 2020	Nigeria	Western	200	-----	-----	30.0
Akalu et al 2020	Ethiopia	Eastern	378	-----	38.6	57.7
Amour et al, 2019	Tanzania	Eastern	238	57.2	65.7	21.7
Awadalla et al, 2017	Sudan	Northern	424	-----	49.3	60.1
Balogun et al 2011	Nigeria	Western	40	59.4	62.5	55.0
Chadli et al. 2016	Morocco	Northern	498	58.0	62.4	20.2
Chahbi et al, 2018	Morocco	Northern	300	-----	93.0	32.6
Chisha et al 2017	Ethiopia	Eastern	270	-----	48.9	85.9
Cohen DB et al 2010	Malawi	Southern	620	52.2	60.1	48.0
Hall et al, 2017	Cameroon	Central	261	56.0	56.3	43.0
Hayfron-Benjamin et al, 2019	Ghana	Western	206	52.9	68.9	37.9
Jingi et al, 2015	Cameroon	Central	407	54.2	41.8	40.4
Kahloun et al, 2014	Tunisia	Northern	2320	54.5	60.2	62.5
Kimando et al 2017	Kenya	Eastern	385	62.1	65.5	50.4
Lewis et al, 2018	Zambia	Southern	921	56.0	45.0	46.6
Lumu et al 2017	Uganda	Eastern	425	52.2	67.0	54.7
Magan et al, 2019	Uganda	Eastern	44	50.4	63.4	34.1
Megallaa et al, 2019	Egypt	Northern	180	-----	24.4	37.8
Muddu et al., 2016	Uganda	Eastern	202	46.0	49.5	38.1
Mwebaze et al 2014	Uganda	Eastern	146	53.9	48.6	1.5
Mwita JC et al 2019	Botswana	Southern	500	58.9	66.0	54.2
Onakpoya et al, 2015	Nigeria	Western	133	-----	48.1	24.1
Rotchford et al., 2002	South Africa	Southern	253	56.5	73.1	14.0
Sobngwi et al 2011	Tanzania, Kenya, Cameroon, Ghana, Senegal, and Nigeria	Eastern, Western, Central	2352	53.0	61.1	21.0
Uloko et al., 2012	Nigeria	Western	531	57.1	60.5	17.0

1
2
3 **Table 4. Indicators of optimal LDLC goal**
4
5

6 **Optimal LDLC goal (n= 11 studies)**
7 Pooled rate of attainment of optimal LDLC goal = 42% (95% CI 32-52, I²=97.4% 95% CI 96.5-98.1), and
8 I² after meta-regression-92.1%)
9 **Attainment of the optimal LDLC goal per region:** Southern: 27% (95% CI 24-30), Eastern: 37% (95%
10 CI 30-45), Western: 51% (95% CI 43-58), and Northern: 53% (95% CI 32-74).

11 Author & year	12 Country (ies)	13 Region of Africa	14 No of study participants	15 Mean age of participants	16 % of females	17 % with optimal LDLC
18 Agboghoroma et al, 2020	Nigeria	Western	200	-----	-----	50.5
19 Amour et al, 2019	Tanzania	Eastern	238	57.2	65.7	26.0
20 Awadalla et al, 2017	Sudan	Northern	424	-----	49.3	47.4
21 Chadli et al. 2016	Morocco	Northern	498	58.0	62.4	38.6
22 Chamba et al 2017	Tanzania	Eastern	119	58.1	49.6	27.7
23 Elnasri et al. 2008	Sudan	Northern	250	52.0	62.0	84.8
24 Kisozi et al 2017	Uganda	Eastern	288	48.5	38.0	37.0
25 Lumu et al 2017	Uganda	Eastern	425	52.2	67.0	38.9
26 Megallaa et al, 2019	Egypt	Northern	180	-----	24.4	37.8
27 Mwebaze et al 2014	Uganda	Eastern	146	53.9	48.6	48.6
28 Mwita et al 2019	Botswana	Southern	500	58.9	66.0	20.4

29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 5. Prevalence of diabetic nephropathy

Prevalence of diabetic nephropathy (n= 40 studies): Pooled prevalence= 31% (95% CI 22-41, I²=99.3% 95% CI 99.2-99.4), and I² after meta-regression-95.6%).

Prevalence of diabetic nephropathy per region: Central: 22% (95% CI 9-39), Eastern: 25% (95% CI 10-43), Southern: 28% (95% CI 18-40), Northern: 38% (95% CI 14-65), and Western: 47% (95% CI 25-69)

Author & year	No of study participants	Country (ies)	Region of Africa	Mean age of participants	% of females	Prevalence of nephropathy, %
Abejew et al, 2015	216	Ethiopia	Eastern	45.0	42.6	2.2
Adeniyi et al, 2020	327	South Africa	Southern	-----	70.3	24.5
Adentunji et al 2006	50	Nigeria	Western	-----	-----	83.0
Ahmed et al, 2017	316	Sudan	Northern	58.0	41.5	40.2
Albalawi et al 2020	159	Sudan	Northern	58.1	65.4	26.4
Alebiosu et al 2013	342	Nigeria	Western	53.4	-----	28.4
Amour et al 2019	315	Tanzania	Eastern	57.2	65.7	72.2
Balogun et al 2011	40	Nigeria	Western	59.4	62.5	90.0
Bello et al, 2017	358	Nigeria	Western	57.8	61.7	53.4
Bentata et al, 2015	637	Morocco	Northern	58.5	62.3	77.2
Blum et al 2020	319	DRC	Central	-----	33.5	38.6
Bouaziz et al 2012	73	Tunisia	Northern	59.3	-----	11.0
Chahbi et al, 2018	300	Morocco	Northern	-----	93.0	26.3
Cohen et al 2010	620	Malawi	Southern	52.2	60.1	34.7
Deribe et al, 2014	216	Ethiopia	Eastern	50.7	40.3	8.8
Dzudie et al 2012	420	Cameroon	Central	56.7	51.0	15.9
Efundem et al, 2017	162	Cameroon	Central	55.3	67.3	14.2
Eghan-Jr et al 2007	109	Ghana	Western	54.1	75.0	43.0
Fasil, et al 2019	367	Ethiopia	Eastern	48.6	59.3	4.4
Gill et al 2008	105	Ethiopia	Eastern	41.0	30.0	51.0
Goro et al, 2019	208	Ethiopia	Eastern	54.8	47.1	26.0
Hayfron-Benjamin et al, 2019	206	Ghana	Western	52.9	68.9	32.0
Janmohamed at al 2013	369	Tanzania	Eastern	54.0	53.4	83.7
Kahloun et al, 2014	2320	Tunisia	Northern	-----	60.2	3.4
Khalil et al 2019	506	Egypt	Northern	-----	-----	33.2
Lebeta et al, 2017	344	Ethiopia	Eastern	40.5	42.7	11.4
Machingura et al, 2017	260	Zimbabwe	Southern	57.6	72.7	45.4
Makwero et al 2018	150	Lesotho	Southern	58.2	80.7	6.7
Megallaa et al, 2019	180	Egypt	Northern	-----	24.4	86.1
Mohmad et al 2011	71	Sudan	Central	-----	42.0	50.7

1

2

3 Molefe-Baikai et al, 4 2018	289	Botswana	Southern	50.7	66.1	44.6
5 Muddu et al. 2019	175	Uganda	Eastern	46.0	48.6	47.4
6 Neuhann et al 2001	474	Tanzania	Eastern	53.8	46.0	7.5
7 Olamoyegun et al, 8 2015	90	Nigeria	Western	62.5	50.0	54.3
9 Rotchford et al., 10 2002	253	South Africa	Southern	56.5	73.1	46.4
11 Sobngwi et al 2011 14 15 16 17 18 19 20	2352	Tanzania, Kenya, Cameroon, Ghana, Senegal, and Nigeria	Eastern, Western, Central	53.0	61.1	2.4
21 Tesfaye et al 2015 22	247	Ethiopia	Eastern	-----	40.5	6.5
23 Thinyane et al 2013	80	Lesotho	Southern	49.0	49.0	6.0
24 Uloko et al, 2012	531	Nigeria	Western	57.1	60.5	3.2
25 Worku et al 2010 26	305	Ethiopia	Eastern	44.4	37.1	15.7

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

Table 6. Prevalence of diabetic peripheral neuropathy

Prevalence of diabetic peripheral neuropathy (n=36 studies): Pooled prevalence= 38% (95% CI 31-45, I²=98.2% 95% CI 98.7-99.0), and I² after meta-regression-88%).

Prevalence of diabetic peripheral neuropathy per region: Central: 22% (95% CI 18-27), Eastern: 26% (95% CI 16-38), Northern: 45% (95% CI 30-61), Southern: 46% (95% CI 42-49), and Western: 61% (95% CI 45-75)

Author & year	No of study participants	Country (ies)	Region of Africa	Mean age of participants	% of females	Prevalence of neuropathy, %
Abejew et al, 2015	216	Ethiopia	Eastern	45.0	42.6	14.4
Albalawi et al 2020	159	Sudan	Northern	58.1	65.4	40.3
Assaad-Khalil et al 2014	958	Egypt	Northern	57.3	50.0	29.3
Awadalla et al 2017	424	Sudan	Northern	-----	49.3	68.2
Bello et al 2019	175	Nigeria	Western	59.8	57.7	41.7
Bentata et al, 2015	637	Morocco	Northern	58.5	62.3	39.6
Chiwanga et al, 2015	404	Tanzania	Eastern	53.6	55.4	44.0
Cohen et al 2010	620	Malawi	Southern	52.2	60.1	46.4
Deribe et al, 2014	216	Ethiopia	Eastern	50.7	40.3	10.6
Dzudie et al 2012	420	Cameroon	Central	56.7	51.0	22.4
Ede et al 2018	90	Nigeria	Western	58.6	34.4	83.3
Ekoru K et al. 2019	2784	Nigeria, Ghana, Kenya	Western and Eastern	56.0	61.0	46.0
Fasil, et al 2019	367	Ethiopia	Eastern	48.6	59.3	7.9
Gill et al 2008	105	Ethiopia	Eastern	41.0	30.0	41.0
Jarso et al 2011	384	Ethiopia	Eastern	-----	54.1	77.0
Jember et al 2017	368	Ethiopia	Eastern	49.0	41.6	52.2
Kahloun et al, 2014	2320	Tunisia	Northern	-----	60.2	18.7
Khalil et al 2019	506	Egypt	Northern	-----	-----	20.0
Kisozi et al 2017	288	Uganda	Eastern	48.5	38.0	29.4
Kuate-Tegueu et al 2016	321	Cameroon	Western	59.8	64.1	33.3
Lebeta et al, 2017	344	Ethiopia	Eastern	40.5	42.7	7.7
Makwero et al 2018	150	Lesotho	Southern	58.2	80.7	43.3
Megallaa et al, 2019	180	Egypt	Northern	-----	24.4	82.0
Miriam et al, 2017	279	Ethiopia	Eastern	48.8	44.8	10.0
Mohmad et al 2011	71	Sudan	Central	-----	42.0	69.0
Neuhann et al 2001	474	Tanzania	Eastern	53.8	46.0	44.0
Olamoyegun et al, 2015	90	Nigeria	Western	62.5	50.0	69.6
Seyum et al 2010	429	Eritrea	Eastern	57.4	-----	4.0
Smide et al 2009	145	Tanzania	Eastern	46.0	48.0	30.0

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Sobngwi et al 2011	2352	Tanzania, Kenya, Cameroon, Ghana, Senegal, and Nigeria	Eastern, Western, Central	53.0	61.1	48.4
Tesfaye et al 2015	247	Ethiopia	Eastern	-----	40.5	10.1
Tilahun et al, 2017	236	Ethiopia	Eastern	47.8	46.6	25.4
Ugoya et al 2006	180	Nigeria	Western	53.0	51.6	75.0
Uloko et al, 2012	531	Nigeria	Western	57.1	60.5	59.2
Vogt et al 2017	100	Zanzibar	Eastern	54.0	49.0	45.0
Worku et al 2010	305	Ethiopia	Eastern	44.4	37.1	29.5

For peer review only

Table 7. Prevalence of diabetic retinopathy

Prevalence of diabetic retinopathy (n= 51 studies): Pooled prevalence= 32% (95% CI 28-36, I²=98% 95% CI 97.8-98.3), and I² after meta-regression-88.5%).

Prevalence of diabetic retinopathy per region: Eastern: 23% (95% CI 19-28), Western: 27% (95% CI 19-36), Southern: 30% (95% CI 23-37), Central: 34% (95% CI 22-47), and Northern: 51% (95% CI 37-65).

Author & year	No of study participants	Country (ies)	Region of Africa	Mean age of participants	% of females	Prevalence of retinopathy, %
Abejew et al, 2015	216	Ethiopia	Eastern	45.0	42.6	28.9
Ahmed et al, 2017	316	Sudan	Northern	58.0	41.5	39.8
Albalawi et al 2020	159	Sudan	Northern	58.1	65.4	34.6
Assaad-Khalil et al 2019	506	Egypt	Northern	-----	-----	34.6
Awadalla et al 2017	424	Sudan	Northern	-----	49.3	72.6
Bello et al 2019	175	Nigeria	Western	59.8	57.7	33.1
Bello et al, 2017	358	Nigeria	Western	57.8	61.7	20.1
Bentata et al, 2015	637	Morocco	Northern	58.5	62.3	35.6
Blake et al 2015	1307	Botswana	Southern	55.0	67.9	17.7
Bouaziz et al 2012	73	Tunisia	Northern	59.3		27.0
Burgress et al 2014	322	Malawi	Southern	55.2	64.6	50.1
Chahbi et al, 2018	300	Morocco	Northern	-----	93.0	34.3
Chisha et al 2017	270	Ethiopia	Eastern	-----	48.9	13.0
Cleland et al, 2015	5729	Tanzania	Eastern	60.8	60.3	27.9
Cohen et al 2010	620	Malawi	Southern	52.2	60.1	34.7
Dzudie et al 2012	420	Cameroon	Central	56.7	51.0	15.7
Ekoru K et al. 2019	2784	Nigeria, Ghana, Kenya	Western and Eastern	56.0	61.0	15.0
Elwali et al 2017	316	Sudan	Northern	58.7	40.8	82.6
Fasil, et al 2019	367	Ethiopia	Eastern	48.6	59.3	17.7
Gill et al 2008	105	Ethiopia	Eastern	41.0	30.0	21.0
Glover et al 2011	281	Malawi	Southern	56.4	72.8	32.5
Hall et al, 2017	261	Cameroon	Central	56.0	56.3	27.2
Hayfron-Benjamin et al, 2019	206	Ghana	Western	52.9	68.9	11.0
Jingi et al, 2014	407	Cameroon	Central	54.2	41.8	38.8
Jingi et al, 2015	407	Cameroon	Central	-----	41.8	40.3
Kahloun et al, 2014	2320	Tunisia	Northern	-----	60.2	26.3
Kizor-Akarairwe et al 2018	80	Nigeria	Western	61.2	48.8	32.1
Lartey et al, 2018	208	Ghana	Western	57.5	70.7	15.5
Lebeta et al, 2017	344	Ethiopia	Eastern	40.5	42.7	25.5
Lewis et al, 2018	921	Zambia	Southern	56.0	45.0	44.0
Magan et al, 2019	44	Uganda	Eastern	50.4	63.4	19.5

1

2

3	Makwero et al 2018	150	Lesotho	Southern	58.2	80.7	4.7
4	Megallaa et al, 2019	180	Egypt	Northern	-----	24.4	90.0
5	Mohmad et al 2011	71	Sudan	Central	-----	42.0	71.2
6	Neuhann et al 2001	474	Tanzania	Eastern	53.8	46.0	14.0
7	Njikam et al, 2016	371	Cameroon	Central	59.2	54.7	49.9
8	Olamoyegun et al, 2015	90	Nigeria	Western	62.5	50.0	48.9
9	Onakpoya et al, 2015	133	Nigeria	Western		48.1	27.8
10	Pirie et al, 2014	292	South Africa	Southern	59.2	79.0	39.0
11	Rotchford et al., 2002	253	South Africa	Southern	56.5	73.1	40.3
12	Seyum et al 2010	429	Eritrea	Eastern	57.4	-----	33.0
13	Sobngwi et al 2011	2352	Tanzania, Kenya, Cameroon, Ghana, Senegal, and Nigeria	Eastern, Western, and Central	53.0	61.1	18.3
14	Tesfaye et al 2015	247	Ethiopia	Eastern	-----	40.5	11.7
15	Thinyane et al 2013	80	Lesotho	Southern	49.0	49.0	35.0
16	Thomas et al 2013	3978	South Africa	Southern	56.8	33.3	20.5
17	Tilahun et al, 2017	236	Ethiopia	Eastern	47.8	46.6	20.3
18	Uloko et al, 2012	531	Nigeria	Western	57.1	60.5	35.5
19	Webb et al 2016	599	South Africa	Southern	57.8	68.0	24.9
20	Woodward et al, 2020	91	Tanzania	Eastern	59.2	62.6	42.9
21	Worku et al 2010	305	Ethiopia	Eastern	44.4	37.1	33.8

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

Table 8. Prevalence of diabetic foot ulcers

Prevalence of diabetic foot ulcers (n= 29 studies): Pooled prevalence= 11% (95% CI 9-14, I²=97.4% 95% CI 96.9-97.8), and I² after meta-regression-1.4%)

Prevalence of diabetic foot ulcers per region: Southern: 7% (95% CI 5-11), Western: 8% (95% CI 6-10), Eastern: 10% (95% CI 8-12), and Northern: 21% (95% CI 4-48).

Author & year	No of study participants	Country (ies)	Region of Africa	Mean age of participants	% of females	Prevalence of foot ulcers, %
Abbas et al, 2002	627	Tanzania	Eastern	53.0	35.0	15.0
Abbas et al, 2011	11866	Tanzania	Eastern	-----	-----	12.0
Abdissa et al, 2020	229	Ethiopia	Eastern	-----	40.4	12.7
Abejew et al, 2015	216	Ethiopia	Eastern	45.0	42.6	4.4
Albalawi et al 2020	159	Sudan	Northern	58.1	65.4	2.5
Amour et al 2019	315	Tanzania	Eastern	57.2	65.7	10.0
Assaad-Khalil et al 2014	958	Egypt	Northern	57.3	50.0	6.1
Awadalla et al 2017	424	Sudan	Northern	-----	49.3	12.7
Chalya et al, 2011 105	136	Tanzania	Eastern	54.3	45.6	3.2
Chiwanga et al, 2015	404	Tanzania	Eastern	53.6	55.4	15.0
Deribe et al, 2014	216	Ethiopia	Eastern	50.7	40.3	14.8
Ekoru K et al. 2019	2784	Nigeria, Ghana, Kenya	Western and Eastern	56.0	61.0	5.0
Elwali et al 2017	316	Sudan	Northern	58.7	40.8	17.7
Gebre Kirstos et al, 2015	228	Ethiopia	Eastern	-----	38.0	12.0
Lebeta et al, 2017	344	Ethiopia	Eastern	40.5	42.7	21.2
Mamo et al, 2015	200	Ethiopia	Eastern	50.0	72.5	15.0
Mariam et al, 2017	279	Ethiopia	Eastern	48.8	44.8	13.6
Megallaa et al, 2019	180	Egypt	Northern	-----	24.4	86.7
Neuhann et al 2001	474	Tanzania	Eastern	53.8	46.0	10.0
Nyamu et al, 2003	1788	Kenya	Eastern	56.9	-----	4.6
Rotchford et al., 2002	253	South Africa	Southern	56.5	73.1	6.0
Seyum et al 2010	429	Eritrea	Eastern	57.4	-----	14.0
Sobngwi et al 2011	2352	Tanzania, Kenya, Cameroon, Ghana, Senegal, and Nigeria	Eastern, Western, Central	53.0	61.1	11.7

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Tesfaye et al 2015	247	Ethiopia	Eastern	-----	40.5	0.4
Thinyane et al 2013	80	Lesotho	Southern	49.0	49.0	14.0
Tilahun et al, 2017	236	Ethiopia	Eastern	47.8	46.6	8.5
Uloko et al, 2012	531	Nigeria	Western	57.1	60.5	3.8
Unachukwu et al, 2006	315	Nigeria	Western	54.6	36.7	19.1
Worku et al 2010	305	Ethiopia	Eastern	44.4	37.1	4.6

For peer review only

Table 9. Prevalence of peripheral arterial disease

Prevalence of peripheral arterial disease (PAD) (n= 18 studies): Pooled prevalence= 19% (95% CI 12-25, I²=98.1% 95% CI 97.6-98.4), and I² after meta-regression-70.9%).

Prevalence of PAD per region: Southern: 8% (95% CI 6-10), Northern: 15% (95% CI 4-29), Eastern: 18% (95% CI 11-27), and Western: 29% (95% CI 13-48)

Author & year	No of study participants	Country (ies)	Region of Africa	Mean age of participants	% of females	Prevalence of PAD, %
Agboghroma et al, 2020	200	Nigeria	Western	-----	-----	38.5
Akalu et al, 2020	280	Ethiopia	Eastern	-----	38.6	30.7
Assaad-Khalil et al 2014	958	Egypt	Northern	57.3	50.0	11.0
Chahbi et al, 2018	300	Morocco	Northern	-----	93.0	2.7
Chiwanga et al, 2015	404	Tanzania	Eastern	53.6	55.4	15.0
Cohen et al 2010	620	Malawi	Southern	52.2	60.1	7.6
Gill et al 2008	105	Ethiopia	Eastern	41.0	30.0	6.0
Hayfron-Benjamin et al, 2019	206	Ghana	Western	52.9	68.9	11.2
Khalil et al 2019	506	Egypt	Northern	-----	-----	32.6
Mariam et al, 2017	279	Ethiopia	Eastern	48.8	44.8	9.7
Megallaa et al, 2019	180	Egypt	Northern	-----	24.4	20.0
Mwebaze et al 2014	146	Uganda	Eastern	53.9	48.6	39.0
Ogbera et al 2015	225	Nigeria	Western	61.4	57.0	40.0
Okello et al 2014	229	Uganda	Eastern	60.0	63.7	24.0
Oyelade et al 2012	219	Nigeria	Western	-----	58.9	52.5
Smide et al 2008	145	Tanzania	Eastern	46.0	48.0	13.0
Sobngwi et al 2011	2352	Tanzania, Kenya, Cameroon, Ghana, Senegal, and Nigeria	Eastern, Western, Central	53.0	61.1	4.7
Uloko et al, 2012	531	Nigeria	Western	57.1	60.5	10.7

Figures caption

Figure 1: PRISMA flow diagram of selection of eligible studies

Figure 2: Forest plot summarising studies on the proportion of attainment of an optimal low-density lipoprotein cholesterol goal in percentage

Figure 3: Forest plot summarising studies on the proportion of attainment of an optimal blood pressure goal in percentage

Figure 4: Forest plot summarising studies on the proportion of attainment of an optimal glycated haemoglobin goal in percentage

Figure 5: Forest plot summarising studies on the prevalence of diabetic retinopathy

Figure 6: Forest plot summarising studies on the prevalence of diabetic foot ulcers

Figure 7: Forest plot summarising studies on the prevalence of diabetic nephropathy

Figure 8: Forest plot summarising studies on the prevalence of diabetic neuropathy

Figure 9: Forest plot summarising studies on the prevalence of peripheral arterial disease

Supplementary figure 1: Funnel plot for studies investigating prevalence of diabetic nephropathy

Supplementary figure 2: Funnel plot for studies investigating prevalence of diabetic neuropathy

Supplementary figure 3: Funnel plot for studies investigating prevalence of peripheral arterial disease

Supplementary figure 4: Funnel plot for studies investigating prevalence of diabetic retinopathy

Supplementary figure 5: Funnel plot for studies investigating prevalence of diabetic foot ulcers

1
2
3 **Supplementary figure 6:** Funnel plot for studies investigating rate of attainment of an
4 optimal HbA1c goal
5
6

7 **Supplementary figure 7:** Funnel plot for studies investigating rate of attainment of an
8 optimal BP goal
9
10

11 **Supplementary figure 8:** Funnel plot for studies investigating rate of attainment of an
12 optimal LDLC goal
13
14
15
16

17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1. PRISMA flow diagram of selection of eligible studies






Figure 2. Forest plot summarising studies on the proportion of attainment of an optimal low-density lipoprotein cholesterol goal in percentage




ES= Effect size

Figure 3. Forest plot summarising studies on the proportion of attainment of an optimal blood pressure goal in percentage




ES= Effect size

Figure 4. Forest plot summarising studies on the proportion of attainment of an optimal glycated haemoglobin in percentage




ES= Effect size

Figure 5. Forest plot summarising studies on the prevalence of diabetic retinopathy




ES= Effect size

Figure 6. Forest plot summarising studies on the prevalence of diabetic foot ulcers




ES= Effect size

Figure 7. Forest plot summarising studies on the prevalence of diabetic nephropathy




ES= Effect size

Figure 8. Forest plot summarising studies on the prevalence of diabetic peripheral neuropathy




ES= Effect size

Figure 9. Forest plot summarising studies on the prevalence of peripheral arterial disease




ES= Effect size

Supplementary figure 1: Funnel plot for studies investigating the prevalence of diabetic nephropathy




Supplementary figure 2: Funnel plot for studies investigating the prevalence of diabetic neuropathy



Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Supplementary figure 3: Funnel plot for studies investigating the prevalence of peripheral arterial disease



Only


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplementary figure 4: Funnel plot for studies investigating the prevalence of diabetic retinopathy




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


Supplementary figure 5: Funnel plot for studies investigating the prevalence of diabetic foot ulcers




1
2
3 **Supplementary figure 6: Funnel plot for studies investigating the rate of**
4 **attainment of an optimal HbA1c goal**
5
6
7



Supplementary figure 7: Funnel plot for studies investigating the rate of attainment of an optimal BP goal



1
2
3 **Supplementary figure 8: Funnel plot for studies investigating the rate of**
4 **attainment of an optimal LDLC goal**
5
6
7



Supplementary table 1. PRISMA checklist for the systematic review and meta-analysis

Section and Topic	Item #	Checklist item	Page where item is reported
TITLE			
Title	1	Identify the report as a systematic review.	1
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	5-6
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	6
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	8
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	6
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	6-7
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	7-8
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	8
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	9-10
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	9-10
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	10
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	10
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	10-11

Section and Topic	Item #	Checklist item	Page where item is reported
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	10-11
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	10
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	10-11
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	10-11
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	11
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	11
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	11
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	11-12
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	12
Study characteristics	17	Cite each included study and present its characteristics.	12
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	13-14
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	14-17
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	13-14
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	14-17
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	12
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	17
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	13
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	13
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	17-21
	23b	Discuss any limitations of the evidence included in the review.	21

Section and Topic	Item #	Checklist item	Page where item is reported
	23c	Discuss any limitations of the review processes used.	21
	23d	Discuss implications of the results for practice, policy, and future research.	22
OTHER INFORMATION			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	6
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	A protocol was not prepared
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	Search period was changed from September 2020 to December 2020
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	22-23
Competing interests	26	Declare any competing interests of review authors.	23
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	23

Supplementary table 2. Criteria for the adapted Newcastle-Ottawa Scale regarding star allocation to assess quality of included studies

Study details (Author et al, year)	Selection				Comparability (**)	Outcome		
	Representativeness of sample (*)	Sample size (*)	Non respondents (*)	Ascertainment of exposure (*)		Assessment of outcome (*)	Statistical test (*)	Total (8*)
Mariam et al, 2017	*	*	*	*	**	*	*	8
Okello et al, 2014	*	*	*	*	**	*	*	8
Amour et al, 2019	*	*	*	*	**	*	*	8
Abdissa et al, 2019	*	*	*	*	**	*	*	8
Fasil et al, 2019	*	*	*	*	**	*	*	8
Jember et al,2017	*	*	*	*	**	*	*	8
Chisha et al, 2017	*	*	*	*	**	*	*	8
Deribe et al, 2014	*	*	*	*	**	*	*	8
Seyum et al, 2008	*	*	*	*	**	*	*	8
Muddu et al,2019	*	*	*	*	**	*	*	8
Mamo et al., 2015	*	*	*	*	**	*	*	8
Muddu et al., 2019	*	*	*	*	**	*	*	8
Blake et al., 2015	*	*	*	*	**	*	*	8
Bello et al., 2019	*	*	*	*	**	*	*	8
Elnasri et al., 2008	*	*	*	*	**	*	*	8
Iwuala et al., 2015	*	*	*	*	**	*	*	8
Chadli et al., 2016	*	*	*	*	**	*	*	8
Jingi et al., 2014	*	*	*	*	**	*	*	8
Hall et al., 2017	*	*	*	*	**	*	*	8
Efundem et al., 2017	*	*	*	*	**	*	*	8
Attoye et al., 2020	*	*	*	*	**	*	*	8
Chetoui et al., 2020	*	*	*	*	**	*	*	8
Diaf et al., 2017	*	*	*	*	**	*	*	8
Elwali et al., 2017	*	*	*	*	**	*	*	8
Kahloun et al., 2014	*	*	*	*	**	*	*	8
Noor et al., 2017	*	*	*	*	**	*	*	8
Bello et al., 2017	*	*	*	*	**	*	*	8
Uloko et al., 2012	*	*	*	*	**	*	*	8
Ede et al., 2018	*	*	*	*	**	*	*	8

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Hayfron-Benjamin et al., 2019	*	*	*	*	**	*	8
Kizor-Akaraiwe et al., 2016	*	*	*	*	**	*	8
Ogbera et al., 2015	*	*	*	*	**	*	8
Olamoyegun et al., 2015	*	*	*	*	**	*	8
Oyelade et al., 2012	*	*	*	*	**	*	8
Ugoya et al., 2006	*	*	*	*	**	*	8
Ahmed et al., 2017	*	*	*	*	**	*	8
Albalawi et al., 2020	*	*	*	*	**	*	8
Ashur et al., 2016	*	*	*	*	**	*	8
Blum et al., 2020	*	*	*	*	**	*	8
Burgess et al., 2014	*	*	*	*	**	*	8
Glover et al., 2012	*	*	*	*	**	*	8
Lewis et al., 2018	*	*	*	*	**	*	8
Machingura et al., 2017	*	*	*	*	**	*	8
Molefe-Baikai et al., 2018	*	*	*	*	**	*	8
Mwita et al., 2019	*	*	*	*	**	*	8
Pirie et al., 2014	*	*	*	*	**	*	8
Rotchford et al., 2002	*	*	*	*	**	*	8
Thomas et al., 2013	*	*	*	*	**	*	8
Webb et al., 2015	*	*	*	*	**	*	8
Omar et al., 2018	*	*	*	*	**	*	8
Adeniyi et al., 2020	*	*	*	*	**	*	8
Assaad-Khalil et al., 2015	*	*	*	*	**	*	8
Khalil et al., 2019	*	*	*	*	**	*	8
Awadalla et al., 2017	*	*	*	*	**	*	8
Bentata et al., 2015	*	*	*	*	**	*	8
Bouaziz et al., 2012	*	*	*	*	**	*	8
Jingi et al., 2015	*	*	*	*	**	*	8

bmjopen-2022-061786 on 8 November 2022. Downloaded from <http://bmjopen.bmj.com/> on April 23, 2024 by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Chahbi et al., 2018	*	*	*	*	**	*	8
Adetunji et al., 2006	*	*	*	*	**	*	8
Jarso et al., 2011	*	*	*	*	**	*	8
Janmohamed et al, 2013	*	*	*	*	*	*	7
Chalya et al, 2011	*	*	*	*	*	*	7
Goro et al, 2019	*	*	*	*	*	*	7
Muddu et al, 2016	*	*	-	*	**	*	7
Kisozi et al, 2017	*	*	*	*	*	*	7
Akalu et al, 2020	*	*	*	*	*	*	7
Lumu et al, 2017	*	*	*	*	*	*	7
Chamba et al, 2017	*	*	-	*	**	*	7
Smide et al, 2008	*	-	*	*	**	*	7
Sobngwi et al 2011	*	-	*	*	**	*	7
Camara et al, 2014	*	-	*	*	**	*	7
Ekoru et al,2019	*	-	*	*	**	*	7
Mwebaze et al, 2014	*	*	*	*	*	*	7
Agboghoroma et al,2020	*	*	*	*	*	*	7
Kimando et al, 2017	*	*	-	*	**	*	7
Clealand et al, 2015	*	*	*	*	*	*	7
Njikam et al., 2016	*	*	-	*	**	*	7
Dzudie et al., 2012	*	*	*	-	**	-	7
Alebiosu et al., 2003	*	*	-	*	**	*	7
Kuate-Tegueu et al., 2015	*	*	-	*	**	*	7
Mohmad et al., 2011	*	*	-	*	**	*	7
Cohen et al., 2010	*	*	-	*	**	*	7
Makwero et al., 2018	*	*	-	*	**	*	7
Onakpoya et al., 2016	*	-	-	*	**	*	7
Lebeta et al, 2016	*	*	*	*	-	*	6
Kibirige et al, 2017	*	-	-	*	**	*	6
Mbwete et al, 2020	*	-	*	*	*	*	6
Tiahun et al,2017	*	*	*	*	-	*	6

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Chiwanga et al, 2015	*	-	*	*	*	*	6
Lumu et al, 2017	*	-		*	**	*	6
Balogu et al., 2011	*	-	-	*	**	*	6
Megallaa et al., 2019	*	*	*	*	-	*	6
Eghan et al., 2007	*	*	-	-	**	*	6
Unachukwu et al., 2007	*	-	-	*	**	*	6
Abejew et al, 2015	*	*	-	*	-	*	5
Nyamu et al, 2003	*	-	*	*	-	*	5
Gulam-Abbas et al, 2002	*	-	*	*	-	*	5
Abbas et al, 2011	*	*	*	*	-	-	5
Gill et al, 2008	*	*	*	*	-	-	5
Cairncross et al., 2017	-	-	-	*	**	*	5
Amod et al., 2012	*	*	*	-	-	*	5
Vogt et al, 2017	*	-	-	*	-	*	4
Worku et al, 2010	*	*	*	-	-	-	4
Gebre Kirstos et al, 2015	*	-	*	*	-	-	4
Magan et al, 2019	-	-	-	*	-	*	3
Woodward et al, 2020	-	-	-	*	-	*	3
Lartey et al., 2018	-	-	-	*	-	*	3
Tesfatsion et al, 2015	-	-	-	*	-	-	2
Neuhann et al, 2001	-	-	-	*	-	-	2